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Abstract
The Effect of Manipulation of the Phosphoinositide 3-kinase Pathway on Axon
Regeneration in vivo
Rachel Shane Evans
Millions worldwide are visually impaired by optic nerve diseases, and glaucoma, the
leading cause of irreversible blindness, is due to affect approximately 80 million people
by 2020. The optic nerve is comprised of retinal ganglion cell (RGC) axons, and like all
mammalian central nervous system axons, they fail to regenerate due to a combination of
extrinsic and intrinsic factors. Current treatments have limited success preventing disease
progression, and this failed regeneration presents a major barrier to restoring vision.
Previous research has demonstrated that manipulation of the phosphoinositide 3-kinase
(PI3K) pathway by transgenic knockout of phosphatase and tensin homolog (PTEN) promotes
survival and regeneration of murine RGC axons in an optic nerve crush (ONC) model.
However, translation issues are yet to be addressed. PI3K converts phosphatidylinositol (3,4)-
bis-phosphate (PIP2) lipids to phosphatidylinositol (3,4,5)-tris-phosphate (PIP3). PTEN acts
as a pathway regulator, converting PIP3 back into PIP2. PIP3 is a second messenger molecule
for several pathways, including the mammalian target of rapamycin (mTOR) pathway, which
has been demonstrated to promote axon regeneration in RGCs, the spinal cord, and cortical
neurons. The PI3K pathway is activated by growth factors, integrins and cytokine receptors.
Integrins have also been shown to promote axon regeneration via the focal adhesion kinase
pathway.
This thesis aimed to determine the effects on axon regeneration of manipulating the PI3K
pathway in various ways. A transgenic approach was adopted to conditionally express the
hyperactive p110α and p110δ PI3K isoforms using viral Cre recombination. Both survival
and axon regeneration were significantly increased 4 weeks post-ONC injury in young and
aged mice. No significant difference between the two isoforms was observed, except that
p110α promoted RGC survival in aged mice whereas p110δ had no significant effect. This
was developed further using viral vectors to upregulate PI3K and to knockdown PTEN
for a more translational approach: AAV2.shPTEN.GFP and AAV2.PI3K(p110δ ). PTEN
vi
knockdown promoted both RGC survival and axon regeneration, while PI3K upregulation
promoted axon regeneration. No significant difference in axon regeneration was seen between
the two strategies. Where regeneration was seen, activation of the mTOR pathway was
demonstrated.
It is becoming increasingly clear that strategies need to be combined to achieve
long-distance, robust regeneration. In this thesis, PI3K upregulation was combined with
PTEN knockdown and then with integrin activation using AAV2.Integrin.V5 and
AAV2.Kindlin.GFP viruses. While PI3K upregulation and PTEN knockdown promoted RGC
survival and axon regeneration compared to control, this was not significantly more than
PI3K upregulation alone. The experiments involving integrin activation were unsuccessful
and the viruses need to be investigated further.
While the field has achieved small numbers of regenerating axons up to the optic chiasm,
key challenges for future work are reaching central targets in the brain and assessing axon
regeneration in an aged model to better reflect the clinical setting, where neurodegenerative
diseases predominately affect the aging population.
In summary, the work in this thesis investigated the pro-regenerative effects of potential
gene therapy targets, advancing our knowledge for developing future clinical strategies.
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Chapter 1
Introduction
1.1 The Visual System: Anatomy and Pathology
1.1.1 The Retina
Within the visual system, the eyes detect light and convert it into electro-chemical impulses
for processing in the brain. Light enters the eye through the cornea and is focused onto the
retina, which is made up of six layers of five neuronal cell types: photoreceptors, horizontal
cells, bipolar cells, amacrine cells, and ganglion cells, as illustrated in Fig. 1.1A[82]. The
light passes through the retina to its most distal point, where it is absorbed by photopigment
in the photoreceptors, known as rods and cones, altering their membrane potential. This
signal is then transmitted to bipolar cells and on to ganglion cells. These three neuronal cell
types are organised into distinct layers to facilitate the vertical flow of information, with the
cell bodies of photoreceptors, bipolar cells, and ganglion cells found in the outer nuclear
layer, the inner nuclear layer, and the ganglion cell layer respectively. The processes and
synaptic contacts of the photoreceptors and bipolar cells are found in the outer plexiform
layer, while those of the bipolar and ganglion cells are found in the inner plexiform layer.
In addition to the vertical flow of information, horizontal and amacrine cells mediate
lateral interactions[82]. Their cell bodies are located in the inner nuclear layer with the
bipolar cells. The processes of horizontal cells are found in the outer plexiform layer, while
the processes of amacrine cells are found in the inner plexiform layer. At the most proximal
point of the retina, the nerve fibre layer is made up of the ganglion cell axons, more commonly
referred to as retinal ganglion cell (RGC) axons.
Several subtypes of each of these neuronal cell types exist, which accounts for the
diversity and complexity of information conveyed to central targets in the brain. About 40
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subtypes of RGCs have now been identified, with differences in morphology, localisation,
function, susceptibility to degeneration, and regenerative capacity[86].
In addition to neuronal cells, the retina also contains three glial cell types: Müller cells,
astrocytes, and microglia. These glial cells maintain neuronal health and homeostasis, includ-
ing providing structural support and playing a role in metabolism, phagocytosis of debris,
and release of certain transmitters[99]. Müller cells account for 90% of retinal glia. Their
cell bodies reside in the inner nuclear layer and their processes project in either direction,
ensheathing the cell bodies and processes of the retinal neurons. Müller cells have a range of
functions related to development, survival, and information processing [85, 11]. Astrocytes
are mainly found in the nerve fibre layer of the retina, ensheathing the axons, where they
have several functions including providing neurotrophic support and enhanced mechanical
support in degenerating axons[99]. Both Müller cells and astrocytes also surround blood
vessels and are involved in the maintenance of the blood-retina barrier [84, 43]. Microglia
are found throughout the retina and play a key role in the immune response[106], as well as
tissue homeostasis[36].
1.1.2 The Central Targets of Retinal Ganglion Cells
RGC axons exit the retina and extend towards central targets in the brain, forming a bundle
referred to as the optic nerve, as illustrated in Fig. 1.1B[82]. The two optic nerves converge at
the optic chiasm, which is located behind the hypothalamus. In humans, approximately 60%
of axons from each nerve exit the chiasm contralaterally and 40% exit ipsilaterally, forming
the two optic tracts, which therefore contain input from both eyes[82]. Axons from the optic
tracts have a few targets in the brain involved in circuitry for different functions, including
vision, pupillary light reflex, regulation of the day/night cycle, and coordination of head
and eye movements. The primary visual pathway is referred to as the retinogeniculostriate
pathway. In this pathway, axons of the optic tracts connect to the lateral geniculate nuclei,
located in the thalamus, from which they ultimately terminate at the primary visual cortex,
where the initial light signal is perceived as sight[82].
1.1.3 Optic Nerve Pathology
According to data from 2015, approximately 1.3 billion people worldwide were visually
impaired to varying degrees, due to several conditions, including uncorrected refractive
errors, cataracts, diabetic retinopathy, and optic nerve disorders, like glaucoma[10]. Of these,
217 million people had moderate to severe impairment, and 36 million were blind. With
an ever-increasing and aging population, these numbers are set to increase. Glaucoma, the
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Fig. 1.1 Anatomy of the Visual System. In panel A, the neuronal cell types and their
arrangement within the retina are illustrated (image from [82]). In panel B, the basic anatomy
of the visual pathway is shown (image adapted from [98].)
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leading cause of irreversible blindness, is due to affect approximately 80 million people by
2020, increasing from 6.9 million moderate to blind cases in 2015, up to a predicted 7.7
million moderate to blind cases in 2020[30].
Optic nerve disorders result in damage to the RGCs and their axons, which make up
the optic nerves, resulting in vision loss. There are many optic nerve disorders, including
glaucoma, optic neuritis, and optic nerve atrophy. The most prevalent is glaucoma, which is
an umbrella term for a group of optic nerve diseases, often linked to a build-up of intraocular
pressure[101]. Optic neuritis is inflammation of the optic nerve and can be caused by
infections and autoimmune conditions, like multiple sclerosis[22]. Optic nerve atrophy
can be hereditary or caused by environmental factors, like trauma and exposure to toxic
substances[74].
In glaucoma, elevated intraocular pressure is often associated with optic nerve damage,
although some patients with glaucoma never have eye pressures outside the statistically
normal range and the full aetiology of the condition has not been elucidated[101]. Other
risk factors include age, race, and family history. Current methods for diagnosis are visually
examining the optic nerve for characteristic changes, monitoring intraocular pressure, and
performing visual field tests. However, in the initial stages of disease, the majority of patients
have no symptoms because the brain compensates for vision loss. It is only when a sufficient
number of neurons have been lost, that loss of peripheral vision develops, followed by
progressive blindness. This delays diagnosis and therefore, treatment. Regular opticians
appointments are recommended to catch the disease early, but this is less feasible in the
developing world.
Sustained reduction in pressure has been shown to slow glaucoma progression, preventing
RGC death, optic nerve damage, and subsequent vision loss[32, 102, 14]. This forms the
basis of current treatments, which are eye drops or surgery[67]. Eye drops can reduce the
formation of fluid in the eye or increase its outflow. However, these daily drops require patient
cooperation and can have side effects, including stinging, redness, and irritation[71, 91].
Laser surgery can be used to remove fluid blockage and increase the outflow of fluid from the
eye. Trabeculectomy is a microsurgery which involves creating a new channel to drain the
fluid from the eye. These surgeries carry risks of infection, and temporary, or even permanent,
vision loss. They also require highly trained surgeons and medical care, so they are not
easily accessible in the developing world[50, 52, 33]. Unfortunately, all these treatments
have limited success in preventing disease and in many cases, the disease continues even
after pressure returns to normal. At present, there are no treatments to restore vision loss due
to the weak regenerative capacity of RGCs, as described in Chapter 1.1.4.
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Future treatments aim to address these issues using gene therapy to both prevent disease
progression and restore vision loss, with the advantage that a single injection can deliver
long-term effects. This is particularly viable in the field of ophthalmology because the eye
is easily accessible and is an immune-privileged site. Many genes have been associated
with an increased risk of glaucoma, providing potential targets. However, focus on broader
cell signalling pathways is a more feasible approach for maximising reach to patients. To
date, such methods have focused on either reducing intraocular pressure[9, 73] or providing
neuroprotection to RGCs[76, 64]. In Wu et al., I was involved in disrupting aquaporin
1, a gene involved in aqueous humour production, using the CRISPR-Cas9 system[104].
This approach resulted in a significant reduction in intraocular pressure in mice, with some
promising ex vivo human data. In this thesis, I focus on promoting neuroprotective and
pro-regenerative effects in RGCs, providing fundamental knowledge that may help guide
clinical trials.
1.1.4 Injury to Retinal Ganglion Cells
The retina and optic nerve are an extension of the central nervous system (CNS), along with
the brain and spinal cord. During development, CNS axons grow and are guided to form
connections with their targets using numerous guidance cues, which can either be permissive
or inhibitory. However, once matured, the intrinsic factors promoting growth become less
abundant, and inhibitory extrinsic factors are switched on, preventing cellular overgrowth.
As a result, axons in the adult mammalian CNS have a weak capacity for regeneration after
injury. This creates a challenge for treatments for diseases involving vision impairment,
spinal cord injury, and neurodegeneration.
In contrast, peripheral nervous system (PNS) axons maintain regenerative potential
throughout adult life. The primary reasons for this are that PNS neurons can mount a
regenerative response[83, 87, 92] and they support efficient transport of growth-promoting
receptors[3, 44], both of which are downregulated in mature CNS axons. In addition, the
glial environment of the mature CNS is different from that in the PNS and the embryonic
nervous system, and this has been shown to play a role in inhibiting axon regeneration[108].
By two weeks post-ONC injury, approximately 80% of RGCs die and less than 1% of
those that survive extend axons beyond the crush site [79, 62]. As mentioned above, about
40 RGC subtypes have now been identified, with differences in susceptibility to damage and
ability to regenerate[86]. Duan et al. identified 11 different subtypes of RGCs using immuno-
histochemical and transgenic approaches and assessed their response to ONC injury[23].
Alpha RGCs (α-RGCs) are the largest RGCs, with at least three subsets, whilst W3-
RGCs are the smallest and most numerous RGCs, with at least two subsets (W3B and W3D).
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There are four groups of ON-OFF direction-selective RGCs (ooDSGCs), which are tuned
into motion in a single direction: ventral, dorsal, nasal, and temporal. The listed RGCs were
assessed, in addition to two subsets of intrinsically photosensitive RGCs (M1-RGCs and
M2-RGCs). α-RGCs showed the highest survival rate at 2 weeks post-ONC, followed closely
by M1-RGCs [23]. In contrast, M2-RGCs and ooDSGCs showed little, if any, survival.
However, the RGC axons degenerated regardless of their retinal soma [17].
Duan et al. used phosphatase and tensin homolog (PTEN) knockdown to promote axon re-
generation, a known pro-regenerative approach discussed in Chapter 1.2. Among survivors,
α-RGCs accounted for nearly all axon regeneration, with little, if any, regeneration from
M1-RGCs or the other subtypes [23]. The group then promoted regeneration by administering
a combination of osteopontin and insulin-like growth factor 1 (IGF-1), an equally effective
pro-regenerative approach discussed in Chapter 1.2. Again, α-RGCs accounted for nearly all
regeneration seen. The group investigated this mechanistically and found that α-RGCs have
high endogenous levels of mammalian target of rapamycin (mTOR) activity, a key pathway
involved in the pro-regenerative effect of PTEN knockdown. α-RGCs also selectively express
both osteopontin and IGF-1 receptors. This explains why α-RGCs respond favourably to
these two pro-regenerative approaches. Future work needs to assess the regenerative ability
of RGC subtypes using a variety of pro-regenerative approaches.
1.2 Targeting Extrinsic Factors to Promote Axon Regener-
ation
One approach for promoting CNS axon regeneration has been the targeting extrinsic fac-
tors that inhibit regeneration. These extrinsic factors can either be inhibitory guidance cues
involved during development that persist in the mature CNS or components of the glial envi-
ronment, including myelin-associated inhibitors and proteoglycans associated with astroglial
scarring [108].
As the CNS matures, oligodendrocytes ensheath the axons with myelin to prevent aber-
rant sprouting and protect the neural networks formed. After injury, the myelin structure
can become damaged, exposing severed axons to myelin-associated inhibitors, such as
Nogo-A, myelin-associated glycoprotein (MAG), and oligodendrocyte myelin glycoprotein
(OMgp)[108]. Both Nogo-A and MAG are expressed by CNS oligodendrocytes [38, 46, 89],
whilst OMgp is enriched in membranes of oligodendroglia-like cells that encircle nodes
of Ranvier [45]. Inhibitory axon guidance cues involved in pathway-finding during devel-
opment have also been found in CNS myelin, including the transmembrane semaphorin
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4D (Sema4D/CD100)[68] and Ephrin B3[7]. All these factors inhibit axon regeneration,
although their respective contributions remain unclear.
Glial scar-derived inhibitors also limit axon regeneration. After CNS injury, microglia,
oligodendrocyte precursors, meningeal cells, and astrocytes are recruited to the lesion
site[108]. Whilst some astrocytes promote regeneration [28], others become reactive and
release inhibitory extracellular matrix molecules known as chondroitin sulfate proteoglycans
(CSPGs) [65]. During development, astrocytes express CSPGs to limit structural changes
in the maturing CNS. When CSPG expression is upregulated by these reactive astrocytes
after injury, it forms an inhibitory gradient and therefore prevents axon regeneration. The
mechanisms by which CSPGs exert their inhibitory effects are not entirely clear.
Both genetic deletion and pharmacological interventions have been used to block these
inhibitory pathways, targeting either myelin-associated inhibitors or glial scar-derived in-
hibitors [108]. Other studies have targeted the Nogo-66 receptor complex in an attempt to
neutralise all three major myelin-associated inhibitors[37, 29, 55], based on findings that
removal of the Nogo-66 receptor reduces neuronal responses to all three. Further studies
have targeted intracellular pathways common to myelin-associated inhibitors and CSPGs, for
example using C3 transferase to inhibit RhoA [20, 53]. Whilst these studies have shown some
success promoting regeneration, this has been limited [108]. Therefore, focus has shifted to
targeting intrinsic factors, like signalling molecules.
1.3 Targeting Intrinsic Factors to Promote Axon Regener-
ation: The PI3K Pathway
As mentioned, another approach for promoting CNS axon regeneration has been the targeting
of intrinsic factors, with a focus on broader cell signalling pathways to maximise patient
reach. One such pathway is the phosphoinositide 3-kinase (PI3K) pathway.
1.3.1 The PI3K Pathway
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases, which can be divided into
three classes based on sequence similarity, substrate specificity, and mode of activation[94,
41, 42]. In this thesis, I was interested in the class I PI3Ks, which function as heterodimers
with a catalytic subunit and a regulatory subunit. Activation of class I PI3Ks results in
conversion of the membrane phospholipid, phosphatidylinositol(3,4)-bis-phosphate (PIP2),
to phosphatidylinositol (3,4,5)-tris-phosphate (PIP3), as shown in Fig. 1.2. Phosphatase and
tensin homolog (PTEN) is the primary regulator of this pathway, converting PIP3 back into
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PIP2. PIP3 is a second messenger for several pathways, including the mTOR pathway, which
is known to promote cell growth.
The class I PI3K catalytic subunit has four isoforms; class IA includes p110α (gene
PI3KCA), p110β (gene PI3KCB), and p110δ (gene PI3KCD), and class IB includes p110γ
(gene PI3KCG)[94]. The different isoforms have distinct functions and are found at different
levels within different cell types[8]. For example, p110α and β have largely ubiquitous
distribution, whereas p110δ and γ are mainly found in immune cells, like lymphocytes and
neutrophils[42]. The exact role of these isoforms in neuronal cells had not been comprehen-
sively studied but was investigated by R. Eva and B. Nieuwenhuis, as described in Chapter
3.2. In brief, p110α and δ were shown to be essential for axon growth and regeneration
in both PNS and CNS neurons, whereas p110β and p110γ did not have significant roles in
these processes[5].
PI3K mediates signalling through growth factor, integrin, and cytokine receptors[41].
The class IA PI3Ks are activated when growth factors bind to receptor tyrosine kinases
(RTKs). The RTKs are a large family of receptors, including the insulin-like growth factor 1
(IGF-1) receptor (IGFR-1), which is activated by IGF-1, and the tropomyosin receptor kinase
B (TrkB) receptor, which is activated by brain-derived neurotrophic factor (BDNF).
Integrins are heterodimeric cell-surface receptors, consisting of an α and a β subunit[70].
Through different combinations of the α and β subunits, about 24 unique integrin receptors
are generated. When inactive, integrins have a bent conformation, which shifts into a straight
conformation following activation, allowing the integrin receptor to bind ligands in the
extracellular matrix. Integrins can be activated in several ways, including the binding of
kindlins and talins to their β subunit. Focal adhesion kinase (FAK) is recruited to activated
integrins, activating downstream proteins like paxillin and Src. Integrin-linked kinase (ILK)
is also activated by integrins and phosphorylates several downstream proteins, including
feeding into the PI3K pathway, as in Fig. 1.3.
The TrkB [105, 56, 59], IGF-1 [4, 77, 44] and integrin [81, 2] receptors all play an
important role during development so are highly upregulated, but they are absent from the
axons of mature corticospinal tract neurons to prevent uncontrolled cellular growth. Evidence
suggests that these receptors are not present at useful levels on mature RGC axons either[90].
In Osborne et al., delivery of BDNF to RGCs had neuroprotective effects, but these were
limited by the downregulation of TrkB receptors. Delivery of BDNF combined with TrkB
receptor showed more robust neuroprotection[76]. In Dupraz et al., they demonstrated that
IGFR is present at low levels in RGC cell bodies, but did not specifically assess levels
on their axons. They found that re-expression and activation of IGFR-1 are required for
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Fig. 1.2 The PI3K Pathway Class IA PI3Ks are activated by receptor tyrosine kinases. PI3K
then converts the membrane phospholipid, PIP2, into PIP3. PTEN is the primary pathway
regulator, converting PIP3 back into PIP2. PIP3 has several downstream signalling pathways,
including the mTOR pathway (panel B), which are simplified in this diagram. Figure adapted
from Hawkins et al. 2006 [41].
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Fig. 1.3 The PI3K Pathway and Integrin Activation In addition to RTKs, the PI3K path-
way can be also be activated by integrin and cytokine receptors. Integrin receptors activate
the PI3K pathway just downstream of PIP3, as shown in the schematic, as well as other
pathways including the FAK pathway. Integrin signalling is more complex but is highly
simplified in this diagram.
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axon regeneration[24]. Overall, these findings highlight the importance of the presence of
receptors when manipulating intracellular pathways.
1.3.2 PTEN Deletion Promotes Axon Regeneration
In Park et al.[79], Zhigang He’s lab compared the pro-regenerative effects of conditional
knockout of different cell growth control genes using Rb f/ f [63], P53 f/ f [63], Smad4 f/ f [107],
Dicer f/ f [40], LKB1 f/ f [6] and PTEN f/ f [39] mice. Adult mice were intravitreally injected
with an adeno-associated virus (AAV) expressing Cre (AAV.Cre), or AAV.GFP as a control, to
induce knockout, and optic nerve crush (ONC) was performed 2 weeks later. The percentage
survival of RGCs at 2 weeks post-ONC was estimated using immunostaining of retinal
wholemounts (RWMs) with β -III tubulin (Tuj1) antibody, or by prelabelling with FluoroGold.
Both techniques yielded similar results. The 20% RGC survival seen in the control group
significantly increased to about 45% in the PTEN knockout mice. To assess axon regeneration,
axonal fibres labelled with the anterograde tracer, cholera toxin subunit-β (CTB), were
examined in optic nerve sections across the lesion site. Robust regeneration along the optic
nerve was observed, with about 8 to 10% of the surviving RGCs in the PTEN knockout mice
showing regeneration beyond 0.5mm distal to the lesion site, with some extending beyond
3mm. This was also seen at later time points, with some fibres reaching the optic chiasm
at 4 weeks post-ONC. At 2 weeks post-ONC, approximately 1500 regenerating axons were
observed at 0.5mm from the crush site, which increased to 1750 axons at 4 weeks post-ONC.
Approximately 1000 regenerating axons were seen at 1.0mm for both time points. Of the
targets investigated, only PTEN deletion and P53 deletion resulted in increased RGC survival,
but only the PTEN deletion also increased axon regeneration. Therefore, PTEN deletion acts
upon mechanisms promoting RGC survival and overcoming inhibition of axon regeneration
after injury.
As mentioned above, PTEN is the primary regulator of the PI3K pathway, which has
several downstream targets including the mTOR pathway. Therefore, PTEN deletion pro-
motes PI3K/mTOR pathway signalling. Inhibition of the mTOR pathway by administering
rapamycin largely neutralised both the survival and regeneration effects observed in the
PTEN f/ f mice, although not completely. Conversely, constitutive activation of the mTOR
pathway by conditional knockout of a negative regulator of the mTOR pathway, tuberous
sclerosis complex I (TSC1), resulted in significant RGC survival and regeneration. However,
these effects were weaker than PTEN deletion. Both experiments demonstrated that mTOR
pathway activation plays a major role in the pro-regenerative effects seen from PTEN dele-
tion, but also indicate involvement from other pathways downstream of PTEN. The group
also used immunohistochemistry (IHC) for phospho-S6 ribosomal protein (pS6), an mTOR
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pathway marker, to confirm that mTOR pathway signalling is suppressed in mature adult
RGC neurons and upregulated following PTEN deletion. Suppression of the mTOR pathway
may limit protein synthesis, and reactivating this pathway would increase protein synthesis,
which is necessary for axon regeneration.
Having shown a pro-regenerative effect from PTEN deletion in the optic nerve, He’s
group went on to investigate this in other CNS axons. In Liu et al., they demonstrated that
transgenic PTEN deletion promotes regrowth, both due to sprouting and due to regeneration,
in adult corticospinal tract axons. Such a robust regenerative response had never been seen
before in the mammalian spinal cord[58].
While transgenic knockouts are useful for demonstrating proof of principle, non-genetic
methods allow translation and more flexibility for combining strategies. In Zukor et al.,
He’s lab used short hairpin RNA (shRNA) targeted against PTEN, packaged in an AAV,
to knockdown PTEN and significantly enhance regeneration following a crush spinal cord
injury[110]. It is worth noting that often RNA interference methods only partially suppress
the expression of target genes, as opposed to complete suppression by genetic deletion. This
shRNA was not assessed using the ONC model, so this was done as part of this thesis in
Chapter 4.
1.3.3 The Pro-regenerative Role of PIP3
Deletion of PTEN, as described above, reduces the breakdown of PIP3 into PIP2, thereby
increasing PIP3 levels and promoting its downstream effects, like mTOR pathway activation.
In Al-Ali et al., inhibition of S6 kinase 1 (S6K1) promoted neurite outgrowth in vitro and
stimulated corticospinal tract axon regeneration and locomotor recovery in vivo[1]. Like
PTEN, S6K1 has a negative feedback effect on PI3K signalling. The group showed that
inhibition of S6K1 promoted PI3K signalling, mediating the regenerative effect seen. Cosker
et al. reviewed the literature, highlighting the critical role of PI3K signalling in neuronal
development and axon growth[16]. These studies, as well as others, indicate a crucial role
for PI3K signalling, and therefore PIP3, in axon growth and regeneration[26, 109, 66, 25].
RNASeq data and the literature indicate that PI3K is downregulated in mature CNS
neurons, and that the receptors activating PI3K are also downregulated or absent in their
axons. Both factors would result in low PIP3 levels in mature neurons, which was confirmed
experimentally in Chapter 3.2[5]. Therefore, while deleting PTEN reduces the breakdown
of PIP3, it should be noted that PIP3 levels are very low to begin with. PTEN deletion
enhances regeneration through downstream signalling within the cell body, but it is not
known whether it also has effects within the axon. It may not have effects within the axon,
given the downregulation of PI3K-activating receptors in CNS axons. In this thesis, we
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aimed to take the PTEN deletion work further by targeting PI3K directly, bypassing the lack
of PI3K-activating receptors, and directly generating more PIP3 in both the cell body and
axons.
1.3.4 Integrin Activation Promotes Regeneration
As mentioned, integrins are highly upregulated in neurons during development but are
downregulated or completely absent in CNS axons once they mature. Integrins are involved
in several cellular processes, including axon regeneration in the PNS[31, 27], which has
made them targets for regeneration studies. Integrin α9 overexpression has been shown
to promote regeneration both in vitro and in vivo in a spinal cord injury model [2, 3, 12].
There are three isoforms of kindlin, which is one of the factors that activates integrins.
Kindlin-1 is not expressed in neurons, but its introduction into neurons has been shown to
promote axon regeneration both in vitro and in vivo using a spinal cord injury model[96, 12,
70]. Combination of integrin-α9 and kindlin-1 leads to more robust axonal regeneration,
exceeding that of either one individually[12].
1.4 Targeting Intrinsic Factors to Promote Axon Regener-
ation: Other Pathways
Beyond targeting the PI3K pathway, many other strategies have been shown to promote
axon regeneration. Suppressor of cytokine signalling 3 (SOCS3), a negative regulator of
the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway,
has been shown to promote regeneration[93]. Several polypeptide trophic factors have also
been investigated, including BDNF[62], fibroblast growth factor 2 (FGF2)[88] and ciliary
neurotrophic factor (CNTF)[69]. Of these, CNTF has been the most effective, and CNTF
released by glial cells showed robust regeneration and neuronal survival[80]. Administration
of either osteopontin or IGF-1 promoted regeneration in Duan et al.[23]. The pro-regenerative
effects of inflammation have also been demonstrated and found to be promoted by factors
like macrophage-derived growth factor, Oncomodulin, and zymosan, a glucan which induces
an inflammatory response[51].
While single target strategies have shown moderate regeneration along the optic nerve,
these have failed to provide robust long-distance regeneration into the brain. It has be-
come increasingly clear that simultaneously administering different approaches is required.
Several studies combining multiple strategies have shown long-distance regeneration, with
some functional recovery. These include a combination of PTEN deletion and SOCS3
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deletion[95], a combination of osteopontin and IGF-1[23], a combination of intraocular
inflammation, PTEN deletion, and elevation of intracellular cyclic adenosine monophosphate
(cAMP)[51], a combination of mTOR pathway activation and increased neural activity[57],
and a combination of PTEN deletion, zymosan, and cAMP[19].
1.5 Further Challenges in Axon Regeneration
1.5.1 Axon Regeneration to Restore Visual Function
Optic nerve disorders arise when RGCs and their axons are damaged by a range of stimuli,
resulting in vision loss. The ultimate aim for clinical intervention is to re-establish these
axonal connections and restore visual function, replicating the route RGC axons travel to
form the visual pathway during embryonic development. In brief, RGC axons extend from
the eye to the optic chiasm, and on to central targets in the brain.
As described above, initial studies using the ONC model showed successful axon regen-
eration partway along the optic nerve from strategies like PTEN deletion. However, these
axons failed to pass through the optic chiasm and into the brain[79]. In more recent studies,
long-distance regeneration into the brain has been achieved, with some partial functional
recovery [57, 51, 19, 80, 60]. For example, Lim et al. promoted regeneration using a combi-
nation of mTOR pathway activation and visual stimulation to increase neural activity[57].
Crucially, these studies have demonstrated target specificity, as RGC axons reconnected
with their appropriate targets in the brain and avoided incorrect targets, as was shown using
genetically-labelled RGCs in Lim et al.[57].
However, even in studies achieving longer distance regeneration, low numbers of axons
make it through the optic chiasm, and path-finding errors are common, including frequent
U-turns growing back towards the lesion site and misguidance into the contralateral optic
nerve[80, 79, 57, 51, 19, 60]. The extracellular environment of the optic chiasm and axonal
guidance have therefore come to the fore as key factors limiting the effects of pro-regenerative
stimuli, and these need to be further studied.
During development, axons are guided by several guidance cues expressed in a highly
organised spatiotemporal fashion. These guidance cues include glial markers, slits, CSPGs,
neutrins, semaphorins, laminin and multiple members of the Ephrin/Eph families. Interest-
ingly, the pathfinding errors of regenerating RGC axons are phenotypically similar to errors
documented in RGC axon development when key guidance cues are absent or ectopically
expressed[15].
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In Conceição et al., we aimed to identify whether key developmental guidance cues
were retained or lost in the adult optic chiasm and whether any of them were expressed
following injury. The guidance cues studied were radial glial cell marker (RC2), brain lipid-
binding protein (BLBP), and slit guidance ligand 1 (Slit1), which are three glial markers,
CSPGs, which is an extracellular marker, and pair box-containing gene (Pax2), which is a
developmental marker. In addition, the glial cell population of the optic chiasm was examined
[15]. Overall the study found differences in key axonal guidance cue expression between
embryonic and adult (uninjured) tissue and additional changes following injury. Despite
some potentially reparative responses early on, this signal had disappeared by 6 weeks
post-ONC, the point at which regenerating axons would reach the optic chiasm. This may be
part of the reason for small numbers of regenerating axons reaching the optic chiasm and the
misguidance seen in regeneration studies[51, 80, 19]. Future work should characterise more
guidance cues at more time points, as well as under regenerating conditions.
1.5.2 Addressing Age in Axon Regeneration Studies
While studies of mammalian CNS axon regeneration have focused on younger animals, the
majority of neurodegenerative diseases affect the aged population. However, the effect of
aging on CNS axon regeneration is not well understood and this needs to be addressed to
better match the clinical setting. Even PNS axons, which have a high regenerative potential,
are subject to an age-associated decline in regeneration[100]. This has been shown to be due
to neuron-extrinsic factors, including slower clearance of nerve and myelin debris[48, 78].
However, this has not been fully explained and neuron-intrinsic factors may also be involved.
Geoffroy et al. used a similar experimental model to Liu et al. to investigate the effects of
aging on axon regeneration in corticospinal tract (CST) and rubrospinal tract (RST) axons.
PTEN conditional knockout mice (PTEN f/ f ) received an AAV.Cre injection at either P1, 4
to 6 weeks old, 10 weeks old, or 12 to 18 months old, and CST regeneration was assessed
following injury. An age-dependent decline in axon regeneration was observed, with sig-
nificantly less regeneration in the 10 week group and little, if any, in the 12 to 18 month
group. RST regeneration was then assessed in (PTEN f/ f ) mice that received an AAV.Cre
injection at either 4 weeks old or 7 to 8 months old. A similarly diminished effect was seen.
To understand the mechanisms behind this, Geoffroy et al. assessed mTOR activation by
measuring pS6 levels and neuronal soma size. They found that PTEN deletion remained
effective in promoting mTOR activity based on these readouts in both CST and RST axons,
even in aged mice. As the neuron-intrinsic growth factors remain unaffected, this heavily
implicates neuron-extrinsic factors for the age-dependent decline observed. However, it is
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important to note that other aspects of the mTOR pathway or other intrinsic pathways were
not studied and may be affected by age.
Potential extrinsic factors that may affect regeneration in aged animals include changes
in the glial and fibrotic scar, inflammation, growth factor expression, and extracellular matrix
components[35]. In Geoffroy et al., IHC showed that both the astroglial and macrophage
response to injury were higher or more sustained in older mice compared to younger mice,
although this needs to be characterised further[34].
Neuron-intrinsic factors may also contribute to the age-dependent decline in regeneration.
For example, changes in receptor compositions and concentrations at the neuronal or axonal
surface can result in an enhanced response to an inhibitory external environment. The intrinsic
signalling and molecules in the cell can change as animals age, as epigenetics control the
expression levels of genes and their corresponding proteins. As highlighted, whilst pS6 levels
were unaffected in the Geoffroy et al. study, other aspects of PTEN-mTOR signalling may be
compromised in older animals, which needs to be investigated. For example, decreased levels
of p-Akt and p-GSK3β have been reported in the hippocampus of aged mice [75]. Other
pathways known to promote regeneration, like IGF and SOCS/STAT3 signalling, may be
altered in aged animals. Indeed, STAT3 levels are decreased in the aged human brain [13, 18].
Other intrinsic neuronal properties like neuronal viscosity, changes in axon transport, and
reduced mitochondrial activity may also be involved.
It is likely both intrinsic and extrinsic factors play significant roles in the age-dependent
decline of CNS axon regeneration and this needs to be further elucidated to better develop
treatments.
1.6 Objectives
The primary aim of this thesis was to investigate the effects of manipulation of the PI3K
pathway on axon regeneration.
The four PI3K isoforms were investigated in vitro by R. Eva and B. Nieuwenhuis.
Building on this work, the most relevant isoforms, p110α and p110δ , were tested in vivo
using a conditional transgenic approach and an ONC paradigm in Chapter 3. We hypothe-
sised that p110α and p110δ would promote axon regeneration in vivo, with no significant
difference between the two, as was seen in vitro.
In Chapter 4, a more translatable approach using viral PI3K(p110δ ) was trialed. This
was compared to viral PTEN knockdown, which had been tested with a spinal cord injury
model but not with an ONC model. We hypothesised that viral PI3K(p110δ ) would promote
survival and axon regeneration to a greater extend than viral PTEN knockdown, based on the
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fact that PI3K should increase PIP3 levels directly, whereas PTEN prevents the breakdown
of already low PIP3 levels. We also expected that viral PI3K(p110δ ) would be more effective
than the transgenic approach because inserting a transgene at the Rosa26 locus only leads to
moderate expression levels.
In Chapter 5, the PI3K(p110δ ) virus was combined with other strategies, like PTEN
knockdown and integrin activation. It was expected that combining strategies would have
a summative effect, as seen from other studies in the literature, and would further promote
regeneration than PI3K(p110δ ) individually.
The ultimate aim of this work was to investigate potentially translational methods that
may guide future clinical practice for optic nerve disorders.

Chapter 2
Methods
For each experimental chapter, a full set of methods is provided within that chapter, with
references to Chapter 2: Methods for more detail where appropriate.
2.1 Cell Culture Work
Before being used for in vivo experiments, the viral vectors in this thesis were tested in
human embryonic kidney (HEK) 293 cells.
2.1.1 Maintenance
HEK 293 cells were maintained using standard cell culture practice. The cells were grown in
Dulbecco’s modified eagle medium (DMEM) (Gibco, cat no. 41966-029) supplemented with
10% fetal calf serum, penicillin/streptomycin, and L-glutamate, and passaged every 2 or 3
days.
2.1.2 Preparing Cells for Transfection
Coverslips were sterilised in 100% ethanol and placed into a 24-well plate (one coverslip
per well). 500µL of freshly prepared poly-L-lysine (10g/mL) (Sigma, cat no. p1274) was
then added to each well and left to set for 30 minutes at room temperature. Coating the wells
in poly-L-lysine enhances cell adhesion. Two quick washes with phosphate-buffered saline
(PBS) were performed, and the plate was left to dry for 1 or 2 hours.
HEK 293 cells from a flask were harvested and resuspended in fresh medium. The viable
cells were counted using trypan blue and a haemocytometer, and the concentration of cells in
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Viral Construct Source Catalogue Number Stock Titre
AAV2.Cre.GFP Vector Biolabs 7016 1.00 x 1013GC/mL
AAV2.Cre.GFP SignaGen Labs SL100814 1.45 x 1013GC/mL
AAV2.GFP Vigene Biosciences CV10004 various
AAV2.shPTEN.GFP gifted by He lab N/A 3.94 x 1014GC/mL
AAV2.shScram.GFP SignaGen Labs SL100815 1.17 x 1013GC/mL
AAV2.shScram.GFP Vigene Biosciences P100042 1.20 x 1013GC/mL
AAV2.PI3K(p110δ ) produced for project N/A 2.04 x 1013GC/mL
AAV2.GFP Vigene Biosciences CV17169-AV2 various
AAV2.Integrin.V5 produced for project N/A 1.12 x 1013GC/mL
AAV2.Kindlin.GFP produced for project N/A 1.19 x 1013GC/mL
Table 2.1 Viral constructs used for transfection in HEK 293 cells
the medium was calculated. 150,000 cells were suspended in 500µL of medium for each
well of the poly-L-lysine-coated 24-well plate.
2.1.3 Viral Transfection of HEK 293 Cells
The following day, the viral vectors listed in Table 2.1 were diluted to a titre of 1.0 x 1013
genome copies per mL (GC/mL), using sterile PBS. The medium was removed from the
wells and replaced with 2mL of plain DMEM with 2µL of diluted viral vector, giving a final
titre of 1.0 x 1010GC/mL in the wells. This titre was the optimal titre for viral transfection
of HEK 293 cells found from dose-response experiments carried out by the Martin group.
Schematics of the viral constructs are provided in Chapter 2.3. In addition, three wells were
left untransfected (naive), and their medium was replaced with plain DMEM. The cells were
left for 72 hours, after which they were fixed with chilled 4% paraformaldehyde (PFA) for
1 hour. The wells were washed twice with PBS and were stored in PBS at 4°C, ready for
immunohistochemistry (IHC).
2.2 Ethics Statement
All animal research was conducted in accordance with UK Home Office regulations for the
care and use of laboratory animals, the Animals (Scientific Procedures) Act (1986), and the
University of Cambridge Animal Welfare and Ethical Review Body. Animals were housed in
light- and temperature-controlled conditions with freely available food and water.
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2.3 Intravitreal Injections
Mice were anaesthetised via intraperitoneal injection of ketamine (100mg/kg) and xylazine
(10mg/kg). Topical analgesics were applied to the eyes being injected, and eyes not being
injected were kept moist with viscotears. 2µL of solution was drawn up into a sterile 5µL
Hamilton syringe with a 33-gauge removable needle, and the solution was slowly injected
intravitreally. Before removing this needle, a sterile 33-gauge needle was used to puncture
the cornea and drain the anterior chamber, to reduce intraocular pressure and prevent reflux of
the injected solution. Between injections, the syringe was rinsed with 70% ethanol, followed
by PBS.
2.3.1 Injection of Viral Vectors or PBS
For the validation work specified in Chapters 3 to 5, young adult (6 to 16 weeks old)
mice received a 2µL intravitreal injection into the left eye of the treatment virus(es), and
a 2µL intravitreal injection into the right eye of the control virus(es). The viral vectors
were either commercially sourced, gifted, or produced in collaboration with Joost Verhaagen
(Netherlands Institute for Neuroscience, Amsterdam), as specified in Table 2.2. A schematic
of the viral constructs is shown in Fig. 2.1. All viruses for in vivo work were diluted to a
titre of 1.0 x 1013GC/mL with sterile PBS. This titre was the optimal titre for viral intravit-
real injections in mice found from dose-response experiments carried out by Dr Barber. In
Chapter 3, a few mice received a 2µL intravitreal injection of PBS into the left eye, while
the right eye was left uninjected (naive).
For the regeneration studies specified in Chapters 3 to 5, young adult (6 to 8 weeks old)
and aged adult (9 to 12 months old) mice received 2µL intravitreal injections into the left
eye of the viral vectors.
Multiple injections were required in Chapter 5, and these were performed either 4 days
or 1 week apart, as specified.
2.3.2 Injection of Cholera Toxin Subunit-β
In the regeneration studies in Chapters 3 to 5, 2 days before tissue collection, all mice
received a 2µL intravitreal injection into the left eye of cholera toxin subunit-β (CTB) with
an Alexa Fluor 555 conjugate (CTB-555) (Thermo Fisher Scientific, cat no. C22843). The
CTB-555 was diluted to 1.0mg/mL using sterile PBS.
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Fig. 2.1 A schematic of the viral constructs used in vivo. A. Cre recombination using Cre-
recombinase was driven by a CMV promoter (Ai) and its corresponding control construct
contained GFP (Aii). B. PTEN knockdown using shRNA (shPTEN) was driven by a U6
promoter (Bi) and its corresponding control construct contained a non-targeting scrambled
sequence (shScram) (Bii). Both constructs also contained a GFP viral tag, driven by a CMV
promoter. C. PI3K expression was driven by a CAG promoter (Ci), and its corresponding
control construct contained GFP (Cii). D. The viruses from panel B and C were used. E. The
viruses from panel C were used. Both integrin and kindlin expression were driven by a CAG
promoter. The constructs also contained a V5 or GFP viral tag.
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Viral Construct Source Stock Titre Mouse Strain Injected
AAV2.Cre.GFP Vector Biolabs 1.00 x 1013GC/mL p110αH1047R, p110δ ,
Cre-reporter,
C57BL/6J
AAV2.GFP Vigene Biosciences various p110αH1047R, p110δ ,
C57BL/6J
AAV2.shPTEN.GFP gifted by He lab 3.94 x 1014GC/mL p110αH1047R, p110δ ,
C57BL/6J
AAV2.shScram.GFP SignaGen Labs 1.17 x 1013GC/mL p110αH1047R, p110δ ,
C57BL/6J
AAV2.PI3K(p110δ ) produced in lab 2.04 x 1013GC/mL C57BL/6J
AAV2.GFP Vigene Biosciences various C57BL/6J
AAV2.Integrin.V5 produced in lab 1.12 x 1013GC/mL C57BL/6J
AAV2.Kindlin.GFP produced in lab 1.19 x 1013GC/mL C57BL/6J
Table 2.2 Viral constructs used for intravitreal injections in vivo
2.4 Optic Nerve Crush Injury
Mice were anaesthetised via intraperitoneal injection of ketamine (100mg/kg) and xylazine
(10mg/kg) and received a subcutaneous injection of Carprieve as an analgesic. Both eyes
were kept moist with viscotears during and after the procedure. Optic nerve crush (ONC)
injury was performed as previously described[79]. In brief, the optic nerve was exposed
intraorbitally and crushed for 10 seconds with curved forceps approximately 1mm from the
eye so as not to cut off the retinal blood supply.
In the regeneration studies in Chapters 3 to 5, ONC injury was performed 2 weeks after
the final intravitreal injection.
2.5 Cardiac Perfusion
Mice were intraperitoneally injected with a fatal dose of euthatol (sodium pentobarbitone,
0.3mL per mouse). Shortly after, the mice were transcardially perfused with PBS to flush out
the blood and then with 4% PFA to fix the tissue. All tissue collection and dissections were
performed on the day of perfusion.
In Chapters 3 to 5, mice from the regeneration studies were perfused 4 weeks post-ONC,
and mice for the validation work were perfused 2 weeks after the final intravitreal injection,
the point at which they would receive an ONC injury in regeneration studies.
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2.6 Tissue Collection
2.6.1 Optic Nerves
In the regeneration studies in Chapters 3 to 5, mice were perfused, and the optic nerves were
carefully dissected and laid flat on a strip of filter paper (Millipore, cat no. AABG01300) to
help keep them straight. The nerves and filter paper were placed into a 1.5mL Eppendorf
tube and post-fixed in 4% PFA at 4°C overnight. The nerves were then transferred to 30%
sucrose for at least 24 hours for cryoprotection. The nerves were mounted onto a block of
Tissue-Tek OCT compound and cryosectioned (14µm longitudinal sections) using a Leica
cryostat (Leica Biosystems, CM 3050S Research Cryostat). Slides were dried for about 1
hour at room temperature and stored at -20°C.
2.6.2 Eyes: Retinal Sections
In the validation work in Chapters 3 to 5, mice were perfused, and whole eyes were collected,
post-fixed in 4% PFA at room temperature for 2 hours, and then transferred to 20% sucrose
overnight at 4°C for cryoprotection. The eyes were then embedded in Tissue-Tek OCT
compound and cryosectioned (12µm thick) using a Leica cryostat (Leica Biosystems, CM
3050S Research Cryostat). Slides were dried for about 1 hour at room temperature and stored
at -20°C.
2.6.3 Eyes: Retinal Wholemounts
In the regeneration studies in Chapters 3 to 5 and in the validation work in the Cre-reporter
mouse line in Chapter 3, mice were perfused, and whole eyes were collected. The retinas
were extracted, and four small incisions were made to form retinal wholemounts (RWMs).
RWMs were collected into a 24-well plate (one RWM per well) and post-fixed in 4% PFA for
2 hours. After this, the solution was replaced with PBS, and the plates were stored at 4°C.
2.6.4 Eyes: Retinas for Western Blots
In the validation work in Chapter 3, mice were culled by a rising concentration of carbon
dioxide and cervical dislocation. Whole eyes were immediately removed, and the retinas were
extracted, collected into 1.5mL Eppendorf tubes, and put on dry ice, ready for processing.
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2.7 Immunohistochemistry
All antibodies mentioned below are summarised in Table 2.3. The IHC protocols and anti-
body concentrations used were found within the Martin group by trial and error to produce
optimum results. For each antibody, a negative control using no primary antibody was
performed, along with positive controls where appropriate.
2.7.1 Histology in HEK 293 Cells
Each of the viral vectors used in this thesis was tested in HEK 293 cells before being used in
vivo. Viral-transfected HEK 293 cells were fixed in a 24-well plate and then counterstained
with DAPI (1:10,000). Where appropriate, they were also immunostained for the viral tags,
phosphoinositide 3-kinase (PI3K)(p110δ ) or V5.
Keeping the HEK 293 cells in the 24-well plate, the cells were washed three times with
PBS for 10 minutes each. For PI3K(p110δ ) IHC, the cells were blocked in 2% bovine
serum albumin (BSA), 5% normal goat serum (NGS) in 0.3% PBS-TritonX100 for 1 hour
at room temperature. For V5 IHC, the cells were blocked in 3% BSA, 5% NGS in 0.4%
PBS-TritonX100 for 2 hours at room temperature. Primary antibodies for PI3K(p110δ )
(rabbit, 1:500, Abcam, cat no. ab1678) and V5 (mouse, 1:300, Invitrogen, cat no. R96025)
were diluted in blocking solution for overnight incubation at 4°C.
The following day, the HEK 293 cells were washed three times with PBS for 10 min-
utes each, 20 minutes for V5. Goat anti-rabbit IgG (H+L) with Alexa Fluor-555 (1:1000,
Invitrogen, cat no. A21428) and goat anti-mouse IgG (H+L) with Alexa Fluor-555 (1:1000,
Invitrogen, cat no. A21424) were used as secondary antibodies for a 2 hour incubation period
at room temperature, while counterstaining with DAPI (1:10,000). The HEK 293 cells were
washed three times with PBS for 10 minutes each, 20 minutes for V5. Finally, the coverslips
were carefully removed from the 24-well plates and mounted onto slides with Fluorsave
reagent (Millipore, cat no. 345789).
2.7.2 Histology in Retinal Sections
In Chapters 3 to 5, IHC was used to identify viral tags, with antibodies against green
fluorescent protein (GFP), PI3K(p110δ ) or V5, or retinal ganglion cells (RGCs), with
antibody against β III tubulin (Tuj1). IHC was also used to quantify mammalian target of
rapamycin (mTOR) pathway activity, with antibodies against phospho-AKT (pAKT) and
phospho-S6 ribosomal protein (pS6). In Chapter 4, IHC was used to quantify phosphatase
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and tensin homolog (PTEN) knockdown, with antibody against PTEN, and PI3K upregulation,
with antibody against PI3K(p110δ ).
All slides were washed three times with PBS for 10 minutes each, except for V5-stained
slides, which were washed for 15 minutes each. For GFP, PI3K(p110δ ), Tuj1, pAKT, and
pS6 IHC, sections were blocked with 2% BSA, 5% NGS in 0.3% PBS-TritonX100 for 1
hour at room temperature. For V5 IHC, sections were blocked with 3% BSA, 5% NGS
in 0.4% PBS-TritonX100 for 2 hours at room temperature. For PTEN IHC, sections were
blocked with 2% BSA, 10% NGS in 0.3% PBS-TritonX100 for 1 hour at room temperature.
The primary antibodies were diluted in blocking solution for incubation at 4°C overnight:
GFP (rabbit, 1:500, Abcam, cat no. ab290), PI3K(p110δ ) (rabbit, 1:500, Abcam, cat no.
ab1678), V5 (mouse, 1:200, Invitrogen, cat no. R96025), Tuj1 (mouse, 1:400, Promega, cat
no. G7121), pAKT (Thr308) (D25E6) XP (rabbit, 1:200, Cell Signaling Technology, cat no.
13038), pS6 (Ser235/236) (91B2) (rabbit, 1:200, Cell Signaling Technology, cat no. 4857),
and PTEN (D4.3) XP (rabbit, 1:100, Cell Signaling Technology, cat no. 9188).
The next day, slides were washed three times with PBS for 10 minutes each, except for
V5-stained slides, which were washed for 20 minutes each. Goat anti-rabbit IgG (H+L) with
Alexa Fluor-488 (1:1000, Invitrogen, cat no. A11034), goat anti-rabbit with Alexa Fluor-555
(at double the primary antibody concentration, Invitrogen, cat no. A21428), goat anti-mouse
IgG (H+L) with Alexa Fluor-488 (1:1000, Invitrogen, cat no. A32723), goat anti-mouse
IgG (H+L) with Alexa Fluor-555 (1:500, Invitrogen, cat no. A21424), goat anti-mouse IgG
(H+L) with Alexa Fluor-647 (1:1000, Invitrogen, cat no. A21235) were used as secondary
antibodies for a 2 hour incubation period at room temperature, whilst also counterstaining
with DAPI (1:10,000). The slides were washed three times with PBS for 10 minutes each,
except for V5-stained slides, which were washed for 20 minutes each. Coverslips were
placed over the tissue with Fluorsave reagent (Millipore, cat no. 345789) and the slides were
stored at 4°C.
2.7.3 Histology in Retinal Wholemounts
In Chapters 3 to 5, IHC using an antibody against Brn3A, an RGC marker, was used to
quantify RGC survival in RWMs following ONC injury. As described above, RWMs were
collected into a 24-well plate and post-fixed in 4% PFA. The PFA was removed and replaced
with PBS.
Keeping the samples in the 24-well plate, free-floating RWMs were washed four times
with 0.5% PBS-TritonX100 for 10 minutes each. All steps were performed on a rocking
plate at slow speed. In between the second and third wash, the retinas were frozen in 0.5%
PBS-TritonX100 for 10 minutes at -70°C. The freezing permeates the nuclear membrane,
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improving antibody penetration for Brn3A, which is a nuclear protein. The washes were
resumed after thawing. The RWMs were then blocked with 2% BSA, 10% normal donkey
serum (NDS) in 2% PBS-TritonX100 for 1 hour at room temperature. Brn3A (C-20) (goat,
1:200, Santa Cruz Biotechnology, cat no. sc-31984) was diluted in blocking solution for a 2
hour incubation at room temperature, followed by overnight incubation at 4°C.
The next day, the RWMs were washed once with 2% PBS-TritonX100 for 5 minutes
and three times with 0.5% PBS-TritonX100 for 30 minutes each. Donkey anti-goat IgG
(H+L) with an Alexa Fluor-647 (1:500, Invitrogen, cat no. A21447) was used as secondary
antibody, diluted in 2% PBS-TritonX100 for a 2 hour incubation period at room temperature.
Samples were then washed three times for 30 minutes in PBS and counterstained with DAPI
(1:10,000). Finally, the RWMs were mounted onto slides using Fluorsave reagent (Millipore,
cat no. 345789), with the RGC layer facing upward, and stored at 4°C.
2.8 Western Blots
Western blots of whole retinal lysate were used to confirm successful viral transduction,
using antibody against GFP, and to quantify mTOR pathway activity, using antibodies against
pAKT, mTOR, and pS6. The protocols and antibody concentrations used were found within
the Martin group by trial and error to produce optimum results.
2.8.1 Sample Preparation
As mentioned above, fresh retinal tissue was collected and stored on dry ice, ready for
processing. 100µL of freshly prepared lysis buffer, made using cOmplete™ Lysis-M EDTA-
free (Roche, cat no. 04719964001), was added to each tube. The tissue was homogenised
using a sterile pestle, and the samples were kept on ice for 15 minutes, before spinning them
down to separate the dissolved protein from insoluble components (13,000 revolutions per
minute (rpm) for 10 minutes at 4°C). The supernatant was collected from each sample, and
its protein concentration was quantified using a Pierce BCA Protein Assay Kit (Thermo
Scientific, cat no. 23227). Samples were stored at -20°C.
2.8.2 Electrophoresis
Western blots were performed using standard western blot protocol.
For each sample, 8µg of protein was made up to a total volume of 15µL, with 10%
NuPAGE Sample Reducing Agent (10x) (Invitrogen, cat no. NP0009) and 25% NuPAGE
LDS Sample Buffer (4x) (Invitrogen, cat no. NP0007) in water. A positive control for pS6
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Primary
Antibody
(Ab)
Secondary
Ab
Specificity Species Type Company Ab Di-
lution
Factor
GFP Goat
α-rabbit,
AF555+488
GFP Rabbit Polyclonal Abcam 1:500
V5 Goat
α-mouse,
AF555
V5-tag Mouse Monoclonal Invitrogen 1:200
Tuj1 Goat
α-mouse,
AF488+647
neuronal
cells
(including
RGCs)
Mouse Monoclonal Promega 1:400
PI3K(p110δ ) Goat
α-rabbit,
AF555
PI3K(p110δ ) Rabbit Polyclonal Abcam 1:500
PTEN Goat
α-rabbit,
AF555
PTEN Rabbit Monoclonal Cell Sig-
naling
Tech
1:100
phospho-
AKT
(Thr308)
(D25E6) XP
Goat
α-rabbit,
AF555
pAKT Rabbit Monoclonal Cell Sig-
naling
Tech
1:200
phospho-S6
(Ser235/236)
(91B2)
Goat
α-rabbit,
AF555
pS6 Rabbit Monoclonal Cell Sig-
naling
Tech
1:200
Brn3A Donkey
α-goat,
AF647
RGCs Goat Polyclonal Santa
Cruz
Biotech
1:200
Table 2.3 Antibodies used for immunohistochemistry
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was prepared in the same way, using viral-transfected HEK 293 cells known to show strong
pS6 signal.
The samples were denatured at 70°C for 10 minutes, and proteins were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions. For GFP, pS6, PTEN, and PI3K(p110δ ), NuPAGE 4-12% Bis-Tris gels (1.5mm
x 15 well) (Invitrogen, cat no. NP0336) were used in NuPAGE MOPS SDS Running Buffer
(20x) (Invitrogen, cat no. NP0001) and water. For pAKT and mTOR, NuPAGE 3-8% Tris-
Acetate gels (1.0mm x 15 well) (Invitrogen, cat no. EA03755) were used in Tris-Acetate
SDS Running Buffer (20x) (Invitrogen, cat no. LA0041) and water. The inner chamber was
filled with running buffer plus 0.25% NuPAGE Antioxidant (Invitrogen, cat no. NP0005).
15µL of each sample was loaded, alongside 10µL of Precision Plus Protein Kaleidoscope
(Bio-Rad, cat no. 1610375) for GFP, pS6, PTEN, and PI3K(p110δ ), or alongside 10µL of
HiMark Pre-Stained HMW Protein Standard (Invitrogen, cat no. LC5699) for pAKT and
mTOR. The gels were run at 150V and 420A.
The gels were then transferred to a 0.45µm polyvinylidene difluoride (PVDF) membrane
(Invitrogen, cat no. LC2005), using a solution made from 5% NuPAGE Transfer Buffer
(Invitrogen, cat no. NP0006-1), 10% methanol and 0.1% antioxidant in water. The transfers
were run at 30V and 420A on ice.
Immunoblotting
All antibodies mentioned below are summarised in Table 2.4. Antibody concentrations were
found within the Martin group by trial and error to produce optimum results.
After transfer, the membranes were washed twice with PBS for 5 minutes each. All steps
were performed on a rocking plate at slow speed. Membranes were then incubated for 1
hour at room temperature in blocking solution, made from 5% milk in 0.2% PBS-Tween20
(PBST). For in vivo work, primary antibodies for GFP (rabbit, 1:1000, Abcam, cat no. ab290),
pAKT (T308) (D25E6) XP(R) (rabbit, 1:300, Cell Signaling Technology, cat no. 13038),
mTOR (7C10) (rabbit, 1:800, Cell Signaling Technology, cat no. 2983), pS6 (S235/236)
(91B2) (rabbit, 1:200, Cell Signaling Technology, cat no. 4857) and β -actin (rabbit, 1:1000,
Cell Signaling Technology, cat no. 4967) were diluted in blocking solution for overnight
incubation at 4°C. For in vitro work, primary antibodies for PTEN (D4.3) XP (rabbit, 1:1000,
Cell Signaling Technology, cat no. 9188), PI3K(p110δ ) (rabbit, 1:1000, Abcam, cat no.
ab1678) and β -actin (rabbit, 1:1000, Cell Signaling Technology, cat no. 4967) were diluted
in blocking solution for overnight incubation at 4°C.
The next day, membranes were washed three times with blocking solution for 10 minutes
each. The membrane was incubated with the secondary antibody, peroxidase-labelled goat
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anti-rabbit IgG (1:10000, Vector laboratories, cat no. PI-1000), in blocking solution for 2
hours at room temperature. The membrane was washed twice with blocking solution for
10 minutes each and once with 0.2% PBST for 10 minutes. ECL Prime western blotting
detection reagent (GE Healthcare Amersham, cat no. RPN2232) was added to the membranes
for 5 minutes before imaging.
The immunoblotting method for pS6 had been used successfully in the lab for HEK
293 cells, and in my experiments, pS6 signal was detected from the HEK 293 cell-positive
control. However, pS6 signal was not detected in whole retinal lysate. In an attempt to see
signal, I tried an alternative protocol using tris-buffered saline (TBS) instead of PBS.
After transfer, membranes were washed with TBS twice for 5 minutes each. Membranes
were blocked in 5% milk in 0.1% TBS-Tween20 (TBST) for 1 hour at room temperature.
The membrane was washed three times with 0.1% TBST for 5 minutes each. The primary
antibodies for pS6 (S235/236) (91B2) (rabbit, 1:200, Cell Signaling Technology, cat no.
4857) and β -actin (rabbit, 1:1000, Cell Signaling Technology, cat no. 4967) were diluted in
5% BSA in 0.1% TBST for overnight incubation at 4°C.
The next day, membranes were washed three times with TBST for 5 minutes each. The
membranes were incubated with the secondary antibody, peroxidase-labelled goat anti-rabbit
IgG (1:10000, Vector laboratories, cat no. PI-1000), in 5% BSA in 0.1% TBST for 2 hours at
room temperature. The membrane was washed three times with 0.1% TBST for 5 minutes
each.
2.9 Microscopy and Quantification
Immunofluorescence was analysed using fluorescence microscopy (Leica, DM6000 and
DMi8) and confocal microscopy (Leica, SPE and Sp5). Where stated, some images were
taken using a Zeiss AxioScan Z1 by the Histopathology/ISH core facility at the Cancer
Research UK (CRUK) Cambridge Institute.
2.9.1 Viral Transfection In Vitro
HEK 293 cells transfected with each viral vector were counterstained with DAPI, and where
appropriate, were immunostained for the viral tag markers, PI3K(p110δ ) and V5. These
were imaged by confocal microscopy at x40 magnification. The images were used to confirm
that the appropriate viral tag was observed and that this signal was not seen in untransfected
cells.
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Primary
Antibody (Ab)
Species Type Company Ab Dilution
Factor
Molecular
Weight (kDa)
GFP Rabbit Polyclonal Abcam 1:1000 27
β -actin Rabbit Polyclonal Cell Signaling
Technology
1:1000 45
phospho-AKT
(Thr308)
(D25E6) XP
Rabbit Monoclonal Cell Signaling
Technology
1:200 60
mTOR Rabbit Monoclonal Cell Signaling
Technology
1:800 289
phospho-S6
(Ser235/236)
(91B2)
Rabbit Monoclonal Cell Signaling
Tech
1:200 32
PTEN Rabbit Monoclonal Cell Signaling
Technology
1:1000 54
PI3K(p110δ ) Rabbit Polyclonal Abcam 1:1000 110
Table 2.4 Antibodies used for immunoblotting
2.9.2 Viral Transduction In Vivo
Successful viral transduction in vivo of AAV2.Cre.GFP and AAV2.GFP was confirmed in
western blots of whole retinal lysate by the presence of the viral tag, GFP.
Successful transduction of all viral vectors was confirmed in retinal sections injected
with each viral vector, immunostained for viral tag markers, GFP, PI3K(p110δ ), and V5,
and counterstained with DAPI. The presence of viral tag was confirmed, and eye cups were
imaged using a Zeiss AxioScan Z1 at x20 magnification (0.22µm/pixel) by the team at the
Histopathology/ISH core facility at the CRUK Cambridge Institute. Retinal sections were
imaged using confocal microscopy at x40 magnification.
2.9.3 RGC Survival
In Chapters 3 to 5, images of Brn3A-labelled RWMs were taken at x20 magnification using
fluorescence microscopy, sampling both the more central and more peripheral regions of
each of the four quadrants (eight images total). These images were analysed in Image J Fiji
(Fiji-win64) using The Image-Based Tool for Counting Nuclei (ITCN) Plugin (University
of California, Santa Barbara, CA, USA) for automated counting of Brn3A-positive cells
with the following settings: width 22, minimum distance 5 and threshold 0.1. Two custom
programs written by S. S. Deshpande were used to expedite the ImageJ analysis.
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J. Cave calculated the retinal surface area of several images and found that on average,
21.5% of the total retinal surface area was sampled by taking eight images. Therefore,
the sum of the RGC counts from the eight images was multiplied by 4.65 to calculate the
estimated total RGC count of the retina. The total RGC count in each ONC-injured (left) eye
was divided by the mean RGC count from all the uninjured contralateral control (right) eyes.
This value was then expressed as a percentage, referred to as percentage RGC survival.
2.9.4 Axon Regeneration
Prior to tissue collection, CTB-555 was intravitreally injected into eyes that had received
an ONC injury. This anterograde tracer was used to label regenerating axons for quantifica-
tion. The optic nerves were then collected and sectioned longitudinally (14µm thick) (t =
thickness of each section). Four nerve sections were analysed per animal.
The CTB-555-labelled axons were visualised using fluorescence microscopy at x40 mag-
nification. Axon regeneration was quantified by counting the number of CTB-labelled axons
extending from the end of the crush site at 0.5mm increments (ie. 0.5mm, 1.0mm, 1.5mm,
2.0mm...), as illustrated in Fig. 2.2. The crush site was identified using the characteristic
autofluorescent scar material of glia and macrophages. The cross-sectional width of the nerve
was also measured at each point at which the counts were taken and was used to calculate
the number of axons per millimeter of nerve width (n = number of axons counted/mm).
In addition, the maximum radius recorded across all four nerve sections at each 0.5mm
increment was noted (r = maximum radius).
Modelling the nerve as a cylinder, the total number of regenerating axons per nerve was
calculated for each nerve section at each distance from the end of the crush site using a
previously developed formula[54, 79]:
N =
nπr2
t
(2.1)
N = total number of regenerating axons per nerve
n = the number of axons counted/mm (eg. 10axons/mm)
r = the maximum radius recorded at that distance from the crush site (eg. 0.15mm)
t = thickness of each section (eg. 14µm = 0.014mm)
For each 0.5mm increment, the total number of regenerating axons per nerve was then
averaged from the four sections to give one result per animal.
Axonal sections were imaged using a Zeiss AxioScan Z1 at x40 magnification
(0.11µm/pixel) by the Histopathology/ISH core facility at the CRUK Cambridge Institute.
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Fig. 2.2 A diagram to illustrate quantification of axon regeneration.
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2.9.5 mTOR Pathway Activation in Retinal Sections
The RGC layer of retinal sections injected with each virus, immunostained for pAKT or
pS6, and counterstained with DAPI, was examined at x40 magnification by fluorescence
microscopy. 100 GFP-positive RGCs (identified using DAPI and GFP signal from the
viral vector(s)) were counted from retinal sections immunostained with pAKT and were
identified as either positive or negative for pAKT. This method was repeated for retinal
sections immunostained with pS6. Four mice were counted for each group (100 RGCs per
mouse), and the average was expressed as a percentage of GFP-positive cells co-localised
with pAKT or pS6. AAV2.PI3K(p110δ ) lacked a clear viral tag, so the total number of pS6-
positive RGCs was counted across the retina from 12 retinal sections sampled sequentially
throughout the whole eye, using Tuj1 as a marker of RGCs. This method was repeated for
AAV2.GFP-transduced retinal sections for comparison. The pAKT signal was not clear
enough to count in this way. Representative images were taken at x80 magnification by
confocal microscopy.
2.10 Statistics
All statistical tests were performed using GraphPad Prism 7.0 (GraphPad Software, La Jolla,
CA). Unpaired one-tailed T-tests were used to compare the effects of two groups which were
control versus treatment. Unpaired two-tailed T-tests were used to compare the effects of two
groups. One-way ANOVA with Tukey’s post-hoc analysis was used to compare the effects
of multiple groups. Two-way ANOVA with Tukey’s post-hoc analysis was used to compare
the effects of multiple groups with two variables (ie. axon regeneration). Asterisks indicate
significance levels on graphs: NS = no significance (p>0.05), * = p<0.05, ** = p<0.01, *** =
p<0.001, **** = p<0.0001. Data are presented as mean±standard deviation unless otherwise
stated. The statistical tests used, n values and error bars are specified on all graphs.
Chapter 3
Transgenic Manipulation of the PI3K
Pathway and its Effects on Axon
Regeneration
3.1 Declaration
The work presented in Chapters 3 and 4 of this thesis has been submitted to EMBO
Molecular Medicine for publication. At the time of thesis submission, we are responding
to reviewers’ comments. This work is cited in the thesis as: *Barber, A.C., *Evans, R.S.,
*Nieuwenhuis, B., Pearson, C.S., Fuchs, J., MacQueen, A.R., van Erp, S., Hänzi, B., Hulshof,
L-A., Osborne, A., Conceição, R., Deshpande, S.S., Cave, J., ffrench-Constant, C., Smith,
P.D., Okkenhaug, K., Eickholt, B.J., Martin, K.R., Fawcett, J.W., and Eva, R. (2020), PI3
kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS (not yet
published)[5]. * = the authors contributed equally.
The phosphoinositide 3-kinase (PI3K) in vitro data from this paper is summarised in
the introduction of this chapter, with appropriate referencing. The majority of the data
investigating the effects of the PI3K isoforms was generated by R. Eva and B. Nieuwenhuis.
Phospholipid fixation and labelling procedures were developed and performed by J. Fuchs
and R. Eva. S. van Erp performed laser axotomy procedures in human embryonic stem cell
neurons, supervised by C. ffrench-Constant.
The viral PI3K in vivo data from this paper is presented in the results section of Chapter
4, and acknowledgments are covered in that chapter’s declaration.
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The transgenic PI3K in vivo data from this paper is presented in the results section of this
chapter. The data in this chapter was generated by me, under the supervision of A.C. Barber,
with contributions from others declared below.
Transgenic mouse lines: A.R. MacQueen generated the conditional knock-in PI3K
mouse lines, supervised by K. Okkenhaug, and these were kindly donated to the Martin-
Fawcett group. At the time of thesis submission, these lines have not yet been published.
The hyperactive p110α (p110αH1047R) mouse line was derived and established from donated
founder mice by P.D. Smith and then maintained by C.S. Pearson. The p110δ mouse line
was derived and established from donated founder mice by R. Conceição and me. The
isolated p110δ mouse line was derived and established by me. From October 2016, all mouse
lines were maintained by me. Four Cre-reporter mice were kindly donated by C. Kapeni
(University of Cambridge).
p110αH1047R regeneration data (Part of Fig3.10, 3.11, 3.12 and 3.13): The
p110αH1047R regeneration data was generated by A.C. Barber, P.D. Smith, C.S. Pearson, J.
Cave, and R. Conceição. While I was not involved in the p110αH1047R regeneration study,
the data is presented in the results section of this chapter alongside my data for completeness,
with appropriate referencing in the text.
p110δ regeneration data: The p110δ regeneration data was generated by me under the
supervision of A.C. Barber. While I was learning the techniques, A.C. Barber performed
the initial ONC surgeries and taught me how to collect and analyse tissue for RGC survival
and axon regeneration. A.C. Barber also counted axon regeneration alongside me and we
compared values for accuracy and to check my counting technique. S.S. Deshpande created a
program to speed up RGC survival analysis and did some manual counting to compare with
data generated by the program. R. Conceição assisted with some retinal wholemounts during
tissue collection.
Validation data: All validation data, including testing the viral vectors in vitro and in
vivo, and quantifying mTOR pathway activity, was generated by me.
R. Eva wrote the manuscript. R. Eva, J.W. Fawcett, B.J. Eickholt, K. Okkenhaug, B.
Nieuwenhuis, S. van Erp, A.C. Barber and I edited the manuscript.
3.2 Introduction
3.2.1 The PI3K Pathway and Axon Regeneration
Key points from Chapter 1 are summarised below.
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The regenerative ability of central nervous system (CNS) neurons, including cortical
neurons, declines as they mature. However, this capacity is maintained throughout life by
peripheral nervous system (PNS) neurons, including dorsal root ganglion (DRG) neurons.
Phosphoinositide 3-kinase (PI3K) converts phosphatidylinositol(3,4)-bis-phosphate
(PIP2) to phosphatidylinositol (3,4,5)-tris-phosphate (PIP3). In the reverse, phosphatase and
tensin homolog (PTEN), converts PIP3 back into PIP2. PI3K is made up of a catalytic subunit
(p110) and a regulatory subunit, and there are four catalytic subunit isoforms: p110α , β , δ
and γ . The contribution of these isoforms to neuronal function had not been comprehensively
studied.
In the literature, PI3K has been implicated to play a role in the regulation of axon growth
and regeneration. Transgenic knockout of PTEN has been shown to have significant effects
on retinal ganglion cell (RGC) survival and axon regeneration in CNS neurons in vivo, using
optic nerve crush (ONC)[79] and spinal cord crush models[58]. This was demonstrated to be
primarily due to PI3K/AKT/mammalian target of rapamycin (mTOR) pathway activation.
PTEN knockout reduces the breakdown of PIP3, which is thought to be at low levels
in mature CNS neurons. In Barber et al., we hypothesised that upregulating PI3K directly
would lead to increased PIP3 production, and therefore a greater increase in PIP3 levels than
that seen from PTEN knockout. We expected this would lead to greater axon regeneration in
CNS neurons. The effects of the different PI3K isoforms on axon regeneration in PNS and
CNS neurons were compared in vitro, as described below, and then these were tested in vivo
using the ONC model.
3.2.2 The Effects of the Different PI3K Isoforms on Axon Regenera-
tion In Vitro
In Barber et al., R. Eva and B. Nieuwenhuis investigated the effects of the different PI3K
isoforms on axon regeneration in vitro, with some input from others as detailed in the
declaration section. Their data is summarised under this heading.
The p110α and p110δ isoforms of PI3K are required for axon regeneration in adult
DRG neurons in vitro
Consulting RNASeq databases, it was found that p110α , β and δ are expressed at all stages
in DRG neurons in vitro, while p110γ is at very low levels. Previous literature has shown
that p110δ is involved in axon regeneration in DRG neurons[25].
In Barber et al. (manuscript submitted, not yet published), the effects of the different
p110 isoforms of PI3K on axon regeneration were compared in rat adult DRG neurons. The
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following small molecule inhibitors against the different isoforms were used: A66 (inhibitor
of p110α), TGX221 (inhibitor of p110β ), IC-87114 (inhibitor of p110δ ), Idelalisib (inhibitor
of p110δ ), LY294002 (inhibitor of p110α , β and δ , referred to as pan-PI3K), and XL147
(inhibitor of p110α and δ ). The axons of adult DRG neurons were severed using laser
axotomy, under the effect of each of these inhibitors or dimethyl sulfoxide as a control.
Pan-PI3K inhibition reduced the rate of growth cone regeneration in severed axons and the
extension rate of uncut axons, as did inhibition of p110α and of p110α and p110δ combined.
Inhibition of p110δ affected growth cone regeneration in severed axons but had no effect on
uncut axons, whereas p110β had no effect on either.
Microfluidic compartmentalised chambers, in which axons extend through microchannels
into a separate compartment from the cell bodies, were used to investigate the localisation
of these effects. Inhibition of p110α in both the axonal and somatic compartments reduced
axon regeneration and increased the time taken to generate a new growth cone. Inhibition of
p110δ also reduced regeneration in the axonal compartment but interestingly had no effect
in the somatic chamber nor on the time to generate a new growth cone. Therefore, both the
p110α and p110δ isoforms of PI3K are necessary for efficient axon regeneration in adult
DRG neurons, whereas p110β is not. p110α is required throughout the neuron whereas
p110δ is specifically required within the axon.
The p110α and p110δ isoforms of PI3K promote axon growth in developing cortical
neurons in vitro
In Barber et al. (manuscript submitted, not yet published), the effects of overexpression of
p110α and p110δ on regulation of axon growth were compared in rat embryonic day 18
(E18) cortical neurons developing in vitro, as well as overexpression of a hyperactive p110α
H1047R mutant (p110αH1047R). p110αH1047R is an oncogenic point mutation, which has
been shown to enhance PIP3 production[61]. p110δ is rarely mutated in cancer. Previous
work has shown that p110αH1047R and p110δ can sustain downstream AKT activation
on overexpression in fibroblasts, while native p110α does not[49]. Overexpression of
p110αH1047R or p110δ led to an increase in axon length, dendrite length, the axon/dendrite
length ratio and the number of dendritic branches compared to green fluorescent protein
(GFP)-transfected controls. Downstream signalling through the PI3K/AKT/mTOR pathway
was confirmed by an increase in cell body size and increased levels of phospho-S6 ribosomal
protein (pS6) compared to GFP controls. Overexpression of native p110α had no effect.
Therefore, both p110αH1047R and p110δ behave similarly and enhance axonal and dendritic
growth.
3.2 Introduction 39
The p110α and p110δ isoforms of PI3K promote axon regeneration in mature cortical
neurons in vitro
In Barber et al. (manuscript submitted, not yet published), the effects of p110α , p110αH1047R
and p110δ on axon regeneration were compared in E18 cortical neurons using an in vitro
model of mature CNS regeneration. Laser axotomy was used to sever axons of cortical
neurons at a stage at which they have limited capacity for regeneration. Overexpression of
p110αH1047R or p110δ led to an increased percentage of regenerating axons, an increase in
length of regenerated axons, and a shorter time of onset to regeneration compared to controls.
Native p110α had no effect. Therefore, both p110αH1047R and p110δ behave similarly in
both developing and mature CNS neurons in vitro.
Overexpression of p110δ was also investigated in human neurons maturing in vitro
(human embryonic stem cells). This fully restored regenerative ability to that of young
neurons.
PIP3 levels are high in DRG neurons and immature cortical neurons, but are downreg-
ulated as cortical neurons develop. Both the p110αH1047R and p110δ isoforms of PI3K
increase PIP3 levels in cortical neurons.
Having investigated the effects of PI3K isoforms on axon regeneration, PIP3 levels were
assessed. In Barber et al. (manuscript submitted, not yet published), PIP3 immunostaining
was optimised and used to examine endogenous PIP3 levels in rat adult DRG neurons and in
rat E18 cortical neurons. High levels of PIP3 were detected in DRG growth cones and in
cortical neurons at day 3 in vitro. However, PIP3 levels were downregulated as the cortical
neurons developed, first in the cell body and then in the axon, which coincided with the loss
of regenerative ability. Therefore, PI3K and PIP3 are developmentally downregulated in
cortical neurons but remain present in mature DRG neurons.
The effects of overexpression of p110α , p110αH1047R and p110δ on PIP3 levels were
compared in rat E18 cortical neurons at 16 days in vitro. Overexpression of p110αH1047R
or p110δ led to a significant increase in PIP3 levels in the cell body, and an even greater
increase at the axon growth cones compared to GFP-transfected controls. Overexpression of
native p110α had no effect on PIP3 levels. Therefore, p110αH1047R and p110δ function in a
hyperactive fashion to generate PIP3 in cortical neurons.
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3.2.3 The Effects of PI3K on Axon Regeneration In Vivo
The in vitro data demonstrated the pro-regenerative effects of PI3K, specifically the
p110αH1047R and p110δ isoforms. The next step was to test whether these results were
translatable to in vivo models. This data is presented in this thesis chapter.
Two conditional knock-in PI3K mouse lines were created in the K. Okkenhaug lab,
making use of Cre-lox recombination technology to allow conditional expression of the
transgenes. A few of these mice were kindly donated to the Martin-Fawcett lab, from which
three mouse lines were then derived and established.
Hyperactive p110α (p110αH1047R) mice
The first mouse line used in this thesis is referred to as the “hyperactive p110α (p110αH1047R)”
mouse line (currently unpublished). The p110αH1047R mice have a knock-in fragment
containing the human PI3KCA gene, which encodes PI3K(p110α), with an H1047R point
mutation. This fragment was inserted at the Rosa26 locus, which results in transgene
expression at moderate levels[72]. The genotype is illustrated in the schematic diagram in
Fig. 3.1. A stop sequence is in front of the transgene, flanked by two loxP sites, preventing
gene expression. Following Cre-mediated recombination, the stop sequence is removed, and
the transgene is expressed. Therefore, these mice overexpress human p110αH1047R in the
presence of endogenous p110α and p110δ .
p110δ mice and isolated p110δ Mice
One mouse line donated by K. Okkenhaug had a knock-in fragment containing the human
PI3KCD gene, which encodes PI3K(p110δ ), inserted at the Rosa26 locus. The genotype is
illustrated in the schematic diagram in Fig. 3.2. Following Cre-mediated recombination, the
stop sequence is removed, and the transgene is expressed. Therefore, these mice overexpress
human PI3K(p110δ ). In addition, the mice have floxed mouse PI3KCA and floxed mouse
PI3KCD genes. The mouse PI3KCA gene is flanked by two loxP sites, as is the mouse
PI3KCD gene. Following Cre-mediated recombination, the genes are removed. Therefore,
these mice do not express endogenous mouse p110α and p110δ .
The second mouse line used in this thesis, referred to as the “p110δ " mouse line (currently
unpublished), carries the human PI3KCD gene but the floxed PI3KCA and PI3KCD were
bred out. Therefore, these mice overexpress PI3K(p110δ ) in the presence of endogenous
p110α and p110δ .
The third mouse line used in this thesis, referred to as the “isolated p110δ" mouse line
(currently unpublished), carries the human PI3KCD gene and kept the floxed mouse PI3KCA
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Fig. 3.1 Hyperactive p110α (p110αH1047R) mice The genotype of the p110αH1047R mice
is illustrated in this schematic. A knock-in fragment containing the human PI3KCA gene
with an H1047R point mutation was inserted at the Rosa26 locus. A stop sequence in front of
the transgene, flanked by two loxP sites, prevents expression of the gene. However, following
Cre recombination, the stop sequence is removed, and human p110αH1047R is expressed. Ex
= exon, SA = splice acceptor, poly A = polyadenylation sequence
and floxed mouse PI3KCD genes. Therefore, these mice overexpress PI3K(p110δ ) in the
absence of endogenous p110α and endogenous p110δ .
3.2.4 Aim
As summarised above, the in vitro data from Barber et al. showed that the p110αH1047R and
p110δ isoforms of PI3K promote axon regeneration and behave in a similar way. In the
results section of this chapter, this was tested in vivo using ONC injury in a conditional knock-
in p110αH1047R mouse line and a conditional knock-in p110δ mouse line. We hypothesised
that both isoforms would promote RGC survival and axon regeneration, behaving in the same
way.
3.3 Methods
Any references to Chapter 2 are clearly stated in the text.
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Fig. 3.2 p110δ and isolated p110δ mice The genotypes of the donated PI3K(p110δ ) mice,
the p110δ mice and isolated p110δ mice are illustrated in this schematic. In panel A, loxP
sites surround a stop sequence in front of the human PI3KCD gene, which prevents gene
expression. Following Cre recombination, this results in human PI3K(p110δ ) expression.
This is found in both the p110δ and isolated p110δ mice. LoxP sites also surround both the
mouse PI3KCA (panel B) and mouse PI3KCD (panel C) genes. Following Cre recombination,
this removes expression of endogenous PI3K(p110α) and PI3K(p110δ ). This was bred out
of the p110δ mice but kept in the isolated p110δ mice. Ex = exon, SA = splice acceptor,
poly A = polyadenylation sequence
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3.3.1 Breeding Strategy for p110δ Mice and Isolated p110δ Mice
Two conditional knock-in PI3K(p110δ ) males were kindly donated by the K. Okkenhaug lab
to the Martin-Fawcett lab. As described in more detail in Chapter 3.2.3, these males were
heterozygous for the human PI3KCD gene, which encodes PI3K(p110δ ), and homozygous
for mouse PI3KCA flx, which encodes floxed PI3K(p110α), and homozygous for mouse
PI3KCD flx, which encodes floxed PI3K(p110δ ). A breeding strategy was devised to
establish the conditional knock-in p110δ and isolated p110δ mouse lines in this thesis, as
laid out in Fig. 3.3.
The two founder males were crossed with C57BL/6J females. 1 in 2 of the offspring
were "intermediate heterozygotes" and these were crossed with C57BL/6J mice. From these
matings, 1 in 8 of the offspring were heterozygous p110δ mice, and 1 in 8 were heterozygous
isolated p110δ mice. To derive the p110δ mice, heterozygous p110δ mice from separate
litters were crossed. 1 in 4 of the offspring were then the desired homozygous p110δ mice.
To derive the isolated p110δ mice, heterozygous isolated p110δ mice from separate litters
were crossed. 1 in 64 of the offspring were then the desired homozygous isolated p110δ
mice. Once the lines were derived, breeding pairs were set up to maintain the colony.
3.3.2 Genotyping of Conditional Knock-in Mice
DNA Extraction
Ear clips were obtained from the conditional knock-in PI3K mice, collected into Eppendorf
tubes, and flash-frozen in liquid nitrogen. 50µL of alkaline lysis buffer (200mg NaOH,
14.88mg EDTA, 200ml water) was added to each sample. The tubes were heated at 95°C
for 1 hour, after which 50µL of neutralisation buffer (1.3g Tris HCl and 200ml water) was
added. Samples were stored at -20°C.
PCR
Three sets of primers were designed by the K. Okkenhaug lab to detect specific sequences in
each of the three transgenes of the PI3K mice, as listed in Table 3.1. One set of primers was
designed to detect the p110 subunit of PI3K, regardless of isoform, inserted at the Rosa26
locus: Rosa26 F1 AMQ, Rosa26 R2 AMG and Rosa26 loxP R1 AMG. A second set of
primers was designed to detect floxed mouse PI3KCA (PI3KCA flx): Ma50 and Ma51. A
third set of primers was designed to detect floxed mouse PI3KCD (PI3KCD flx): Delta flox
F2, Delta flox R2 and Delta flox R4.
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Fig. 3.3 Breeding strategy for p110δ and isolated p110δ mice. p110δ mice and isolated
p110δ mice were derived from 2 founder males, which were donated by K. Okkenhaug, as
shown in the diagram. The breeding strategy had multiple steps, which diverged to produce
the two different strains. Het = heterozygous. Homo = homozygous.
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Transgene Primer ID Primer Sequence
Rosa26 PI3K(p110) Rosa26 F1 AMQ GGCTCAGTTGGGCTGTTTTG
Rosa26 R2 AMQ TCTGTGGGAAGTCTTGTCCC
Rosa26 loxP AMQ GTGGATGTGGAATGTGTGCG
PI3KCA flx Ma50 CTAAGCCCTTAAAGCCTTAC
Ma51 CAGCTCCCATCTCAGTTCA
PI3KCD flx Delta flox F2 CATGCCTACAGTTGATTAAGT
Delta flox R2 AAGTTCAAAACCAGCTTGATG
Delta flox R4 TCAGGCCCCAAAGCAGGAAG
Table 3.1 Primers for genotyping PCR reaction
Cycle Step Temperature Duration
1. Initial denaturation 94°C 2min
2. Denaturation 94°C 30sec
3. Annealing 65 - 55°C (reducing 0.5°C per cycle) 90sec
4. Extension 72°C 90sec
repeat steps 2-4 20 cycles
5. Denaturation 94°C 30sec
6. Annealing 55°C 90sec
7. Extension 72°C 90sec
repeat steps 5-7 20 cycles
8. Final extension 72°C 5min
9. Hold 4°C hold
Table 3.2 PCR reaction protocol for genotyping
For each transgene, a separate polymerase chain reaction (PCR) reaction mixture was
prepared with 0.5µL of DNA, 12.5µL of GoTaq Hot Start Green Master Mix 2x (Promega,
cat no. M512B), 0.5µL of each appropriate primer, and either 6.0µL or 6.5µL of nuclease-
free water to give a total volume of 25µL. The PCR reaction protocol is detailed in Table
3.2.
10µL of each PCR product was run on a 1% agarose gel, made using Tris/Borate/EDTA
(TBE) buffer with 0.01% ethidium bromide, immersed in TBE buffer. 5µL of O’generuler
100bp DNA ladder (Thermo Scientific, cat no. SM1143) was run alongside. Electrophoresis
was performed at 100V for 35 minutes. Bands were imaged under ultraviolet light to confirm
the presence or absence of the transgenes based on band size.
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3.3.3 In Vitro Work
Before injecting the viruses in vivo, they were tested in vitro. Human embryonic kidney
(HEK) 293 cells were transfected with AAV2.Cre.GFP (Vector Biolabs, cat no. 7016),
AAV2.Cre.GFP (SignaGen Labs, cat no. SL100814), and AAV2.GFP (Vigene Biosciences,
cat no. CV10004), as described in Chapter 2.1. Two AAV2.Cre.GFP viruses were trialled
to see which gave the most GFP signal.
3.3.4 In Vivo Work
Viral Validation Work: Retinal Sections
For viral validation work in vivo, young adult (6 to 16 weeks old) p110αH1047R mice and
p110δ mice received a 2µL intravitreal injection of AAV2.Cre.GFP (Vector Biolabs, cat
no. 7016) into the left eye and 2µL of AAV2.GFP (Vigene Biosciences, cat no. CV10004)
into the right eye, as described in Chapter 2.3. Young adult (6 to 16 weeks old) B6;129S6-
Gt(ROSA)26Sortm14(CAG−tdTomato)Hze/J (The Jackson Laboratory, strain no. 007908[97]),
referred to in this thesis as "Cre-reporter" mice, received a 2µL intravitreal injection into
the left eye of AAV2.Cre.GFP (Vector Biolabs, cat no. 7016). All viruses were injected at a
titre of 1.0 x 1013GC/mL, a preoptimised titre for viral intravitreal injections. 2 weeks after
injection, the mice were perfused, as described in Chapter 2.5.
Whole eyes were collected, post-fixed in 4% paraformaldehyde (PFA) at room tempera-
ture for 2 hours, and then transferred to 20% sucrose overnight at 4°C for cryoprotection,
as described in Chapter 2.6.2. The eyes were then embedded in Tissue-Tek OCT com-
pound and cryosectioned (12µm thick) using a Leica cryostat (Leica Biosystems, CM 3050S
Research Cryostat).
For some eyes from the Cre-reporter mice, the retinas were extracted and made into
retinal wholemounts (RWMs). These were post-fixed in 4% PFA at room temperature for 2
hours and stored in phosphate-buffered saline (PBS) at 4°C, as described in Chapter 2.6.3.
Viral Validation Work: Western Blots
For viral validation work in vivo, young adult (6 to 16 weeks old) p110αH1047R mice and
p110δ mice received a 2µL intravitreal injection into the left eye of AAV2.Cre.GFP (Vector
Biolabs, cat no. 7016) and a 2µL intravitreal injection into the right eye of AAV2.GFP
(Vigene Biosciences, cat no. CV10004), as described in Chapter 2.3. All viruses were
injected at a titre of 1.0 x 1013GC/mL, a preoptimised titre for viral intravitreal injections.
A few mice received a 2µL intravitreal injection of PBS into the left eye, while the right
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eye was left uninjected (naive). 2 weeks after injection, the mice were culled by a rising
concentration of carbon dioxide and cervical dislocation.
Whole eyes were immediately removed, and the retinas were extracted, collected into
1.5mL Eppendorf tubes, and put on dry ice, ready for processing.
Regeneration Studies
For the regeneration work, young adult (6 to 8 weeks old) and aged adult (9 to 12 months old)
p110αH1047R mice, p110δ mice, and C57BL/6J mice received a 2µL intravitreal injection of
AAV2.Cre.GFP (Vector Biolabs, cat no. 7016) into the left eye, as described in Chapter 2.3.
2 weeks after injection, the mice received an ONC injury behind the left eye, as described in
Chapter 2.4. At 26 days post-ONC, the mice were intravitreally injected with cholera toxin
subunit-β with an Alexa Fluor 555 conjugate (CTB-555) (Thermo Fisher Scientific, cat no.
C22843), as described in Chapter 2.3. At 4 weeks post-ONC, the mice were perfused, as
described in Chapter 2.5.
The optic nerves were collected, post-fixed in 4% PFA at 4°C overnight, and transferred
to 30% sucrose for at least 24 hours for cryoprotection, as described in Chapter 2.6.1. The
nerves were then cryosectioned (14µm longitudinal sections) using a Leica cryostat (Leica
Biosystems, CM 3050S Research Cryostat).
The retinas were collected, and four small incisions were made to form RWMs as de-
scribed in Chapter 2.6.3. RWMs were post-fixed in 4% PFA for 2 hours at room temperature,
and then the solution was changed to PBS, ready for immunohistochemistry (IHC).
3.3.5 Immunohistochemistry
IHC in HEK 293 Cells
Having been fixed in 4% PFA, HEK 293 cells were counterstained with DAPI as described
in Chapter 2.7.1.
Retinal Section Histology
Having been fixed in 4% PFA and sectioned, IHC was performed as described in Chapter
2.7.2. IHC against GFP was used to identify the viral tags. IHC against phospho-AKT
(pAKT) and pS6 was used to quantify PI3K/AKT/mTOR pathway activity.
48 Transgenic Manipulation of the PI3K Pathway and its Effects on Axon Regeneration
Retinal Wholemount Histology
Having been fixed in 4% PFA, RWMs were then stored in PBS at 4°C. IHC against Brn3A,
an RGC marker, was performed on RWMs as described in Chapter 2.7.3.
3.3.6 Western Blots
Western blots of whole retinal lysate were performed. Immunoblotting against the viral tag,
GFP, was used to confirm successful viral transduction and immunoblotting against mTOR
pathway markers (pAKT, mTOR and pS6) was used to quantify PI3K/AKT/mTOR pathway
activity, as described in Chapter 2.8.
3.3.7 Microscopy and Quantification
Viral Validation In Vitro
HEK 293 cells transfected with either AAV2.Cre.GFP or AAV2.GFP were counterstained
with DAPI. These were imaged by confocal microscopy at x40 magnification. The images
were used to confirm that the GFP viral tag was observed and that this signal was not seen in
untransfected (naive) cells.
Viral Validation In Vivo
Successful viral transduction was confirmed in retinal sections injected with AAV2.Cre.GFP
and AAV2.GFP, immunostained for GFP and counterstained with DAPI. The presence of
viral tag, GFP, was confirmed, and eye cups were imaged using a Zeiss AxioScan Z1 at
x20 magnification (0.22µm/pixel) by the team at the Histopathology/ISH core facility at the
Cancer Research UK (CRUK) Cambridge Institute. The RGC layer of retinal sections was
imaged using confocal microscopy at x40 magnification.
Viral Validation: Cre-mediated Recombination
The Cre recombinase activity of the AAV2.Cre.GFP virus was validated by injecting the
virus in a Cre-reporter mouse line. The RGC layer of retinal sections was imaged by confocal
microscopy at x80 magnification, and co-localisation of the tdTomato fluorescence, a result
of Cre-mediated recombination, with the GFP viral tag was observed. RWMs were imaged
at x20 magnification, and the images were stitched together to show the spread across the
retina.
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RGC Survival
Percentage RGC survival was calculated as described in Chapter 2.9.4. In brief, Brn3A-
stained RWMs were imaged at x20 magnification using fluorescence microscopy. For each
image, the number of RGCs was quantified using a counting program in Image J Fiji (Fiji-
win64). The number of surviving RGCs in the ONC (left) eye was expressed as a percentage
relative to the number of RGCs in the uninjured contralateral control (right) eye.
Axon Regeneration
Axon regeneration was calculated as described in Chapter 2.9.5. In brief, the CTB-555-
labelled axons were visualised using fluorescence microscopy at x40 magnification, counting
the number of axons at 0.5mm increments from the crush site. Modelling the nerve as a
cylinder, the number of regenerating axons per nerve was calculated at each increment using
a previously developed formula. Four sections were counted per nerve and used to average
the total number of regenerating axons per nerve.
Axonal sections were imaged using a Zeiss AxioScan Z1 at x40 magnification
(0.11µm/pixel) by the Histopathology/ISH core facility at the CRUK Cambridge Institute.
Viral Validation: PI3K/AKT/mTOR Pathway Activation
Western Blots of Whole Retinal Lysate
Whole retinal lysate from eyes injected with either AAV2.Cre.GFP or AAV2.GFP
was analysed by immunoblotting. Successful viral transduction from AAV2.Cre.GFP and
AAV2.GFP was confirmed by the presence of the viral tag, GFP. Then immunoblotting for
PI3K/AKT/mTOR pathway markers (pAKT, mTOR, and pS6) was performed. PBS-injected
eyes and naive eyes were also analysed as a control. The pAKT and mTOR signal was
quantified using Image J Fiji and expressed relative to the β -actin signal per sample. The
average signal relative to β -actin for untransfected (naive) retinas was calculated. All values
were then expressed relative to the average for naive eyes.
IHC in Retinal Sections
Retinal sections injected with either AAV2.Cre.GFP or AAV2.GFP and immunostained
with either pAKT or pS6 were examined at x40 magnification by fluorescence microscopy,
as described in Chapter 2.9.3. In brief, 100 GFP-positive RGCs, identified using DAPI
and GFP signal from the viral vector, were counted and identified as either positive or
negative for pAKT. This was repeated for retinal sections immunostained with pS6. Four
mice were counted for each group (100 RGCs per mouse), and the average was expressed as
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a percentage of GFP-positive cells co-localised with pAKT or pS6. Representative images
were taken at x80 magnification by confocal microscopy.
3.4 Results
3.4.1 ONC Validation
As part of my Ph.D., I spent time mastering several in vivo techniques: ear notching,
intravitreal injections, optic nerve crush (ONC) injury, cardiac perfusion, intraperitoneal
injections, subcutaneous injections, and surgery support for ketamine anaesthesia.
To confirm that I had mastered the ONC injury technique, I performed ONC behind the
left eyes of eight C57BL/6J mice. The mice were perfused, and RWMs were collected at 4
weeks post-ONC. IHC against Brn3A, an RGC marker, was used to quantify RGCs. The
number of surviving RGCs in the ONC (left) eye was expressed as a percentage relative to
the uninjured contralateral control (right) eye. As shown in Fig. 3.4, my ONC injury resulted
in 4.61%±1.08 (n=8 retinas) RGC survival at 4 weeks post-ONC, which fits with the 5%
survival typically seen at this time point.
Fig. 3.4 Validating my ONC injury technique. Mice received an ONC injury behind the
left eye. RWMs were stained with Brn3A (red), which was used to quantify RGCs. The
number of RGCs in the ONC (left) eye (panel Bii) was expressed as a percentage survival
relative to the uninjured contralateral control (right) eye (panel Bi). My RGC survival of
4.61% at 4 weeks post-ONC fits with the 5% survival typically seen at this time point. n = 8,
error bar = SD. Scale bar = 100µm.
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3.4.2 Three conditional knock-in PI3K mouse lines were established
and maintained
A.R. MacQueen of the K. Okkenhaug lab generated a conditional knock-in PI3K(hyperactive
p110α (p110αH1047R)) mouse line and a conditional knock-in PI3K(p110δ ) mouse line. At
the time of thesis submission, neither of these lines had been published. A few of these mice
were kindly donated to the Martin-Fawcett lab, from which three conditional knock-in PI3K
mouse lines were established and maintained: a hyperactive p110α (p110αH1047R) mouse
line, a p110δ mouse line, and an isolated p110δ mouse line. These mice are described in
more detail in Chapter 3.2.3.
Establishing the conditional knock-in PI3K mouse lines involved genotyping the mice
for three transgenes: human Rosa26 p110, mouse PI3KCA flx, which encodes floxed
PI3K(p110α), and mouse PI3KCD flx, which encodes floxed PI3K(p110δ ). Genomic DNA
was extracted from mice by ear notching, and the transgenes were confirmed by PCR, using
primers designed by A.R. MacQueen to detect specific sequences within each transgene.
The genotypes of the mouse lines are summarised in Table 3.3. PCR for human Rosa26
p110 was performed with the following three primers: GGCTCAGTTGGGCTGTTTTG,
TCTGTGGGAAGTCTTGTCCC, and GTGGATGTGGAATGTGTGCG. The homozygous
knock-in allele is 606 base pairs (bp), and the homozygous wildtype allele is 359 bp. All
three mouse lines are homozygous for the knock-in allele and mice with the expected 606bp
band were selected.
PCR for mouse PI3KCA flx was performed with the following primer pair: CTAAGC-
CCTTAAAGCCTTAC and CAGCTCCCATCTCAGTTCA. The homozygous knock-in al-
lele is 591 bp, and the homozygous wildtype allele is 527 bp. PCR for mouse PI3KCD
flx was performed with the following three primers: CATGCCTACAGTTGATTAAGT,
AAGTTCAAAACCAGCTTGATG, and TCAGGCCCCAAAGCAGGAAG. The homozy-
gous knock-in allele is 477 bp, and the homozygous wildtype allele is 361 bp. The isolated
p110δ mice are homozygous for both knock-in alleles and mice with the expected 591bp and
477bp bands were selected. Mouse PI3KCA flx and mouse PI3KCD flx were bred out of the
p110δ mice, making them homozygous for the wildtype allele, and mice with the expected
527bp and 361bp bands were selected.
Examples of DNA gels showing the products of the genotyping PCR reactions are shown
in Fig. 3.5. Mice with the desired genotype were identified and bred to maintain a colony.
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Transgene
Knock-in
(KI) allele
band size
Wildtype
(WT) allele
band size
p110αH1047R
mice
p110δ
mice
isolated
p110δ
mice
Human Rosa26 p110 603bp 359bp KI KI KI
Mouse PI3KCA flx 591bp 527bp WT WT KI
Mouse PI3KCD flx 477bp 361bp WT WT KI
Table 3.3 Genotypes of conditional knock-in PI3K mice
Fig. 3.5 Genotyping to establish three conditional knock-in PI3K mouse lines. DNA
gels are shown with the products of the genotyping PCR reactions, which were designed to
detect specific sequences from each of the three transgenes: human Rosa26 p110, mouse
PI3KCA flx and mouse PI3KCD flx. KI denotes homozygous for knock-in allele, WT
denotes homozygous for wildtype allele, Het denotes heterozygous.
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3.4.3 Viral Validation
AAV2.Cre.GFP and AAV2.GFP successfully transfected HEK 293 cells in vitro
Before using the AAV2.Cre.GFP and AAV2.GFP viruses in vivo, successful viral transfection
was confirmed in vitro using HEK 293 cells, as shown in Fig. 3.6. Signal from the viral tag,
GFP, was detected from all viruses. AAV2.Cre.GFP (Vector Biolabs, cat no. 7016) gave
noticeably stronger GFP signal than AAV2.Cre.GFP (SignaGen Labs, cat no. SL100814) so
this virus was used in vivo.
Fig. 3.6 AAV2.Cre.GFP and AAV2.GFP were tested in vitro. Two AAV2.Cre.GFP viruses
and one AAV2.GFP virus were tested in HEK 293 cells prior to in vivo work. The presence
of GFP signal indicates successful transfection. AAV2.Cre.GFP from Vector Biolabs gave a
stronger signal than AAV2.Cre.GFP from SignaGen Labs. Scale bar = 100µm.
AAV2.Cre.GFP and AAV2.GFP successfully transduced RGCs in vivo
Viral transduction of RGCs was tested in vivo. Young adult (6 to 16 weeks old) p110αH1047R
mice and p110δ mice were injected intravitreally with 2µL of AAV2.Cre.GFP in the left eye
and 2µL of AAV2.GFP in the right eye. The eyes were collected 2 weeks later, and 12µm
retinal sections were produced.
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Successful viral transduction of AAV2.Cre.GFP and AAV2.GFP in vivo was confirmed by
signal from the viral tag, GFP, in the RGC layer. Eye cup images showed signal throughout
the retina, and closer inspection of the retinal sections confirmed that this signal was in the
RGC layer, as shown in Fig. 3.7 where staining was indicative of RGCs.
Fig. 3.7 Successful viral transduction of AAV2.Cre.GFP and AAV2.GFP was confirmed
in vivo. In panel A, eye cups and zoomed in images of the RGC layer showed GFP signal in
the RGC layer throughout the retina for AAV2.Cre.GFP (Aii and iv) and AAV2.GFP (Ai and
Aiii) in both p110αH1047R and p110δ mice. Staining was indicative of RGCs. Scale bar =
500µm for eye cups, 100µm for retinal sections.
The Cre recombinase activity of AAV2.Cre.GFP was confirmed in RGCs in vivo
The Cre recombinase activity of AAV2.Cre.GFP was tested in RGCs in vivo using a tdTomato
Cre-reporter mouse line. Young adult (6 to 16 weeks old) Cre-reporter mice were injected
intravitreally with 2µL of AAV2.Cre.GFP in the left eye. The eyes were collected 2 weeks
later, and both RWMs and 12µm retinal sections were produced.
The tdTomato fluorescence produced as a result of Cre-mediated recombination was seen
throughout the retina in RWMs, as shown in Fig. 3.8. On closer inspection of the RGC layer
in retinal sections, co-localisation of tdTomato fluorescence (red) with GFP signal from the
virus (green) was confirmed. Staining in the RGC layer was indicative of RGCs.
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Fig. 3.8 The Cre recombinase activity of AAV2.Cre.GFP was confirmed in vivo. The
Cre recombinase activity of AAV2.Cre.GFP was confirmed using a Cre-reporter mouse line.
tdTomato fluorescence, resulting from Cre-mediated recombination, was seen throughout
the retina in RWMs and within RGCs in retinal sections. Staining in the RGC layer was
indicative of RGCs. Scale bar = 100µm, and 1000µm for full RWM.
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3.4.4 RGC Survival and Axon Regeneration
Young adult (6 to 8 weeks old) and aged adult (9 to 12 months old) p110αH1047R mice,
p110δ mice, and C57BL/6J mice were intravitreally injected with 2µL of AAV2.Cre.GFP
into the left eye. 2 weeks later, ONC surgery was performed. At 26 days post-ONC, 2µL
of cholera toxin subunit-β with an Alexa Fluor 555 conjugate (CTB-555) was intravitreally
injected into the left eye. At 4 weeks post-ONC, the eyes and optic nerves were collected, as
summarised in Fig. 3.9.
Please note that all regeneration experiments in the p110αH1047R mice were not carried
out as part of this thesis, but the results have been provided here for completeness (credit to
A.C. Barber, C.S. Pearson, and J. Cave).
Fig. 3.9 Chapter 3 Experimental Summary
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Transgenic PI3K upregulation via activation of p110αH1047R or of p110δ promoted
RGC survival in young adult (6 to 8 weeks old) mice. p110αH1047R also promoted
survival in aged adult (9 to 12 months old) mice.
The retinas were collected at 4 weeks post-ONC and IHC against Brn3A, an RGC marker,
was used to quantify RGCs. The number of surviving RGCs in the ONC (left) eye was
expressed as a percentage relative to the uninjured contralateral control (right) eye.
In the young adults (6 to 8 weeks old), the AAV2.Cre.GFP-treated p110αH1047R mice
showed 10.7%±4.5 (n=10 retinas) RGC survival at 4 weeks post-ONC and the
AAV2.Cre.GFP-treated p110δ mice showed 11.4%±5.8 (n=6 retinas) RGC survival. Both
groups were significantly higher than the AAV2.Cre.GFP-treated C57BL/6J mice, which
showed 5.6%±2.1 (n=7 retinas) RGC survival (see Fig. 3.10, one-way ANOVA with Tukey’s
post-hoc analysis, p=0.0464 for p110αH1047R and p=0.0478 for p110δ ). There was no
significant difference between the two mouse lines. Therefore, transgenic PI3K upregulation
via activation of p110αH1047R or of p110δ promoted RGC survival at 4 weeks post-ONC.
In the aged adults (9 to 12 months old), the AAV2.Cre.GFP-treated C57BL/6J mice
showed 4.5%±2.7 (n=6 retinas) RGC survival, which was not significantly different from the
5.6%±2.1 (n=7 retinas) seen in young mice, as shown in Fig. 3.11.
The AAV2.Cre.GFP-treated p110αH1047R mice showed 12.8%±4.8 (n=4 retinas) RGC
survival at 4 weeks post-ONC and the AAV2.Cre.GFP-treated p110δ mice showed 4.5%±2.3
(n=7 retinas) RGC survival. The p110αH1047R mice were significantly higher than the
AAV2.Cre.GFP-treated C57BL/6J mice, which showed 4.5%±2.7 (n=6 retinas) RGC survival
(one-way ANOVA with Tukey’s post-hoc analysis, p < 0.0001), whereas the p110δ mice
were not (see Fig. 3.11). In addition, the p110αH1047R mice showed significantly higher
survival than the p110δ mice (one-way ANOVA with Tukey’s post-hoc analysis, p < 0.0001).
No significant difference was found between young and aged p110αH1047R mice. Therefore,
transgenic PI3K upregulation via activation of p110αH1047R promoted RGC survival in both
young and aged adult mice at 4 weeks post-ONC. While activation of p110δ promoted RGC
survival in young adult mice, it had no significant effect in aged mice.
Transgenic PI3K upregulation via activation of p110αH1047R or of p110δ promoted
axon regeneration in young adult (6 to 8 weeks old) and aged (9 to 12 months old) mice
2 days before tissue collection, the left eyes were intravitreally injected with 2µL of CTB-555.
At 4 weeks post-ONC, the optic nerves were dissected, and 14µm longitudinal sections were
produced. Axons were counted using the CTB-555 fluorescence at 0.5mm increments.
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Fig. 3.10 Transgenic PI3K upregulation via activation of p110αH1047R or of p110δ pro-
moted RGC survival in young mice. As seen in panel A, activation of p110αH1047R or
p110δ using AAV2.Cre.GFP promoted RGC survival 4 weeks post-ONC injury. RWMs
were stained with Brn3A (red), which was used to quantify RGCs. The number of RGCs in
the ONC (left) eye (panels Bii, Biv, and Bvi) was expressed as a percentage survival relative
to the uninjured contralateral control (right) eye (Bi, Biii, and Bv). p values measured by
one-way ANOVA with Tukey’s post-hoc analysis, n = 6 to 10 as specified, error bars = SD.
Scale bar = 100µm. p110αH1047R data provided by A.C. Barber, C.S. Pearson, J. Cave.
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Fig. 3.11 Transgenic PI3K upregulation via activation of p110αH1047R promoted RGC
survival in aged mice, but p110δ had no significant effect. As seen in panel A, activation
of p110αH1047R using AAV2.Cre.GFP promoted RGC survival 4 weeks post-ONC injury
in aged mice, but p110δ had no significant effect. RWMs were stained with Brn3A (red),
which was used to quantify RGCs. The number of RGCs in the ONC (left) eye (panels Bii
and Biv) was expressed as a percentage survival relative to the uninjured contralateral control
(right) eye (Bi and Biii). p values measured by one-way ANOVA with Tukey’s post-hoc
analysis to compare aged data, n = 4 to 10 as specified, error bars = SD. Scale bar = 100µm.
p110αH1047R data provided by A.C. Barber, C.S. Pearson, J. Cave.
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In the young adults (6 to 8 weeks old), the AAV2.Cre.GFP-treated p110αH1047R mice
showed 72±45 regenerating axons (n=11 nerves) at 0.5mm from the crush site, and the
p110δ mice showed 61±35 axons (n=6 nerves), as shown in Fig. 3.12. This was a significant
increase compared to 19±23 axons (n=15 nerves) in the control (two-way ANOVA with
Tukey’s post-hoc analysis, p < 0.0001 for p110αH1047R and p < 0.0001 for p110δ ). No
significant differences were seen between the two mouse lines. Therefore, transgenic PI3K
upregulation via activation of p110αH1047R or of p110δ promoted axon regeneration at 4
weeks post-ONC.
In the aged adults (9 to 12 months old), the AAV2.Cre.GFP-treated C57BL/6J mice
showed 3±2 regenerating axons (n=17 nerves), which was significantly less than the 19±23
axons (n=15 nerves) in the young mice (two-tailed T-test, p<0.0001) as shown in Fig. 3.13.
Therefore, aged C57BL/6J mice have lower regenerative potential than young mice, as has
previously been shown in the literature.
The AAV2.Cre.GFP-treated p110αH1047R mice showed 19±9 regenerating axons (n=4
nerves) at 0.5mm from the crush site, which was significantly less than the 72±45 axons in
the young mice (two-tailed T-test, p=0.0248), but more than the 3±2 axons (n=17 nerves)
in the aged control (one-way ANOVA with Tukey’s post-hoc analysis, p=0.0106). The
AAV2.Cre.GFP-treated p110δ mice showed 20±17 axons (n=7 nerves) at 0.5mm from the
crush site, which was significantly less than the 61±35 axons in the young mice (two-tailed
T-test, p=0.0200), but more than the 3±2 axons (n=17 nerves) in the aged control (one-way
ANOVA with Tukey’s post-hoc analysis, p=0.0007). This difference between young and
aged adult mice fits with our data from the C57BL/6J mice and the literature, showing
significantly less regeneration. No significant difference was found between the two mouse
lines. Therefore, transgenic PI3K upregulation via activation of p110αH1047R or of p110δ
promoted axon regeneration in aged mice at 4 weeks post-ONC, but to a lesser extent than in
young adult mice.
3.4.5 mTOR Pathway Activation
The regeneration data showed that activation of p110αH1047R and p110δ by Cre-mediated
recombination promoted both RGC survival and axon regeneration. To validate that this was
due to activation of PI3K, PI3K/AKT/mTOR pathway activity was assessed.
RGCs could not be successfully isolated
In mice, RGCs account for less than 1% of total retinal cells[47, 103]. Therefore, we planned
to isolate RGCs from the retina to more accurately assess their mTOR pathway activation.
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Fig. 3.12 Transgenic PI3K upregulation via activation of p110αH1047R or of p110δ pro-
moted axon regeneration. As shown in panel A, transgenic PI3K upregulation via activation
of p110αH1047R or of p110δ promoted axon regeneration following ONC injury. The same
graph but with a different scale for comparison to other chapters is shown in panel B. Im-
ages of crushed nerves are shown in panel C for AAV2.Cre.GFP in C57BL/6J (Ci) and
AAV2.Cre.GFP in p110δ (Cii). p values measured by two-way ANOVA with Tukey’s post-
hoc analysis, n = 6 to 15 as specified, error bars = SEM. Scale bar = 100µm. p110αH1047R
data provided by A.C. Barber, C.S. Pearson, J. Cave.
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Fig. 3.13 Transgenic PI3K upregulation via activation of p110αH1047R or of p110δ pro-
moted axon regeneration in aged mice, although less so than young mice. As shown in
panel A, aged p110δ mice promote axon regeneration following ONC injury compared to
aged controls, but less so than young p110δ mice. Images of crushed nerves are shown in
panel B for AAV2.Cre.GFP in aged C57BL/6J (Bi) and AAV2.Cre.GFP in aged p110δ mice
(Bii). Summary data in panel C shows that transgenic PI3K upregulation via activation of
p110αH1047R or of p110δ promoted axon regeneration in aged mice, but to a lesser extent
than in young mice. p values measured by two-way ANOVA (graph A) and one-way ANOVA
(graph C: comparing aged data) with Tukey’s post-hoc analysis and two-tailed T-test (graph
C: comparing young and aged data within each strain), n = 4 to 17 as specified, error bars =
SEM (graph A) and SD (graph C). Scale bar = 100µm. p110αH1047R data provided by A.C.
Barber, C.S. Pearson, J. Cave.
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Within the lab, immunopanning, microbead isolation, fluorescence-activated cell sorting, and
laser capture microdissection were tried. However, a reliable RGC isolation method with
enough yield to analyse was not found, so whole retinal tissue had to be assessed.
mTOR pathway activation could not be confirmed using western blots of whole retinal
lysate
Immunoblotting against the viral tag, GFP, and against mTOR pathway markers (pAKT,
mTOR, and pS6) was performed on whole retinal lysate using the western blot technique,
as seen in Fig. 3.14. As expected, GFP signal was seen from the AAV2.Cre.GFP and
AAV2.GFP viruses, but not from PBS-injected or naive eyes. This confirmed successful viral
transduction. The GFP signal of AAV2.Cre.GFP was fainter than that of the AAV2.GFP.
This was not a surprise because the GFP of AAV2.Cre.GFP is under the control of a second
promoter, which can result in lower expression levels.
pS6 was detected in the positive control, which was HEK 293 cells transfected with a
virus known to increase pS6 levels. However, this could not be detected in the whole retinal
lysate, even with increasing antibody concentration and exposure times. pAKT and mTOR
were detected, but the signal was variable, and no clear pattern was seen. As mentioned,
RGCs only make up less than 1% of retinal cells, so any potential changes in mTOR pathway
marker proteins were too diluted to detect.
mTOR pathway activation was confirmed in retinal sections using IHC
IHC against mTOR pathway markers (pAKT and pS6) was performed on the retinal sections
used for viral validation, as shown in Fig. 3.15. The percentage of GFP-labelled cells in the
RGC layer co-localised with either pAKT or pS6 was quantified and compared to control
injection. Staining was indicative of RGCs.
In p110αH1047R mice, eyes injected with AAV2.GFP showed 23.8%±4.2 pAKT-GFP-
labelled cells, which increased to 62.3%±5.3 in AAV2.Cre.GFP-injected eyes (one-tailed
T-test, p<0.0001). The average fold change in pAKT was 2.70±0.63. Eyes injected with
AAV2.GFP showed 45.3%±6.8 pS6-GFP-labelled cells, which increased to 80.0%±5.4 in
AAV2.Cre.GFP-injected eyes (one-tailed T-test, p=0.0010). The average fold change in pS6
was 1.79±0.21.
In p110δ mice, eyes injected with AAV2.GFP showed 21.5%±3.9 pAKT-GFP-labelled
cells, which increased to 53.3%±8.7 in AAV2.Cre.GFP-injected eyes (one-tailed T-test,
p=0.0003). The average fold change in pAKT was 2.49±0.22. Eyes injected with AAV2.GFP
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Fig. 3.14 mTOR pathway activation could not be verified in western blots of whole
retinal lysate in vivo. GFP signal from the viral tag was observed in AAV2.Cre.GFP- and
AAV2.GFP-treated whole retinal lysate, as shown in panel A. The western blots in panels B
and C and the graph in panel D, show that a clear pattern in pAKT or mTOR signal could not
be detected, and pS6 could not be detected at all. p values measured by one-way ANOVA
with Tukey’s post-hoc analysis, n = 2 to 3 as specified, error bars = SD.
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showed 42.3%±2.2 pS6-GFP-labelled cells, which increased to 64.5%±6.8 in AAV2.Cre.GFP-
injected eyes (one-tailed T-test, p=0.0004). The average fold change in pS6 was 1.52±0.10.
The raw percentage of pS6-GFP-labelled cells in AAV2.Cre.GFP-treated eyes was signif-
icantly greater in p110αH1047R mice compared to p110δ mice (two-tailed T-test, p=0.0116).
However, no significant difference was found between the two mouse lines when looking at
the fold change in pAKT and pS6 signal.
Therefore, activation of PI3K and the downstream activation of the PI3K/AKT/mTOR
pathway was confirmed to result from Cre-mediated recombination in the conditional knock-
in mice.
3.5 Discussion
Using viral Cre-mediated recombination in conditional knock-in PI3K mouse lines, PI3K
was upregulated through activation of hyperactive p110α (p110αH1047R) and p110δ . Both
were shown to significantly promote RGC survival and axon regeneration in young adult
mice following ONC injury, with no difference between the two isoforms. It should be noted
that the p110αH1047R and p110δ in vivo experiments were carried out at different times.
However, the results obtained fit with the in vitro data, which showed no difference between
the two isoforms in CNS neuron regeneration.
Both p110αH1047R and p110δ were also shown to promote axon regeneration in aged
mice, although to a lesser extent than in young mice. Aged C57BL/6J mice were shown to
have lower regenerative potential than young C57BL/6J mice, which fits with the
literature[34]. No difference between the two isoforms was seen.
Interestingly, only p110αH1047R promoted RGC survival in aged mice. This could be due
to the p110αH1047R and p110δ data being collected at different times or the low n number
for the aged p110αH1047R data (n=4). From the in vitro data in DRG neurons, p110α was
demonstrated to be essential for regeneration in both the soma and axons, whereas p110δ
was only required in the axon. Perhaps this explains why the RGCs, in other words the soma,
survived better under p110αH1047R than under p110δ , while no difference was in the axon
regeneration data.
The observed pro-regenerative effects were shown to be at least in part due to upregulation
of the PI3K/AKT/mTOR pathway. Unfortunately, we were unable to isolate RGCs to assess
mTOR pathway activation, so this was shown using IHC in whole retina, as in previous
literature. To quantify this, pAKT and pS6 positive cells were counted. If this were to
be examined more thoroughly, the fluorescence levels of pAKT and pS6 in RGCs could
be compared between the treatment and control groups. Previous work looking at PTEN
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Fig. 3.15 Transgenic PI3K upregulation via activation of p110αH1047R or of p110δ re-
sulted in increased mTOR pathway activity in vivo. As shown in the graphs in panels
A and B, pAKT and pS6 signal increased in AAV2.Cre.GFP-treated eyes compared to
AAV2.GFP-treated eyes. Representative images are shown in panel C. Staining in the RGC
layer was indicative of RGCs. p values measured by one-tailed T-test, n = 4, errors bars =
SD. Scale bar = 100µm.
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deletion had demonstrated the role of the mTOR pathway, both by using rapamycin, an
mTOR pathway inhibitor, and by conditional knockout of a negative regulator of the mTOR
pathway, tuberous sclerosis complex I (TSC1)[79]. The effect of rapamycin on regeneration
in these conditional knock-in PI3K mice could be investigated to see to what extent this
neutralised the effects seen.
Further work using the conditional knock-in PI3K mice could look at combining the
p110αH1047R and p110δ isoforms by crossing the two strains. Leading on from the transgenic
work, a more translatable approach was developed using a viral vector for PI3K(p110δ ).
Unfortunately, as a commonly mutated cancer gene, the p110αH1047R isoform was deemed
too unsafe for viral work. In addition, the effect of targeting PI3K was compared to PTEN
knockdown. These results are covered in Chapter 4.

Chapter 4
Viral Manipulation of the PI3K Pathway
and its Effects on Axon Regeneration
4.1 Declaration
The work presented in Chapters 3 and 4 of this thesis has been submitted to EMBO
Molecular Medicine for publication. At the time of thesis submission, we are responding
to reviewers’ comments. This work is cited in the thesis as: *Barber, A.C., *Evans, R.S.,
*Nieuwenhuis, B., Pearson, C.S., Fuchs, J., MacQueen, A.R., van Erp, S., Hänzi, B., Hulshof,
L-A., Osborne, A., Conceição, R., Deshpande, S.S., Cave, J., ffrench-Constant, C., Smith,
P.D., Okkenhaug, K., Eickholt, B.J., Martin, K.R., Fawcett, J.W., and Eva, R. (2020), PI3
kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS (not yet
published). * = the authors contributed equally.
The phosphoinositide 3-kinase (PI3K) in vitro data from this paper is summarised in
Chapter 3.2, and the transgenic PI3K in vivo data is presented in Chapter 3.4. Acknowl-
edgments are covered in that chapter’s declaration.
The viral phosphatase and tensin homolog (PTEN) knockdown and viral PI3K upregula-
tion in vivo data from this paper is presented in the results section of this chapter. The data in
this chapter was generated by me, under the supervision of A.C. Barber, with contributions
from others declared below.
Viruses: The AAV2.shPTEN.GFP virus was kindly donated by Z. He. The
AAV2.PI3K(p110δ ) virus was generated by B. Hänzi, A. Osborne and L-A. Hulshof.
In vitro data (Fig 4.3A&C and Fig 4.4A&C): R. Conceição quantified PTEN and PI3K
levels in human embryonic kidney (HEK) 293 cells transfected with these viruses. While I
was not involved in measuring the PTEN and PI3K levels in vitro, the data is presented in the
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results section of this chapter alongside my in vivo data for completeness, with appropriate
referencing in the text.
Regeneration data: The regeneration data was generated by me under the supervision of
A.C. Barber. A.C. Barber counted axon regeneration alongside me and we compared values
for accuracy and to check my counting technique. S.S. Deshpande created a program to speed
up RGC survival analysis and did some manual counting to compare with data generated
by the program. R. Conceição assisted by creating some retinal wholemounts during tissue
collection.
Validation data: All validation data, including testing the viral vectors in vitro and in
vivo, and quantifying PTEN knockdown, PI3K upregulation, and mTOR pathway activity in
vivo, was generated by me.
R. Eva wrote the manuscript. R. Eva, J.W. Fawcett, B.J. Eickholt, K. Okkenhaug, B.
Nieuwenhuis, S. van Erp, A.C. Barber and I edited the manuscript.
4.2 Introduction
4.2.1 PTEN Deletion Promotes RGC Survival and Axon Regeneration
In Vivo
As described in detail in Chapter 1.3.2, Park et al. compared the effects on axon regeneration
of several different cell growth control genes using a murine optic nerve crush (ONC) model.
They found that transgenic knockout of phosphatase and tensin homolog (PTEN) significantly
promoted both retinal ganglion cell (RGC) survival and axon regeneration in young adult
mice[79]. These pro-regenerative results were also seen after spinal cord injury[58]. This
effect was shown to be primarily due to mammalian target of rapamycin (mTOR) pathway
activation. The group then investigated a more translatable approach, knocking down PTEN
with viral short hairpin RNA (shRNA) targeted to PTEN, driven by a U6 promoter. The
AAV2.shPTEN.GFP viral vector promoted regeneration after spinal cord injury[110]. In this
chapter, we tested this viral vector in an ONC model, which had not been previously done
before. Viral shRNA targeted to PTEN would give lower levels of PTEN knockdown than
transgenic knockout. Therefore, less than 45% RGC survival and less axon regeneration than
seen in Park et al. would be expected.
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4.2.2 The p110α and p110δ Isoforms of PI3K Promote Axon Regener-
ation Both In Vitro and In Vivo
The phosphoinositide 3-kinase (PI3K) pathway is described in Chapter 1.3. As described
in detail in Chapter 3, Barber et al. investigated the effects of the different PI3K isoforms
on axon regeneration in vitro and found that hyperactive p110α (p110αH1047R) and p110δ
were involved in promoting axon regeneration. These two isoforms were then tested in
vivo, using a conditional transgenic approach. Overall the work found that p110αH1047R and
p110δ promoted both RGC survival and axon regeneration in young adult mice, with no
difference between the two isoforms. Moving forward with a more translatable approach, an
AAV2.PI3K(p110δ ) virus was generated, driven by a CAG promoter. The PI3K construct
was too large to add a viral tag. Unfortunately, as a commonly mutated cancer gene, the
p110αH1047R isoform was deemed too unsafe for viral work.
All regeneration studies in this thesis follow the same experimental paradigm as in Park
et al., allowing effective comparison. As mentioned, inserting a transgene at the Rosa26
locus results in moderate expression levels[72]. Therefore, viral PI3K(p110δ ) would be
expected to increase PI3K expression levels further than in the transgenic approach and to
have greater regenerative effects. Viral AAV2.PI3K(p110δ ) and AAV2.shPTEN.GFP were
also compared. We hypothesised that PI3K upregulation would have greater regenerative
effects than PTEN knockdown because PI3K directly increases phosphatidylinositol (3,4,5)-
tris-phosphate (PIP3) levels, unlike PTEN which prevents the breakdown of already low
PIP3 levels.
4.2.3 Aim
This work aimed to assess viral PTEN knockdown and viral PI3K(p110δ ) upregulation
using an ONC model. The same experimental paradigm was used throughout this thesis
to allow comparison between the different groups. It was expected that viral PI3K(p110δ )
would promote both survival and regeneration more than transgenic p110δ and viral PTEN
knockdown.
4.3 Methods
Any references to Chapter 2 are clearly stated in the text.
72 Viral Manipulation of the PI3K Pathway and its Effects on Axon Regeneration
4.3.1 In Vitro Work
Before injecting the viruses in vivo, they were tested in vitro. Human embryonic kidney
(HEK) 293 cells were transfected with AAV2.shPTEN.GFP (gifted by Z. He),
AAV2.shScram.GFP (SignaGen Labs, cat no. SL100815), AAV2.shScram.GFP (Vigene
Biosciences, cat no. P100042), AAV2.PI3K(p110δ ) (produced for project), and AAV2.GFP
(Vigene Biosciences, cat no. CV17169-AV2), as described in Chapter 2.1. Two
AAV2.shScram.GFP viruses were trialled to see which gave the most GFP signal.
4.3.2 In Vivo Work
Viral Validation Work: Retinal Sections
For viral validation work in vivo, young adult (6 to 16 weeks old) C57BL/6J mice received
a 2µL intravitreal injection of AAV2.shPTEN.GFP (gifted by Z. He) into the left eye and
2µL of AAV2.shScram.GFP (SignaGen Labs, cat no. SL100815) into the right eye, as
described in Chapter 2.3. Another set of mice received a 2µL intravitreal injection of
AAV2.PI3K(p110δ ) (produced for project) into the left eye, and 2µL of AAV2.GFP (Vigene
Biosciences, cat no. CV17169-AV2) into the right eye. All viruses were injected at a titre of
1.0 x 1013GC/mL, a preoptimised titre for viral intravitreal injections. 2 weeks after injection,
the mice were perfused, as described in Chapter 2.5.
Whole eyes were collected, post-fixed in 4% paraformaldehyde (PFA) at room tempera-
ture for 2 hours, and then transferred to 20% sucrose overnight at 4°C for cryoprotection,
as described in Chapter 2.6.2. The eyes were then embedded in Tissue-Tek OCT com-
pound and cryosectioned (12µm thick) using a Leica cryostat (Leica Biosystems, CM 3050S
Research Cryostat).
Regeneration Studies
For the regeneration work, young adult (6 to 8 weeks old) C57BL/6J mice received a 2µL
intravitreal injection of AAV2.shPTEN.GFP (gifted by Z. He), AAV2.shScram.GFP (Signa-
Gen Labs, cat no. SL100815), AAV2.PI3K(p110δ ) (produced for project), or AAV2.GFP
(Vigene Biosciences, cat no. CV17169-AV2) into the left eye, as described in Chapter 2.3.
2 weeks after injection, the mice received an ONC injury behind the left eye, as described
in Chapter 2.4. At 26 days post-ONC, the mice were intravitreally injected with cholera
toxin subunit-β with an Alexa Fluor 555 conjugate (CTB-555) (Thermo Fisher Scientific,
cat no. C22843), as described in Chapter 2.3. At 4 weeks post-ONC, mice were perfused,
as described in Chapter 2.5.
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The optic nerves were collected, post-fixed in 4% PFA at 4°C overnight, and transferred
to 30% sucrose for at least 24 hours for cryoprotection, as described in Chapter 2.6.1. The
nerves were then cryosectioned (14µm longitudinal sections) using a Leica cryostat (Leica
Biosystems, CM 3050S Research Cryostat).
The retinas were collected, and four small incisions were made to form retinal whole-
mounts (RWMs), as described in Chapter 2.6.3. RWMs were post-fixed in 4% PFA for 2
hours at room temperature, and then the solution was changed to phosphate-buffered saline
(PBS), ready for immunohistochemistry (IHC).
4.3.3 Immunohistochemistry
IHC for HEK 293 Cells In Vitro
Having been fixed in 4% PFA, HEK 293 cells were counterstained with DAPI, and IHC
against PI3K(p110δ ) was performed for AAV2.PI3K(p110δ )- and AAV2.GFP- transfected
cells, as described in Chapter 2.7.1.
Retinal Section Histology
Having been fixed in 4% PFA and sectioned, IHC was performed as described in Chapter
2.7.2. IHC against GFP and PI3K(p110δ ) was used to identify the viral vectors. IHC against
PTEN and PI3K(p110δ ) was used to quantify PTEN knockdown and PI3K upregulation
respectively. IHC against phospho-AKT (pAKT) and phospho-S6 ribosomal protein (pS6)
was used to quantify PI3K/AKT/mTOR pathway activity.
Retinal Wholemount Histology
Having been fixed in 4% PFA, the RWMs were then stored in PBS at 4°C. IHC against
Brn3A, an RGC marker, was performed on RWMs as described in Chapter 2.7.3.
4.3.4 Microscopy and Quantification
Viral Validation In Vitro
HEK 293 cells transfected with either AAV2.shPTEN.GFP, AAV2.shScram.GFP, or
AAV2.GFP were counterstained with DAPI. HEK 293 cells transfected with either
AAV2.PI3K(p110δ ) or AAV2.GFP were immunostained for PI3K(p110δ ) and counterstained
with DAPI. These were imaged by confocal microscopy at x40 magnification. The images
were used to confirm that the GFP viral tag or the PI3K(p110δ ) signal was observed and that
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this signal was not seen in untransfected (naive) cells. They also confirmed that PI3K(p110δ )
signal was not seen in AAV2.GFP-transfected cells.
Viral Validation: Viral Tags
Successful viral transduction was confirmed in retinal sections injected with
AAV2.shPTEN.GFP, AAV2.shScram.GFP and AAV2.GFP, immunostained for GFP and
counterstained with DAPI. For AAV2.PI3K(p110δ ), sections were immunostained for
PI3K(p110δ ) and counterstained with DAPI. GFP or PI3K(p110δ ) signal was used to
confirm the presence of the viral vectors, and eye cups were imaged using a Zeiss AxioScan
Z1 at x20 magnification (0.22µm/pixel) by the team at the Histopathology/ISH core facility
at the Cancer Research UK (CRUK) Cambridge. The RGC layer of retinal sections was
imaged using confocal microscopy at x40 magnification.
PTEN Knockdown and PI3K Upregulation In Vivo
Some data from R. Conceição was included in the results section for completeness. HEK
293 cells transfected with each virus were analysed using western blots and immunoblotting
for PTEN and PI3K(p110δ ), as described in Chapter 2.8. The amount of PI3K(p110δ )
and PTEN signal was quantified using Image J Fiji (Fiji-win64) and expressed relative to
the β -actin signal for each sample. The average signal relative to β -actin for AAV2.GFP-
transfected cells was calculated. All values were then expressed relative to this average for
AAV2.GFP.
For the in vivo work, which I did, retinal sections transduced with either
AAV2.shPTEN.GFP or AAV2.shScram.GFP were immunostained with PTEN antibody and
imaged by confocal microscopy at x95 magnification, using consistent settings. Retinal
sections transduced with either AAV2.PI3K(p110δ ) or AAV2.GFP were immunostained
with PI3K(p110δ ) antibody and imaged by confocal microscopy at x40 magnification, using
consistent settings.
Several RGCs were then analysed by drawing around each RGC and using Image J Fiji
(Fiji-win64) to quantify the fluorescence value of each RGC. The average fluorescence value
of the RGCs was found and compared to that seen from the respective control virus.
RGC Survival
Percentage RGC survival was calculated as described in Chapter 2.9.4. In brief, Brn3A-
stained RWMs were imaged at x20 magnification using fluorescence microscopy. For each
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image, the number of RGCs was quantified using a counting program in Image J Fiji (Fiji-
win64). The number of surviving RGCs in the ONC (left) eye was expressed as a percentage
relative to the number of RGCs in the uninjured contralateral control (right) eye.
Axon Regeneration
Axon regeneration was calculated as described in Chapter 2.9.5. In brief, the CTB-555-
labelled axons were visualised using fluorescence microscopy at x40 magnification, counting
the number of axons at 0.5mm increments from the crush site. Modelling the nerve as a
cylinder, the number of regenerating axons per nerve was calculated at each increment using
a previously developed formula. Four sections were counted per nerve and used to average
the total number of regenerating axons per nerve.
Axonal sections were imaged using a Zeiss AxioScan Z1 at x40 magnification
(0.11µm/pixel) by the Histopathology/ISH core facility at the CRUK Cambridge Institute.
Viral Validation: PI3K/AKT/mTOR Pathway Activation
Retinal sections injected with the viral vectors and immunostained with either pAKT or pS6
were examined at x40 magnification by fluorescence microscopy, as described in Chapter
2.9.3. In brief, for AAV2.shPTEN.GFP and AAV2.shScram.GFP, 100 GFP-positive RGCs,
identified using DAPI and GFP signal from the viral vector, were counted and identified
as either positive or negative for pAKT. This method was repeated for retinal sections
immunostained with pS6. Four mice were counted for each group (100 RGCs per mouse),
and the average was expressed as a percentage of GFP-positive cells co-localised with pAKT
or pS6.
AAV2.PI3K(p110δ ) lacked a clear viral tag, so the total number of pS6-positive RGCs
was counted across the retina from 12 retinal sections, sampled sequentially throughout the
whole eye, using β III tubulin (Tuj1) as a marker of RGC neurons. This method was repeated
for AAV2.GFP-transduced retinal sections for comparison. The pAKT signal was not clear
enough to count in this way.
Representative images were taken at x80 magnification by confocal microscopy.
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4.4 Results
4.4.1 Viral Validation
AAV2.shPTEN.GFP, AAV2.shScram.GFP, AAV2.PI3K(p110δ ), and AAV2.GFP
successfully transfected HEK 293 cells in vitro
Before using the AAV2.shPTEN.GFP, AAV2.shScram.GFP, AAV2.PI3K(p110δ ), and
AAV2.GFP viruses in vivo, successful viral transfection was confirmed in vitro using HEK
293 cells, as shown in Fig. 4.1. Signal from the viral tag, GFP, was detected from all viruses,
except AAV2.PI3K(p110δ ). AAV2.shScram.GFP (SignaGen Labs, cat no. SL100815)
gave noticeably stronger GFP signal than AAV2.shScram.GFP (Vigene Biosciences, cat
no. P100042) so this virus was used in vivo. PI3K(p110δ ) signal was seen for the
AAV2.PI3K(p110δ ) virus but was absent in the AAV2.GFP virus, confirming antibody
specificity, as seen in Fig. 4.4 panel C.
Fig. 4.1 AAV2.shPTEN.GFP and AAV2.shScram.GFP were tested in vitro. One
AAV2.shPTEN.GFP and two AAV2.shScram.GFP viruses were tested in HEK 293 cells
prior to in vivo work. The presence of GFP signal indicates successful transfection.
AAV2.shScram.GFP from SignaGen Labs gave a stronger signal than AAV2.shScram.GFP
from Vigene Biosciences. Scale bar = 100µm.
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AAV2.shPTEN.GFP, AAV2.shScram.GFP, AAV2.PI3K(p110δ ), and AAV2.GFP
successfully transduced RGCs in vivo
Viral transduction of RGCs was tested in vivo. Young adult (6 to 16 weeks old) C57BL/6J
mice were injected intravitreally with 2µL of either AAV2.shPTEN.GFP or
AAV2.PI3K(p110δ ) in the left eye and 2µL of either AAV2.shScram.GFP or AAV2.GFP
respectively in the right eye. The eyes were collected 2 weeks later and 12µm retinal sections
were produced.
Successful viral transduction of AAV2.shPTEN.GFP, AAV2.shScram.GFP, and
AAV2.GFP in vivo was confirmed by signal from the viral tag, GFP, in the RGC layer. The
presence of PI3K(p110δ ) was confirmed for the AAV2.PI3K(p110δ ) virus. Eye cup images
showed signal throughout the retina, and closer inspection of the retinal sections confirmed
that this signal was in the RGC layer, as shown in Fig. 4.2, where staining was indicative of
RGCs.
Fig. 4.2 Successful viral transduction of AAV2.shPTEN.GFP, AAV2.shScram.GFP,
AAV2.PI3K(p110δ ) and AAV2.GFP was confirmed in vivo. In panel A, eye cups and
zoomed in images of the RGC layer showed GFP signal in RGCs throughout the retina for
AAV2.shScram.GFP (i), AAV2.shPTEN.GFP (ii) and AAV2.GFP (iii), and PI3K(p110δ )
signal in RGCs throughout the retina for AAV2.PI3K(p110δ ) (iv). Staining was indicative of
RGCs. Scale bar = 500µm for eye cups, 100µm for retinal sections.
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Successful PTEN Knockdown and PI3K Upregulation were confirmed both in vitro
and in vivo
To confirm that the AAV2.shPTEN.GFP virus resulted in PTEN knockdown, an antibody
against PTEN was used in HEK 293 cells in vitro and in retinal sections in vivo, as shown
in Fig. 4.3. Western blots of transfected HEK 293 cells performed by R. Conceição (in-
cluded here for comparison with my in vivo work) showed 1.28±0.15 signal (n=3 wells) in
AAV2.shScram.GFP-treated cells (fold change in PTEN relative to AAV2.GFP-treated cells),
which decreased to 0.10±0.03 (n=3 wells) in AAV2.shPTEN.GFP-treated cells (one-tailed
T-test, p<0.0001). There was 12.8-fold more PTEN signal in the control group than the
PTEN knockdown group in vitro. In retinal sections, staining in the RGC layer was indicative
of RGCs and a fluorescence value per RGC of 22.5±11.4 (n=20 RGCs) was observed in
AAV2.shScram.GFP-treated eyes, which significantly decreased to 4.1±2.0 (n=19 RGCs)
in AAV2.shPTEN.GFP-treated eyes (one-tailed T-test, p<0.0001). There was 5.5-fold more
PTEN signal in the control group than the PTEN knockdown group in vivo.
To confirm that the AAV2.PI3K(p110δ ) virus resulted in PI3K upregulation, an antibody
against PI3K(p110δ ) was used in HEK 293 cells in vitro and in retinal sections in vivo.
Western blots of transfected HEK 293 cells performed by R. Conceição (included here for
comparison with my in vivo work) showed 1.00±0.76 signal (n=3 wells) in AAV2.GFP-treated
cells (fold change in PI3K(p110δ ) relative to AAV2.GFP-treated cells), which increased to
46.08±8.79 (n=3 wells) in AAV2.PI3K(p110δ )-treated cells (one-tailed T-test, p=0.0005), as
shown in Fig. 4.4. There was 46.1-fold more PI3K(p110δ ) signal in the AAV2.PI3K(p110δ )
group compared to control in vitro. In retinal sections, a fluorescence value per RGC of
5.7±2.5 (n=41 RGCs) was observed in AAV2.GFP-treated eyes, which significantly increased
to 7.6±3.9 (n=31 RGCs) in AAV2.PI3K(p110δ )-treated eyes (one-tailed T-test, p=0.0080).
There was 1.3-fold more PI3K(p110δ ) signal in the AAV2.PI3K(p110δ ) group compared to
control in vivo.
4.4.2 RGC Survival and Axon Regeneration
Adult (6 to 8 weeks old) C57BL/6J mice received a 2µL intravitreal injection of either
AAV2.shPTEN.GFP, AAV2.shScram.GFP, AAV2.PI3K(p110δ ), or AAV2.GFP into the left
eye. 2 weeks later, ONC surgery was performed. At 26 days post-ONC, 2µL of cholera toxin
subunit-β with an Alexa Fluor 555 conjugate (CTB-555) was intravitreally injected into the
left eye. At 4 weeks post-ONC, the eyes and optic nerves were collected, as summarised in
Fig. 4.5.
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Fig. 4.3 AAV2.shPTEN.GFP successfully knocked down PTEN levels both in vitro and
in vivo In panel A and C, a 12.8-fold knockdown of PTEN was shown in vitro. In panel
B and D, a 5.5-fold knockdown was shown in vivo. Staining in the RGC layer of retinal
sections was indicative of RGCs. p values measured by one-tailed T-test, n = 3 for in vitro
and 19 to 20 for in vivo as specified, error bars = SD. Scale bar = 100µm. in vitro data
provided by R. Conceição
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Fig. 4.4 AAV2.PI3K(p110δ ) successfully upregulated PI3K(p110δ ) levels both in vitro
and in vivo. In panel A and C, a 46.1-fold increase of p110δ was shown in vitro. In panel
B and D, a 1.3-fold increase of PI3K(p110δ ) was shown in vivo. p values measured by
one-tailed T-test, n = 3 for in vitro and n = 31 to 41 for in vivo as specified, error bars = SD.
Scale bar = 100µm. in vitro data provided by R. Conceição.
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Fig. 4.5 Chapter 4 Experimental Summary.
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PTEN knockdown promoted RGC Survival, but PI3K upregulation had no significant
effect
The retinas were collected at 4 weeks post-ONC and IHC against Brn3A, an RGC marker,
was used to quantify RGCs. The number of surviving RGCs in the ONC (left) eye was
expressed as a percentage relative to the uninjured contralateral control (right) eye.
Young adult (6 to 8 weeks old) mice treated with AAV2.shPTEN.GFP showed 14.7%±7.6
(n=6 retinas) RGC survival at 4 weeks post-ONC, which was a significant increase from
the 5.0%±3.9 (n=8 retinas) RGC survival seen in the AAV2.shScram.GFP-treated mice (see
Fig. 4.6, one-tailed T-test, p=0.0044). Therefore, viral PTEN knockdown promotes RGC
survival at 4 weeks post-ONC.
Young adult (6 to 8 weeks old) mice treated with AAV2.PI3K(p110δ ) showed
11.3%±11.8 (n=7 retinas) RGC survival at 4 weeks post-ONC, compared to 4.7%±1.7 (n=4
retinas) RGC survival seen in the AAV2.GFP-treated mice (see Fig. 4.7). The increase in
survival was not statistically significant. Therefore, viral PI3K upregulation had no significant
effect on RGC survival at 4 weeks post-ONC in this experiment.
Comparison of viral PI3K upregulation with transgenic PI3K upregulation, which showed
11.4%±5.8 RGC survival in Chapter 3.4.4, and with viral PTEN knockdown, showed no
statistical difference between the groups, as shown in Fig. 4.8.
PTEN knockdown and PI3K upregulation promoted axon regeneration
2 days before tissue collection, the left eyes were intravitreally injected with 2µL of CTB-
555. At 4 weeks post-ONC, the optic nerves were dissected, and 14µm thick sections were
produced. Axons were counted using the CTB-555 fluorescence at 0.5mm increments.
Young adult (6 to 8 weeks old) mice treated with AAV2.shPTEN.GFP showed 117±93
regenerating axons (n=5 nerves) at 0.5mm from the crush site, which was a significant
increase compared to 16±11 axons (n=4 nerves) in the AAV2.shScram.GFP-treated mice (see
Fig. 4.9, two-way ANOVA with Tukey’s post-hoc analysis, p = 0.0090). Regenerating axons
were seen up to 1.5mm from the crush site. Therefore, viral PTEN knockdown promotes
axon regeneration at 4 weeks post-ONC.
Young adult (6 to 8 weeks old) mice treated with AAV2.PI3K(p110δ ) showed 180±96
regenerating axons (n=6 nerves) at 0.5mm from the crush site, significantly more than
the 31±20 axons (n=5 nerves) in the AAV2.GFP-treated mice (see Fig. 4.10, two-way
ANOVA with Tukey’s post-hoc analysis, p < 0.0001). At 1.0mm from the crush site, the
AAV2.PI3K(p110δ ) mice showed 104±80 regenerating axons, compared to 7±6 axons in the
control (two-way ANOVA with Tukey’s post-hoc analysis, p = 0.0072). Regenerating axons
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Fig. 4.6 Viral PTEN knockdown promoted RGC Survival. As seen in panel A,
AAV2.shPTEN.GFP promotes RGC survival 4 weeks post-ONC injury. RWMs were stained
with Brn3A (red), which was used to quantify RGCs. The number of RGCs in the ONC (left)
eye (panels Bii and Biv) was expressed as a percentage survival relative to the uninjured
contralateral control (right) eye (Bi and Biii). p values measured by one-tailed T-test, n = 6
to 8 as specified, error bars = SD. Scale bar = 100µm.
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Fig. 4.7 Viral PI3K upregulation had no significant effect on RGC survival. As seen in
panel A, viral PI3K(p110δ ) had no significant effect on RGC survival 4 weeks post-ONC
injury. RWMs were stained with Brn3A (red), which was used to quantify RGCs. The
number of RGCs in the ONC (left) eye (panels Bii and Biv) was expressed as a percentage
survival relative to the uninjured contralateral control (right) eye (Bi and Biii). p values
measured by one-tailed T-test, n = 4 to 7 as specified, error bars = SD. Scale bar = 100µm.
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Fig. 4.8 Comparison of viral PI3K upregulation with transgenic PI3K upregulation
and viral PTEN knockdown showed no difference between groups. RGC survival data
from PI3K upregulation, both viral and transgenic, PTEN knockdown were all compared. p
values measured by one-way ANOVA with Tukey’s post-hoc analysis, n = 6 to 10 as specified,
error bars = SD.
were seen up to 3.0mm from the crush site. Therefore, viral PI3K upregulation promotes
axon regeneration at 4 weeks post-ONC.
The viral and transgenic PI3K upregulation strategies were compared in Fig. 4.11.
180±96 regenerating axons were observed at 0.5mm from the crush site in the viral strat-
egy, which was significantly more than 61±36 axons in the transgenic strategy (two-way
ANOVA with Tukey’s post-hoc analysis, p = 0.0495). No statistical significance was found
between AAV2.shPTEN.GFP-treated mice compared to AAV2.PI3K(p110δ )-treated mice
or AAV2.Cre.GFP-treated p110δ mice. Therefore, viral PI3K upregulation promotes axon
regeneration more than the transgenic strategy, but not significantly more than viral PTEN
knockdown at 4 weeks post-ONC.
4.4.3 mTOR Pathway Activation
IHC against mTOR pathway markers (pAKT and pS6) was performed on the retinal sections
used for viral validation.
In the PTEN knockdown mice, the percentage of GFP-labelled cells in the RGC layer
co-localised with either pAKT or pS6 was quantified and compared to control injection, as
shown in Fig. 4.12. Staining was indicative of RGCs. Eyes injected with AAV2.shScram.GFP
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Fig. 4.9 Viral PTEN knockdown promoted axon regeneration. As shown in panel A,
AAV2.shPTEN.GFP promoted axon regeneration following ONC injury. Images of crushed
nerves are shown in panel B for AAV2.shScram.GFP (Bi) and for AAV2.shPTEN.GFP
(Bii). p values measured by two-way ANOVA with Tukey’s post hoc analysis, n = 4 to 5 as
specified, error bars = SEM. Scale bar = 100µm.
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Fig. 4.10 Viral PI3K upregulation promoted axon regeneration. As shown in panel A,
AAV2.PI3K(p110δ promoted axon regeneration following ONC injury. Images of crushed
nerves are shown in panel B for AAV2.GFP (Bi) and for AAV2.PI3K(p110δ ) (Bii). p values
measured by two-way ANOVA with Tukey’s post hoc analysis, n = 5 to 6 as specified, error
bars = SEM. Scale bar = 100µm.
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Fig. 4.11 Viral PI3K upregulation promoted axon regeneration more than the trans-
genic approach, but not significantly more than viral PTEN knockdown. As shown in
panel A, viral PI3K upregulation promoted axon regeneration following ONC injury sig-
nificantly more than the transgenic approach. However, no significant difference was seen
when comparing viral PI3K upregulation with viral PTEN knockdown. Images of crushed
nerves are shown in panel B for AAV2.shPTEN.GFP in C57BL/6J (Bi), AAV2.PI3KDelta in
C57BL/6J (Bii) and AAV2.Cre.GFP in the p110δ transgenic (Biii). p values measured by
two-way ANOVA with Tukey’s post hoc analysis, n = 5 to 6 as specified, error bars = SEM.
Scale bar = 100µm.
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showed 27.0%±5.0 pAKT-GFP-labelled cells, which increased 48.8%±7.0 in the
AAV2.shPTEN.GFP-injected eyes (one-tailed T-test, p=0.0012). The average fold change
in pAKT was 1.91±0.34. Eyes injected with AAV2.shScram.GFP showed 51.8%±4.6 pS6-
GFP-labelled cells, which increased to 72.0%±6.3 in the AAV2.shPTEN.GFP-injected eyes
(one-tailed T-test, p=0.0010). The average fold change in pS6 was 1.41±0.23.
In the PI3K upregulation mice, the AAV2.PI3K(p110δ ) virus lacked a clear viral tag, so
Tuj1 was used to label RGCs. The total number of pS6-labelled RGCs was counted across
12 retinal sections, as shown in Fig. 4.13. Eyes injected with AAV2.GFP showed 650±64
pS6-positive RGCs, which increased to 1140±85 in the AAV2.PI3K(p110δ ) eyes (one-tailed
T-test, p<0.0001). The average fold change in pS6 was 1.77±0.25.
No significant differences were found in the fold-change of pS6 signal when comparing
viral PI3K upregulation with the transgenic strategy and with viral PTEN knockdown.
4.5 Discussion
Both viral PTEN knockdown and viral PI3K upregulation promoted axon regeneration, with
no significant difference between the two. Viral PTEN knockdown also promoted RGC
survival, but surprisingly viral PI3K upregulation had no significant effect in this experiment.
There was a high level of variation in the viral PI3K upregulation data, and repeating this
experiment to increase the n size would likely result in significant survival, especially as
transgenic PI3K upregulation did promote RGC survival.
Next, viral and transgenic PI3K upregulation were compared. No significant difference
in RGC survival was found between these experiments, but viral PI3K(p110δ ) showed
significantly greater axon regeneration as expected. Unfortunately, the PI3K(p110δ ) antibody
gave high levels of background signal in vivo, so it was not easily possible to quantify
PI3K(p110δ ) levels for comparison of the two approaches.
mTOR pathway activation was quantified and compared across the different groups. It
was particularly difficult to assess pS6 and pAKT levels in eyes treated with the
AAV2.PI3K(p110δ ) virus because the virus lacked a viral tag, so this was quantified differ-
ently from the other groups. Although fold change was compared, this was not very accurate
due to the different counting methods used. As mentioned in Chapter 3, if a method for
isolating RGCs were optimised, this would allow more accurate quantification of mTOR
pathway markers.
Treatment with rapamycin, an mTOR inhibitor, neutralised most of the pro-regenerative
effects of transgenic PTEN knockdown in Park et al.[79]. It would be interesting to investi-
gate what pathways other than the PI3K/AKT/mTOR pathway are involved in promoting
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Fig. 4.12 Viral PTEN knockdown resulted in increased mTOR pathway activity in
vivo. As shown in the graphs in panels A and B, pAKT and pS6 signal increased in
AAV2.shPTEN.GFP-treated eyes compared to AAV2.shScram.GFP-treated eyes. Represen-
tative images are shown in panel C. Staining in the RGC layer was indicative of RGCs. p
values measured by one-tailed T-test, n = 4, error bars = SD. Scale bar = 100µm.
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Fig. 4.13 Viral PI3K upregulation resulted in increased mTOR pathway activity in vivo.
As shown in the graphs in panels A and B, pS6 signal increased in AAV2.PI3K(p110δ )-
treated eyes compared to AAV2.GFP-treated eyes. Representative images are shown in panel
C. p values measured by one-tailed T-test, n = 4, error bars = SD. Scale bar = 100µm.
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regeneration. It would also be interesting to see to what extent mTOR inhibition neutralised
the effects of PI3K upregulation.
Further work could investigate these viruses in aged mice to see whether these pro-
regenerative effects are conserved with aging, like with transgenic PI3K upregulation. Addi-
tional work combining PI3K upregulation with other approaches was investigated in Chapter
5.
Chapter 5
Combining PI3K Upregulation with
Other Strategies
5.1 Declaration
Some of the work presented in this thesis chapter is being prepared for publication, along
with some insulin data not shown in this thesis, which was generated by S.S. Desphande.
At the time of thesis submission, the manuscript has not yet been submitted. This work
will be cited as: Evans, R.S., Deshpande, S.S., Conceição, R., Hänzi, B., Hulshof, L-A.,
Osborne, A., Fawcett, J.W., Martin, K.R., Eva, R., Barber, A.C.. (2019) Translatable methods
to stimulate mTOR mediated axon regeneration. (Manuscript in preparation).
The work presented in this thesis chapter was all generated by me, under the supervision
of A.C. Barber, with contributions from others declared below.
Viruses: The AAV2.shPTEN.GFP virus was gifted by Z. He. The AAV2.PI3K(p110δ ),
AAV2.Integrin.V5 and AAV2.Kindlin.GFP viruses were generated by B. Hänzi, A. Osborne
and L-A. Hulshof.
In vitro data (Fig 5.2): R. Conceição quantified PTEN and PI3K levels in human embry-
onic kidney (HEK) 293 cells transfected with the AAV2.PI3K(p110δ ), AAV2.shPTEN.GFP
and AAV2.shScram.GFP viruses. While I was not involved in measuring the PTEN and PI3K
levels in vitro, the data is presented in the results section of this chapter for completeness
with my in vivo data, with appropriate referencing in the text.
Regeneration data: All regeneration data was generated by me under the supervision of
A.C. Barber.
Validation data: All validation data, including testing the viral vectors in vitro and in
vivo, and quantifying mTOR pathway activity, was generated by me.
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5.2 Introduction
5.2.1 Combination of Strategies for Robust Axon Regeneration
As described more fully in Chapter 1.4, it is becoming increasingly clear that combining
clinical interventions is required for robust axon regeneration beyond the optic chiasm and
into the brain. Having assessed phosphoinositide 3-kinase (PI3K) upregulation individually
in Chapters 3 and 4, the next step was to try combining this with other approaches, like
phosphatase and tensin homolog (PTEN) knockdown and integrin activation.
It was demonstrated that PI3K upregulation increased phosphatidylinositol (3,4,5)-tris-
phosphate (PIP3) levels generated, resulting in pro-regenerative effects. By simultaneously
knocking down PTEN, PIP3 levels would be expected to increase further by reducing the
conversion from PIP3 to phosphatidylinositol(3,4)-bis-phosphate (PIP2) and could potentially
have greater pro-regenerative effects than PI3K upregulation alone.
As described in Chapter 1.3, integrin activation upregulates the mammalian target of
rapamycin (mTOR) pathway downstream of PIP3, and upregulates other pathways, including
the focal adhesion kinase (FAK) pathway. Integrin activation has been shown to have
pro-regenerative effects both in vitro and in vivo. Combination of integrin-α9 and kindlin-
1 has been shown to lead to more robust axonal regeneration in spinal cord injury[12].
Therefore, in this experiment we introduced integrin-α9 and kindlin-1 in combination with
PI3K upregulation, expecting to further enhance the regenerative effects seen from PI3K
upregulation alone.
5.2.2 Aim
I investigated the effects on retinal ganglion cell (RGC) survival and axon regeneration
of combining PI3K upregulation with either PTEN knockdown or with integrin activation,
using the same experimental paradigm as in Chapters 3 and 4. We hypothesised that the
combination treatments would increase both RGC survival and axon regeneration compared
to PI3K upregulation alone.
5.3 Methods
Any references to Chapter 2 are clearly stated in the text.
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5.3.1 In Vitro Work
Before injecting the viruses in vivo, they were tested in vitro. Human embryonic kidney
(HEK) 293 cells were transfected with AAV2.Integrin.V5 (produced for project, using integrin
α9) and AAV2.Kindlin.GFP (produced for project, using kindlin-1), as described in Chapter
2.1. AAV2.PI3K(p110δ ) (produced for project) and AAV2.GFP (Vigene Biosciences, cat no.
CV17169-AV2) were validated in Chapter 4.4.1.
5.3.2 In Vivo Work
Viral Validation Work: Retinal Sections
For viral validation work in vivo in Part 1, young adult (6 to 16 weeks old) C57BL/6J mice
were intravitreally injected with 2µL of AAV2.PI3K(p110δ ) (produced for project) plus
2µL of AAV2.shPTEN.GFP (gifted by Z. He) into the left eye and as a control, 2µL of
AAV2.PI3K(p110δ ) (produced for project) plus 2µL of AAV2.shScram.GFP (SignaGen
Labs, cat no. SL100815) into the right eye, as described in Chapter 2.3. The two injections
were performed 4 days apart. All viruses were injected at a titre of 1.0 x 1013GC/mL, a
preoptimised titre for viral intravitreal injections.
For viral validation work in vivo in Part 2, young adult (6 to 16 weeks old) C57BL/6J
mice were injected intravitreally with 2µL of AAV2.PI3K(p110δ ), then 2µL of either
AAV2.Integrin.V5 or AAV2.GFP, then 2µL of AAV2.Kindlin.GFP or AAV2.GFP. An-
other group of mice was intravitreally injected with 2µL of AAV2.Integrin.V5 and 2µL
AAV2.Kindlin.GFP, without the AAV2.PI3K(p110δ ), as a control. Each injection was
performed 4 days apart.
2 weeks after the final injection, the mice were perfused, as described in Chapter 2.5.
Whole eyes were collected, post-fixed in 4% paraformaldehyde (PFA) at room temperature
for 2 hours, and then transferred to 20% sucrose overnight at 4°C for cryoprotection, as
described in Chapter 2.6.2. The eyes were then embedded in Tissue-Tek OCT compound and
cryosectioned (12µm thick) using a Leica cryostat (Leica Biosystems, CM 3050S Research
Cryostat).
Regeneration Studies
For the regeneration work in Part 1, young adult (6 to 8 weeks old) C57BL/6J mice were
intravitreally injected in the left eye with 2µL of AAV2.PI3K(p110δ ) (produced for project)
plus 2µL of AAV2.shPTEN.GFP (gifted by Z. He), or 2µL of AAV2.PI3K(p110δ ) (produced
96 Combining PI3K Upregulation with Other Strategies
for project) plus 2µL of AAV2.shScram.GFP (SignaGen Labs, cat no. SL100815), as
described in Chapter 2.3.
For the regeneration work in Part 2, young adult (6 to 8 weeks old) C57BL/6J mice were
intravitreally injected with 2µL of AAV2.PI3K(p110δ ), then 2µL of either AAV2.Integrin.V5
or AAV2.GFP, then 2µL of AAV2.Kindlin.GFP or AAV2.GFP. Another group of mice was
intravitreally injected with 2µL of AAV2.Integrin.V5 and 2µL AAV2.Kindlin.GFP, without
the AAV2.PI3K(p110δ ), as a control. Each injection was performed 4 days apart.
In the second round of Part 2, the number of injections was reduced from 3 to 2. Young
adult (6 to 8 weeks old) C57BL/6J mice were intravitreally injected with 2µL total of
AAV2.PI3K(p110δ ) plus AAV2.Kindlin.GFP or 2µL total of PI3K(p110δ ) plus AAV2.GFP.
One week later, all mice were injected with 2µL of AAV2.Integrin.V5.
2 weeks after the final injection, the mice received an optic nerve crush (ONC) injury
behind the left eye, as described in Chapter 2.4. At 26 days post-ONC, the mice were
intravitreally injected with cholera toxin subunit-β with an Alexa Fluor 555 conjugate (CTB-
555) (Thermo Fisher Scientific, cat no. C22843), as described in Chapter 2.3. At 4 weeks
post-ONC, mice were perfused, as described in Chapter 2.5.
The optic nerves were collected, post-fixed in 4% PFA at 4°C overnight, and transferred
to 30% sucrose for at least 24 hours for cryoprotection, as described in Chapter 2.6.1. The
nerves were then cryosectioned (14µm longitudinal sections) using a Leica cryostat (Leica
Biosystems, CM 3050S Research Cryostat).
The retinas were collected, and four small incisions were made to form retinal whole-
mounts (RWMs), as described in Chapter 2.6.3. RWMs were post-fixed in 4% PFA for 2
hours at room temperature, and then the solution was changed to phosphate-buffered saline
(PBS), ready for immunohistochemistry (IHC).
5.3.3 Immunohistochemistry
IHC for HEK 293 Cells In Vitro
Having been fixed in 4% PFA, HEK 293 cells were counterstained with DAPI. IHC against
V5 was performed on AAV2.Integrin.V5- and AAV2.GFP- transfected cells, as described in
Chapter 2.7.1.
Retinal Section Histology
Having been fixed in 4% PFA and sectioned, IHC was performed as described in Chapter
2.7.2. IHC against PI3K(p110δ ), GFP and V5 was used to identify the viral vectors. IHC
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against phospho-AKT (pAKT) and phospho-S6 ribosomal protein (pS6) was used to quantify
PI3K/AKT/mTOR pathway activity.
Retinal Wholemount Histology
Having been fixed in 4% PFA, the RWMs were then stored in PBS at 4°C. IHC against
Brn3A, an RGC marker, was performed on RWMs as described in Chapter 2.7.3.
5.3.4 Microscopy and Quantification
Viral Validation In Vitro
HEK 293 cells transfected with either AAV2.Integrin.V5 or AAV2.GFP were immunostained
for V5 and counterstained with DAPI. HEK 293 cells transfected with AAV2.Kindlin.GFP
were counterstained with DAPI. These were imaged by confocal microscopy at x40 magnifi-
cation. The images were used to confirm that the V5 or GFP viral tag signal was observed
and that this signal was not seen in untransfected (naive) cells. They also confirmed that V5
signal was not seen in AAV2.GFP-transfected cells.
Viral Validation: Viral Tags
Successful viral transduction was confirmed in retinal sections injected with
AAV2.Integrin.V5, immunostained for V5, and counterstained with DAPI. For
AAV2.Kindlin.GFP and AAV2.GFP, slides were immunostained for GFP and counterstained
with DAPI. For AAV2.PI3K(p110δ ), sections were immunostained for PI3K(p110δ ) and
counterstained with DAPI. V5, GFP or PI3K(p110δ ) signal was used to confirm the presence
of the viral vectors, and eye cups were imaged using a Zeiss AxioScan Z1 at x20 magnification
(0.22µm/pixel) by the team at the Histopathology/ISH core facility at the Cancer Research
UK (CRUK) Cambridge. The RGC layer of retinal sections was imaged using confocal
microscopy at x40 magnification.
Combination of PI3K Upregulation and PTEN Knockdown in vitro
Some data from R. Conceição was included in the results section for completeness. HEK
293 cells transfected with a combination of PI3K(p110δ ) plus either AAV2.shPTEN.GFP or
AAV2.shScram.GFP were analysed using western blots and immunoblotting for PTEN and
PI3K(p110δ ), as described in Chapter 2.8. The amount of PI3K(p110δ ) and PTEN signal
was quantified using Image J Fiji (Fiji-win64) and expressed relative to the β -actin signal
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for each sample. The average signal relative to β -actin for AAV2.GFP-transfected cells was
calculated. All values were then expressed relative to this average for AAV2.GFP.
RGC Survival
Percentage RGC survival was calculated as described in Chapter 2.9.4. In brief, Brn3A-
stained RWMs were imaged at x20 magnification using fluorescence microscopy. For each
image, the number of RGCs was quantified using a counting program in Image J Fiji (Fiji-
win64). The number of surviving RGCs in the ONC (left) eye was expressed as a percentage
relative to the number of RGCs in the uninjured contralateral control (right) eye.
Axon Regeneration
Axon regeneration was calculated as described in Chapter 2.9.5. In brief, the CTB-555-
labelled axons were visualised using fluorescence microscopy at x40 magnification, counting
the number of axons at 0.5mm increments from the crush site. Modelling the nerve as a
cylinder, the number of regenerating axons per nerve was calculated at each increment using
a previously developed formula. Four sections were counted per nerve and used to average
the total number of regenerating axons per nerve.
Axonal sections were imaged using a Zeiss AxioScan Z1 at x40 magnification
(0.11µm/pixel) by the Histopathology/ISH core facility at the CRUK Cambridge Institute.
Viral Validation: PI3K/AKT/mTOR Pathway Activation
Retinal sections injected with the viral vectors and immunostained with either pAKT or pS6
were examined at x40 magnification by fluorescence microscopy, as described in Chapter
2.9.3. In brief, 100 GFP-positive RGCs, identified using DAPI and GFP signal from the viral
vector, were counted and identified as either positive or negative for pAKT. This method
was repeated for retinal sections immunostained with pS6. Four mice were counted for each
group (100 RGCs per mouse), and the average was expressed as a percentage of GFP-positive
cells co-localised with pAKT or pS6. Representative images were taken at x80 magnification
by confocal microscopy.
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5.4 Results Part 1: Combination of PI3K Upregulation
and PTEN Knockdown
This chapter investigates PI3K upregulation combined with either PTEN knockdown (Part
1) or integrin activation (Part 2), as summarised in Fig. 5.1.
Fig. 5.1 Chapter 5: Experimental summary.
5.4.1 Viral Validation
Before performing regeneration experiments, AAV2.PI3K(p110δ ) (produced for project),
AAV2.shPTEN.GFP (gifted by Z. He), and AAV2.shScram.GFP (SignaGen Labs, cat no.
SL100815) were validated in vitro and in vivo in Chapter 4.4.1.
Successful PTEN knockdown and PI3K upregulation was confirmed in vitro
R. Conceição transfected HEK 293 cells with AAV2.shScram.GFP, AAV2.shPTEN.GFP,
AAV2.GFP, AAV2.PI3K(p110δ ), AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP, and
AAV2.PI3K(p110δ ) plus AAV2.shPTEN.GFP. These were immunoblotted for PTEN and
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PI3K(p110δ ) using the western blot technique (included here for completeness with my in
vivo work).
HEK 293 cells treated with AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP showed
1.48±0.18 PTEN signal (n=3 wells) (fold change in PTEN relative to AAV2.GFP-treated
cells), which decreased to 0.14±0.09 in HEK 293 cells treated with AAV2.PI3K(p110δ ) plus
AAV2.shPTEN.GFP (one-way ANOVA with Tukey’s post-hoc analysis, p<0.0001), as shown
in Fig. 5.2. There was 10.3-fold more PTEN signal in the control group than the PTEN
knockdown group.
HEK 293 cells treated with AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP showed
27.45±14.89 PI3K(p110δ ) signal (n=3 wells) (fold change in PI3K(p110δ ) relative to
AAV2.GFP-treated cells) and HEK 293 cells treated with AAV2.PI3K(p110δ ) plus
AAV2.shPTEN.GFP showed 31.40±7.76 signal (n=3 wells). As expected, there were no
significant differences in PI3K(p110δ ) signal between the two groups.
As expected, the results showed no significant differences in PTEN signal or PI3K(p110δ )
signal between individually transfecting with AAV2.shPTEN.GFP or AAV2.PI3K(p110δ )
versus in combination, as shown in Fig. 5.2.
A combination of AAV2.PI3K(p110δ ) plus either AAV2.shPTEN.GFP or
AAV2.shScram.GFP successfully transduced RGCs in vivo.
Viral transduction of RGCs was tested in vivo. Young adult (6 to 16 weeks old) C57BL/6J
mice were intravitreally injected with 2µL of AAV2.PI3K(p110δ ) plus 2µL of
AAV2.shPTEN.GFP in the left eye and as a control, 2µL of AAV2.PI3K(p110δ ) plus 2µL
of AAV2.shScram.GFP in the right eye. The two injections were performed 4 days apart.
The eyes were collected 2 weeks after the second injection, and 12µm retinal sections were
produced.
Successful viral transduction in vivo was confirmed by signal from the viral tag, GFP, in
the RGC layer from the AAV2.shPTEN.GFP and AAV2.shScram.GFP viruses. The presence
of PI3K(p110δ ) was confirmed for the AAV2.PI3K(p110δ ) virus. Eye cup images showed
signal throughout the retina, and closer inspection of the retinal sections confirmed that this
signal was in the RGC layer, as shown in Fig. 5.3, where staining was indicative of RGCs.
5.4.2 RGC Survival and Axon Regeneration
Young adult (6 to 8 weeks old) C57BL/6J mice were intravitreally injected in the left eye with
2µL of AAV2.PI3K(p110δ ) plus 2µL of either AAV2.shPTEN.GFP or AAV2.shScram.GFP.
The two injections were performed 4 days apart. 2 weeks after the final injection, ONC injury
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Fig. 5.2 Combination of PI3K upregulation and PTEN knockdown in vitro. HEK
293 cells were transfected with AAV2.shScram.GFP, AAV2.shPTEN.GFP, AAV2.GFP,
AAV2.PI3K(p110δ ), AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP, or AAV2.PI3K(p110δ )
plus AAV2.shPTEN.GFP. In panel A, the fold change in PTEN signal is shown for all groups.
In panel B, the fold change in PI3K(p110δ ) signal is shown for all groups. p values measured
by one-way ANOVA with Tukey’s post-hoc analysis, n = 3, error bars = SD. Data provided
by R. Conceição.
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Fig. 5.3 Successful viral transduction of AAV2.PI3K(p110δ ) plus AAV2.shPTEN.GFP
or AAV2.shScram.GFP was confirmed in vivo. Eye cups and zoomed in images of the
RGC layer showed GFP signal in RGCs throughout the retina for AAV2.shScram.GFP (Ai)
and AAV2.shPTEN.GFP (Aii). PI3K(p110δ ) signal was seen in RGCs throughout the retina
for AAV2.PI3K(p110δ ) (Ai and Aii). Staining was indicative of RGCs. Scale bar = 500µm
for eye cups, 100µm for retinal sections.
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was performed behind the left eye. At 26 days post-ONC, 2µL of cholera toxin subunit-β
with an Alexa Fluor 555 conjugate (CTB-555) was intravitreally injected into the left eye. At
4 weeks post-ONC, the eyes and optic nerves were collected.
Combining PI3K upregulation with PTEN knockdown promoted RGC survival com-
pared to the control but was not significantly greater than AAV2.PI3K(p110δ ) or
AAV2.shPTEN.GFP delivered individually.
The retinas were collected at 4 weeks post-ONC and IHC against Brn3A, an RGC marker,
was used to quantify RGCs. The number of surviving RGCs in the ONC (left) eye was
expressed as a percentage relative to the uninjured contralateral control (right) eye.
Young adult (6 to 8 weeks old) mice treated with AAV2.PI3K(p110δ ) plus
AAV2.shPTEN.GFP showed 17.6%±7.6 (n=10 retinas) RGC survival, which was a sig-
nificant increase from the 7.8%±3.1 (n=9 retinas) RGC survival seen in mice treated with
AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP (one-way ANOVA with Tukey’s post-hoc anal-
ysis, p=0.0378), as shown in Fig. 5.4. Interestingly, mice treated with AAV2.PI3K(p110δ )
plus AAV2.shScram.GFP showed a slightly decreased RGC survival (7.8%) compared to
AAV2.PI3K(p110δ ) alone (11.3%), but this was not statistically significant. Therefore, a
combination of viral PI3K upregulation and PTEN knockdown promoted RGC survival at 4
weeks post-ONC relative to control.
Comparing the combination of PI3K upregulation and PTEN knockdown with
AAV2.PI3K(p110δ ) and AAV2.shPTEN.GFP delivered separately, no significant differences
were seen. Therefore, this approach did not yield significantly greater results than individually
targeting either PI3K upregulation or PTEN knockdown.
Combination of PI3K upregulation with PTEN knockdown promoted axon regenera-
tion compared to control, but less so than AAV2.PI3K(p110δ ) delivered individually.
2 days before tissue collection, the left eyes were intravitreally injected with 2µL of CTB-
555. At 4 weeks post-ONC, the optic nerves were dissected, and 14µm thick sections were
produced. Axons were counted using the CTB-555 fluorescence at 0.5mm increments.
Young adult (6 to 8 weeks old) mice treated with AAV2.PI3K(p110δ ) plus
AAV2.shPTEN.GFP showed 77±26 regenerating axons (n=6 nerves) at 0.5mm from the crush
site, significantly higher than the 32±17 axons (n=8 nerves) in the control group (two-way
ANOVA with Tukey’s post-hoc analysis, p=0.0009). The treatment group also showed 33±23
regenerating axons at 1.0mm from the crush site, significantly higher than the 15±10 axons
in the control group (two-way ANOVA with Tukey’s post-hoc analysis, p=0.0335), as shown
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Fig. 5.4 Combination of PI3K upregulation with PTEN knockdown promoted
RGC survival compared to control. As seen in panel A, AAV2.PI3K(p110δ ) plus
AAV2.shPTEN.GFP promoted RGC survival 4 weeks post-ONC injury compared to con-
trol, but not significantly more than AAV2.PI3K(p110δ ) or AAV2.shPTEN.GFP delivered
individually. RWMs were stained with Brn3A (red), which was used to quantify RGCs. The
number of RGCs in the ONC (left) eye (panels Bii and Biv) was expressed as a percentage
survival relative to the uninjured contralateral control (right) eye (Bi and Biii). p values
measured by one-way ANOVA with Tukey’s post-hoc analysis, n = 5 to 10 as specified, error
bars = SD. Scale bar = 100µm.
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in Fig. 5.5. Regenerating axons were seen up to 3.0mm from the crush site. Therefore,
the combination of PI3K upregulation and PTEN knockdown increased axon regeneration
compared to the control.
Comparing these results with AAV2.PI3K(p110δ ) delivered individually, the
AAV2.PI3K(p110δ )-treated mice (180 axons) showed significantly greater axon regeneration
than both AAV2.PI3K(p110δ ) plus AAV2.shPTEN.GFP (77 axons) (two-way ANOVA with
Tukey’s post-hoc analysis, p=0.0128) and AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP
(32 axons) (two-way ANOVA with Tukey’s post-hoc analysis, p=0.0003) at 0.5mm from
the crush site. AAV2.PI3K(p110δ )-treated mice (104 axons) also showed significantly
greater axon regeneration than AAV2.PI3K(p110δ ) plus AAV2.shPTEN.GFP (33 axons)
(two-way ANOVA with Tukey’s post-hoc analysis, p=0.0391) and AAV2.PI3K(p110δ )
plus AAV2.shScram.GFP (15 axons) (two-way ANOVA with Tukey’s post-hoc analysis,
p=0.0056) at 1.0mm from the crush site.
Comparing these results with AAV2.shPTEN.GFP delivered individually,
AAV2.shPTEN.GFP-treated mice (117 axons) showed significantly greater axon regeneration
than AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP (32 axons) (two-way ANOVA with
Tukey’s post-hoc analysis, p=0.2200) at 0.5mm from the crush site.
Therefore, this combination approach did not yield significantly greater results than
individually targeting PI3K upregulation or PTEN knockdown. In fact, PI3K upregulation
individually gave significantly greater results than in combination with PTEN knockdown.
5.4.3 mTOR Pathway Activation
Viral PI3K upregulation combined with viral PTEN knockdown increases the mTOR
pathway activity.
IHC against mTOR pathway markers (pAKT and pS6) was performed on the retinal sections
used for viral validation. The percentage of GFP-labelled cells in the RGC layer co-localised
with either pAKT or pS6 was quantified and compared to control injection, as shown in
Fig. 5.6. Staining was indicative of RGCs.
Eyes injected with AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP (control) showed
49.3%±7.5 pAKT-GFP-labelled cells, which increased in AAV2.PI3K(p110δ ) plus
AAV2.shPTEN.GFP-injected eyes (treatment) to 73.5%±5.1 (one-tailed T-test, p=0.0009).
The average fold change in pAKT was 1.5±0.2. The control-injected eyes showed 65.6%±6.4
pS6-GFP-labelled cells, which increased in treatment-injected eyes to 80.5%±6.4 (one-tailed
T-test, p=0.0092). The average fold change in pS6 was 1.2±0.1.
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Fig. 5.5 Combination of PI3K upregulation with PTEN knockdown promoted axon
regeneration compared to control. As shown in panel A, AAV2.PI3K(p110δ ) plus
AAV2.shPTEN.GFP promoted axon regeneration following ONC injury compared to
control. Images of crushed nerves are shown in panel B for AAV2.shPTEN.GFP (Bi),
AAV2.PI3K(p110δ ) (Bii), AAV2.PI3K(p110δ ) plus AAV2.shPTEN.GFP (Biii), and for
AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP (Biv) p values measured by two-way ANOVA
with Tukey’s post-hoc analysis but not marked on graph, n = 5 to 8 as specified, error bars =
SEM. Scale bar = 100µm.
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Fig. 5.6 Combination of viral PI3K upregulation with viral PTEN knockdown resulted
in increased mTOR pathway activity in vivo. As shown in the graphs in panels A
and B, pAKT and pS6 signal increased in retinal sections from C57BL/6J mice injected
with AAV2.PI3K(p110δ ) plus AAV2.shPTEN.GFP compared to AAV2.PI3K(p110δ ) plus
AAV2.shScram.GFP. Representative images are shown in panel C. Staining in the RGC layer
was indicative of RGCs. p values measured by one-tailed T-test, n = 4, error bars = SD. Scale
bar = 100µm.
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Transgenic PI3K upregulation combined with viral PTEN knockdown increases
mTOR pathway activity
For comparison, mTOR pathway activation was investigated using transgenic PI3K upreg-
ulation with viral PTEN knockdown. Young adult (6 to 16 weeks old) hyperactive p110α
(p110αH1047R) mice and p110δ mice were intravitreally injected with 2µL of AAV2.Cre.GFP
plus 2µL of AAV2.shPTEN.GFP in the left eye and as a control, 2µL of AAV2.Cre.GFP
plus 2µL of AAV2.shScram.GFP in the right eye. The two injections were performed 4 days
apart. The eyes were collected 2 weeks after the second injection, and 12µm retinal sections
were produced.
IHC against mTOR pathway markers (pAKT and pS6) was performed on retinal sections.
The percentage of GFP-labelled cells in the RGC layer co-localised with either pAKT or
pS6 was quantified and compared to control injection, as shown in Fig. 5.7. Staining was
indicative of RGCs.
In the p110αH1047R mice, the AAV2.Cre.GFP plus AAV2.shScram.GFP-injected eyes
(control) showed 60.3%±7.4 pAKT-GFP-labelled cells, which increased to 82.8%±5.3
in AAV2.Cre.GFP plus AAV2.shPTEN.GFP-injected eyes (treatment) (one-tailed T-test,
p=0.0013). The average fold change in pAKT was 1.4±0.1. The control-injected eyes
showed 80.0%±5.4 pS6-GFP-labelled cells, which increased to 90.0%±1.6 in treatment-
injected eyes (one-tailed T-test, p=0.0059). The average fold change in pS6 was 1.1±0.1.
In the p110δ mice, the control-injected eyes showed 48.8%±12.0 pAKT-GFP-labelled
cells, which increased to 77.8%±5.4 in treatment-injected eyes (one-tailed T-test, p=0.0023).
The average fold change in pAKT was 1.7±0.5. The control-injected eyes showed
64.5%±10.4 pS6-GFP-labelled cells, which increased to 87.5%±1.3 in treatment-injected
eyes (one-tailed T-test, p=0.0023). The average fold change in pS6 was 1.4±0.2.
On comparison of mTOR pathway activation in the viral versus the transgenic
PI3K(p110δ ) approach, there were no significant differences in pAKT and pS6 levels.
Interestingly, the PI3K(p110δ ) viral approach showed significantly less pAKT and pS6
signal than in the transgenic p110αH1047R mice (two-tailed T-test, p=0.0453 for pAKT and
p=0.0358 for pS6). However, when fold-change was assessed, no significant differences
were seen.
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Fig. 5.7 Combination of transgenic PI3K upregulation with viral PTEN knockdown
resulted in increased mTOR pathway activity in vivo. As shown in the graphs in panels
A and B, pAKT and pS6 signal increased in retinal sections from p110δ mice and p110
hyperactive alpha mice injected with AAV2.Cre.GFP plus AAV2.shPTEN.GFP compared
to AAV2.Cre.GFP plus AAV2.shScram.GFP. Representative images are shown in panel C.
Staining in the RGC layer was indicative of RGCs. p values measured by one-tailed T-test, n
= 4, error bars = SD. Scale bar = 100µm.
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5.5 Results Part 2: Combination of PI3K Upregulation
and Integrin Activation
5.5.1 Viral Validation
Prior to performing regeneration experiments, AAV2.PI3K(p110δ ) (produced for project)
and AAV2.GFP (Vigene Biosciences, cat no. CV17169-AV2) were validated in vitro and in
vivo in Chapter 4.4.1.
AAV2.Integrin.V5 and AAV2.Kindlin.GFP successfully transfected HEK 293 cells in
vitro
Before using the AAV2.Integrin.V5 and AAV2.Kindlin.GFP viruses in vivo, successful viral
transfection was confirmed in vitro using HEK 293 cells, as shown in Fig. 5.8. Signal from
the viral tags, V5 and GFP, was detected from the viruses, confirming successful transfection.
V5 signal was seen for the AAV2.Integrin.V5 virus but was absent in the AAV2.GFP virus,
confirming antibody specificity.
AAV2.PI3K(p110δ ), AAV2.Integrin.V5, AAV2.Kindlin.GFP and AAV2.GFP success-
fully transduced RGCs in vivo
Viral transduction of RGCs was tested in vivo. Young adult (6 to 16 weeks old) C57BL/6J
mice were injected intravitreally with 2µL of AAV2.PI3K(p110δ ), then 2µL of either
AAV2.Integrin.V5 or AAV2.GFP, then 2µL of AAV2.Kindlin.GFP or AAV2.GFP. An-
other group of mice was intravitreally injected with 2µL of AAV2.Integrin.V5 and 2µL
AAV2.Kindlin.GFP, without the AAV2.PI3K(p110δ ), as a control. Each injection was per-
formed 4 days apart. The eyes were collected 2 weeks after the final injection, and 12µm
retinal sections were produced.
Successful viral transduction of AAV2.Integrin.V5, AAV2.Kindlin.GFP, and AAV2.GFP
in vivo was confirmed by signal from the viral tag, V5 or GFP, in the RGC layer. The
presence of PI3K(p110δ ) was confirmed for the AAV2.PI3K(p110δ ) virus. Eye cup images
showed signal throughout the retina, and closer inspection of the retinal sections confirmed
that this signal was in the RGC layer, as shown in Fig. 5.9, where staining was indicative of
RGCs.
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Fig. 5.8 AAV2.Integrin.V5 and AAV2.Kindlin.GFP were tested in vitro.
AAV2.Integrin.V5 and AAV2.Kindlin.GFP were tested in HEK 293 cells prior to in vivo
work. The presence of GFP signal in AAV2.Kindlin.GFP indicated successful transfection.
V5 signal was seen from AAV2.Integrin.V5 but not in AAV2.GFP, confirming antibody
specificity.
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Fig. 5.9 Viruses for PI3K upregulation and integrin activation were successfully trans-
duced in vivo. Eye cups and zoomed in images of the RGC layer showed p110δ signal in
RGCs throughout the retina from AAV2.PI3K(p110δ ) (Ai and Aiii), V5 signal in RGCs
throughout the retina from AAV2.Integrin.V5 (Aii and Aiii), and GFP signal in RGCs
throughout the retina for AAV2.GFP (Ai) and for AAV2.Kindlin.GFP (Aii and Aiii). Staining
was indicative of RGCs. Scale bar = 500µm for eye cups, 100µm for retinal sections.
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5.5.2 RGC Survival and Axon Regeneration
Young adult (6 to 8 weeks old) C57BL/6J mice were injected intravitreally with 2µL of
AAV2.PI3K(p110δ ), then 2µL of either AAV2.Integrin.V5 or AAV2.GFP, then 2µL of
AAV2.Kindlin.GFP or AAV2.GFP. Another group of mice was intravitreally injected with
2µL of AAV2.Integrin.V5 and 2µL AAV2.Kindlin.GFP, without the AAV2.PI3K(p110δ ), as
a control. Each injection was performed 4 days apart.
As this experiment was unsuccessful, a second round of the experiment was performed,
reducing the number of injections from three to two. Young adult (6 to 8 weeks old)
C57BL/6J mice were intravitreally injected with 2µL total of AAV2.PI3K(p110δ ) plus
AAV2.Kindlin.GFP or 2µL total of PI3K(p110δ ) plus AAV2.GFP. 1 week later, the mice
were intravitreally injected with either 2µL of AAV2.Integrin.V5 or 2µL AAV2.GFP.
2 weeks after the final injection, ONC surgery was performed. At 26 days post-ONC, 2µL
of cholera toxin subunit-β with an Alexa Fluor 555 conjugate (CTB-555) was intravitreally
injected into the left eye. At 4 weeks post-ONC, the eyes and optic nerves were collected,
Combination of PI3K upregulation with integrin activation promoted RGC Survival
compared to control with two injections, but not with three injections
The retinas were collected at 4 weeks post-ONC and IHC against Brn3A, an RGC marker,
was used to quantify RGCs. The number of surviving RGCs in the ONC (left) eye was
expressed as a percentage relative to the uninjured contralateral control (right) eye.
Mice treated with AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 and AAV2.Kindlin.GFP
spread over three injections showed 9.8%±7.5 (n=5 retinas) RGC survival compared to mice
treated with AAV2.PI3K(p110δ ) plus two doses of AAV2.GFP spread over 3 injections,
which showed 5.7%±2.0 (n=8 retinas) survival (see Fig. 5.10). No significant difference was
found between the groups.
Mice treated with AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 and AAV2.Kindlin.GFP
spread over two injections showed 9.0%±2.8 (n=7 retinas) RGC survival, which was signifi-
cantly higher than the 7.0%±1.4 (n=8 retinas) RGC survival in AAV2.PI3K(p110δ ) plus two
doses of AAV2.GFP (one-tailed T-test, p=0.0496), as seen in Fig. 5.11. Mice treated with
AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 and AAV2.Kindlin.GFP also showed signifi-
cantly higher RGC survival than the control with AAV2.Integrin.V5 and AAV2.Kindlin.GFP
alone, which showed 2.0%±0.9 (n=7 retinas) RGC survival one-tailed T-test, p<0.0001). On
comparison with AAV2.PI3K(p110δ ) delivered individually, no significant differences were
found in RGC survival.
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Fig. 5.10 3 Injections: Combination of PI3K upregulation with integrin activation
had no significant effect on RGC survival compared to control. As seen in panel A,
AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 and AAV2.Kindlin.GFP had no significant ef-
fect on RGC survival 4 weeks post-ONC injury. RWMs were stained with Brn3A (red),
which was used to quantify RGCs. The number of RGCs in the ONC (left) eye (Bii and Biv)
was expressed as a percentage survival relative to the uninjured contralateral control (right)
eye (Bi and Biii). p values measured by one-tailed T-test, n = 5 to 8 as specified, error bars =
SD. Scale bar = 100µm.
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Therefore, the combination of PI3K upregulation with integrin activation resulted in a
very slight increase in RGC survival compared to control but was not significantly different
from PI3K upregulation alone.
Combination of PI3K upregulation with integrin activation had no significant effect
on axon regeneration in this experiment
2 days before tissue collection, the left eyes were intravitreally injected with 2µL of CTB-
555. At 4 weeks post-ONC, the optic nerves were dissected, and 14µm thick sections were
produced. Axons were counted using the CTB-555 fluorescence at 0.5mm increments.
Mice treated with AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 and AAV2.Kindlin.GFP
spread over two injections showed 61±37 regenerating axons at 0.5mm from the crush
site, which was significantly more than the 23±14 axons in the AAV2.Integrin.V5 and
AAV2.Kindlin.GFP (two-way ANOVA with Tukey’s post-hoc analysis, p=0.0217), as seen in
Fig. 5.12. However, no significant difference was seen when comparing AAV2.PI3K(p110δ )
plus AAV2.Integrin.V5 and AAV2.Kindlin.GFP with AAV2.PI3K(p110δ ) plus two doses
of AAV2.GFP. Therefore, PI3K upregulation combined with integrin activation had no
significant effect on axon regeneration in this experiment.
The AAV2.PI3K(p110δ )-treated mice (180 axons) showed significantly greater axon re-
generation than both AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 and AAV2.Kindlin.GFP (61
axons) (two-way ANOVA with Tukey’s post-hoc analysis, p=0.0142) and AAV2.PI3K(p110δ )
plus AAV2.GFP (68 axons) (two-way ANOVA with Tukey’s post-hoc analysis, p=0.0124) at
0.5mm from the crush site. Again at 1.0mm from the crush site, AAV2.PI3K(p110δ )-treated
mice (104 axons) showed significantly greater axon regeneration than both
AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 and AAV2.Kindlin.GFP (13 axons) (two-way
ANOVA with Tukey’s post-hoc analysis, p=0.0160) and AAV2.PI3K(p110δ ) plus AAV2.GFP
(25 axons) (two-way ANOVA with Tukey’s post-hoc analysis, p=0.0222).
5.5.3 FAK Pathway Activation
I tried to optimise phospho-FAK IHC to measure FAK pathway activation, but it was difficult
to find a good antibody for retinal sections. D’Onofio et al. were able to detect pFAK in vivo
in western blots of whole retinal lysate, which would be interesting to try[21]. However, this
would require collecting new animal tissue and was not pursued because pro-regenerative
effects were not seen.
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Fig. 5.11 2 Injections: Combination of PI3K upregulation with integrin activation
promoted RGC survival compared to control. Integrin activation alone had no sig-
nificant effect.. As seen in panel A, AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 and
AAV2.Kindlin.GFP promoted RGC survival 4 weeks post-ONC injury, but AAV2.Integrin.V5
and AAV2.Kindlin.GFP had no significant effect. RWMs were stained with Brn3A (red),
which was used to quantify RGCs. The number of RGCs in the ONC (left) eye (panels Bii,
Biv, and Bvi) was expressed as a percentage survival relative to the uninjured contralateral
control (right) eye (Bi, Biii, and Bvi). p values measured one-way ANOVA, n = 5 to 8 as
specified, error bars = SD. Scale bar = 100µm.
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Fig. 5.12 Combination of PI3K upregulation with integrin activation had no sig-
nificant effect on axon regeneration compared to control. As shown in panel A,
AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 plus AAV2.Kindlin.GFP had no significant
effect on axon regeneration following ONC injury compared to control. Images of
crushed nerves are shown in panel B for AAV2.Integrin.V5 plus AAV2.Kindlin.GFP (Bi),
AAV2.PI3K(p110δ ) plus two doses of AAV2.GFP (Bi) and AAV2.PI3K(p110δ ) plus
AAV2.Integrin.V5 and AAV2.Kindlin.GFP (Biii). p values measured by two-way ANOVA
with Tukey’s post-hoc analysis, n = 5 to 7 as specified, error bars = SEM. Scale bar = 100µm.
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5.5.4 Summary of Strategies Tested in this Thesis
The viral treatment strategies investigated in this thesis were: PTEN knockdown, PI3K
upregulation, PI3K upregulation combined with PTEN knockdown, and PI3K upregulation
combined with integrin activation.
On comparison of the data, shown in Fig. 5.13, no significant differences were found
between the groups. The combination of PI3K upregulation and PTEN knockdown showed
the greatest percentage RGC survival, while AAV2.PI3K(p110δ ) showed the greatest axon
regeneration.
5.6 Discussion
In my experiments, delivery of more than one viral vector appeared to lessen the pro-
regenerative effects seen from the viruses individually. It would be expected that the
controls, AAV2.PI3K(p110δ ) plus AAV2.shScram.GFP (2 vectors, 7.8% survival) and
AAV2.PI3K(p110δ ) plus two doses of AAV2.GFP (3 vectors, 7.0% survival), would have
the same RGC survival as AAV2.PI3K(p110δ ) alone (11.3% survival). However, a slight
decrease was seen, although this was not statistically significant. This dulling effect was
even more apparent in axon regeneration, with significantly less regeneration from multiple
viruses compared to AAV2.PI3K(p110δ ) alone.
Combining AAV2.PI3K(p110δ ) plus AAV2.shPTEN.GFP significantly promoted RGC
survival and axon regeneration compared to control. This was demonstrated to be due
to mTOR pathway activation. However, this approach was not significantly greater than
AAV2.PI3K(p110δ ) alone and showed significantly less axon regeneration. As mentioned
above, this is likely due to a negative effect of using multiple viruses.
Combining AAV2.PI3K(p110δ ) plus AAV2.Integrin.V5 and AAV2.Kindlin.GFP had
no significant effect on axon regeneration and only marginally increased RGC survival
compared to control when two injections were given. Taken together with the fact that the
AAV2.Integrin.V5 and AAV2.Kindlin.GFP control showed no significant effect on RGC
survival or axon regeneration, it is likely these viruses were not functioning as expected, and
this should be investigated further. For example, pFAK IHC could be optimised to see if the
pathway was being activated as expected.
Future work could combine PI3K upregulation with other strategies. From this study, it
was shown that combining multiple viruses reduces effectiveness, so non-viral strategies like
insulin eye drops (unpublished work) or recombinant Oncomodulin[51] should be tested.
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Fig. 5.13 Comparison of RGC Survival and Axon Regeneration in the Different Treat-
ment Strategies. p values measured by one-way ANOVA (graph A) or two-way ANOVA
(graph B) with Tukey’s post-hoc analysis, n = 5 to 10 as specified, error bars = SD (graph A)
and SEM (graph B).

Chapter 6
Discussions and Conclusions
Optic nerve disorders, including glaucoma, are highly prevalent and on the rise in an aging
population. In such disorders, retinal ganglion cells (RGCs) and their axons are damaged
and lost, ultimately resulting in vision loss. RGC axons, as with other central nervous system
(CNS) axons, have limited regenerative potential, so there are currently no treatments to
restore visual function. In this thesis, several therapeutic strategies were investigated using
an optic nerve crush (ONC) model to assess RGC survival and axon regeneration.
In Chapter 3, three conditional knock-in phosphoinositide 3-kinase (PI3K) mouse lines
were established and maintained: hyperactive p110α (p110αH1047R), p110δ and isolated
p110δ mice. Using viral Cre-mediated recombination, either the p110αH1047R or the p110δ
isoform was expressed. Both isoforms significantly promoted RGC survival and axon
regeneration in young adult (6 to 8 weeks old) mice 4 weeks post-ONC injury, with no
difference between the two.
It is well-known that neurodegenerative diseases, like glaucoma and Alzheimer’s disease,
primarily impact the aging population and more work needs to be done to elucidate the effect
of aging on CNS axon regeneration. Both PI3K isoforms also promoted axon regeneration
in aged adult (9 to 12 months) mice, although to a lesser degree than in young mice. Aged
p110αH1047R mice showed significant RGC survival, while p110δ mice showed no significant
effect. In Geoffroy et al., little, if any, axon regeneration was seen in a corticospinal tract
(CST) model using PTEN knockout to promote regeneration in aged mice[34]. The fact that
regeneration was recorded here is promising, although comparison with PTEN knockout in
an ONC model would be more meaningful than the CST model.
While transgenic work is informative, this is not translatable. In Chapter 4, viral PI3K
upregulation was investigated using AAV2.PI3K(p110δ ). Unfortunately, the p110αH1047R
isoform was not made into a virus due to safety concerns. Viral phosphatase tensin homolog
(PTEN) knockdown using shRNA targeted against PTEN was also investigated for compari-
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son. Viral PTEN knockdown promoted RGC survival in young adult (6 to 8 weeks old) mice
at 4 weeks post-ONC injury, while viral PI3K upregulation had no significant effect in this
experiment. As the PI3K transgenic approach showed significant RGC survival, it is likely
that with a larger sample size, the PI3K viral approach would also promote RGC survival.
Both viral PTEN knockdown and PI3K upregulation promoted axon regeneration, with no
significant difference between the two. Viral PI3K upregulation showed significantly more
axon regeneration than the PI3K transgenic approach, as expected. However, no significant
difference was seen in terms of RGC survival. It would be interesting to test these viruses
in aged mice, as in Chapter 3. It would be expected that PTEN knockdown would result in
little, if any, regeneration like in the CST study [34]. Given the transgenic PI3K approach
did promote regeneration, I would expect this would be seen to a greater extent from viral
PI3K(p110δ ), which could be a potential advantage of this strategy over PTEN knockdown.
It is worth considering how these results compare to existing data in the literature. At 4
weeks post-ONC, approximately 40% RGC survival was observed from transgenic PTEN
deletion and from transgenic SOCS3 deletion, whereas co-deletion resulted in over 60% RGC
survival[95]. In contrast, viral PTEN knockdown in this thesis only resulted in 14.7% RGC
survival and viral PI3K upregulation resulted in 11.3% survival. RNA interference methods
only partially suppress the expression of target genes, as opposed to complete suppression
by genetic deletion, so a lower value is to be expected from viral PTEN knockdown. In
this thesis, RGCs were quantified by Brn3A staining, whereas Sun et al. used Tuj1 staining,
which may account for a small level of discrepancy in RGC survival.
At 4 weeks post-ONC, transgenic PTEN deletion resulted in around 1750 regenerating
axons at 0.5mm from the crush site and around 1000 axons at 1.0mm from the crush site[79].
SOCS3 deletion yielded similar results, whereas co-deletion of PTEN and SOCS3 resulted
in around 6000 regenerating axons at 0.5mm from the crush site[95]. In contrast, viral PTEN
knockdown in this thesis only resulted in 117 regenerating axons at 0.5mm from the crush
site and viral PI3K upregulation resulted in 180 regenerating axons at 0.5mm. These values
are only a small fraction of those obtained from the He group. Again, viral PTEN knockdown
would be expected to be less effective than transgenic deletion.
At 2 weeks post-ONC, the He group found that transgenic PTEN deletion resulted in
just under 1500 regenerating axons at 0.5mm from the crush site and around 1000 axons
at 1.0mm [79, 95]. In Kurimoto et al., the Benowitz group repeated this transgenic PTEN
deletion experiment and found only 400 regenerating axons at 0.5mm and 200 axons at
1.0mm at 2 weeks post-ONC[51]. They also showed that zymosan resulted in about 150
regenerating axons at 0.5mm from the crush site and around 100 axons at 1.0mm. Zymosan
combined with cAMP showed 325 regenerating axons at 0.5mm and 175 axons at 1.0mm[51].
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In Duan et al., the Sanes group found that at 2 weeks post-ONC, intravitreal injection of viral
vectors carrying either IGF1 or OPN resulted in around 63 regenerating axons at 0.5mm from
the crush site and little, if any, at 1.0mm[23]. However, a combination of IGF1 and OPN
yielded around 500 regenerating axons at 0.5mm and 125 axons at 1.0mm. All papers use
the same method to quantify axon regeneration, yet the values from both these studies are
significantly less than those found by Park et al.. Whilst still higher than the values obtained
in this thesis, these axon regeneration results are closer in range to our data.
Despite being lower than data in the literature, the data presented in this thesis is still
valid as each treatment was compared to an appropriate control carried out and analysed in
parallel. Comparison of viral PTEN knockdown and viral PI3K upregulation was also carried
out and analysed in parallel so this is more accurate to compare than with data from other
groups. While this data is not record-breaking in terms of survival and regeneration, it is still
informative and provides another strategy for promoting regeneration that can be combined
with other targets.
It has become increasingly clear in the field that combining multiple strategies is required
for robust regeneration along the optic nerve and into the brain. In Chapter 5, viral PI3K
upregulation was combined with either PTEN knockdown or with integrin activation. While
the combination of PI3K upregulation with PTEN knockdown promoted RGC survival and
axon regeneration compared to control, the RGC survival was not significantly greater than
viral PI3K alone, and the axon regeneration seen was significantly less. Integrin activation
had no significant effects, except a very minor increase in RGC survival when combined
with PI3K(p110δ ). The viruses used need to be validated further. It became clear from both
studies that combining multiple viruses reduces their effectiveness. Therefore, combining a
viral approach, like AAV2.PI3K(p110δ ) with alternative approaches like insulin eye drops
(unpublished work) or recombinant Oncomodulin[51] may be a better strategy to adopt.
The role of the mammalian target of rapamycin (mTOR) pathway in the regenerative
effects seen was demonstrated with phospho-AKT (pAKT) and phospho-S6 ribosomal protein
(pS6) signal in retinal sections. As mentioned in the chapters, this could be investigated more
thoroughly using RGC isolation and rapamycin. The contributions from other pathways, like
the focal adhesion kinase (FAK) pathway, could also be assessed in future work.
While testing the pro-regenerative effects of these viruses in murine tissue is informative,
the next step would be to test in human tissue. During the first 2 years of my Ph.D., R.
Conceição and S.S. Deshpande, under the supervision of A.C. Barber, made several attempts
to optimise retinal explant cultures, both in mice and human tissue. However, they faced
many challenges, including difficulties obtaining fresh human tissue and issues with culturing
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RGCs ex vivo. In the final year of my Ph.D., I hoped to carry on this work and test the viruses
under the supervision of Professor Christopher Leung at the University of Hong Kong.
The C. Leung lab has developed a highly specialized and robust ex vivo human retinal
modelling system. In brief, human retinas are dissected out and processed using an RGC
isolation kit that targets thy-1 positive RGCs. These RGCs are then grown as single cells in
culture, with the number of axons peaking at 3 weeks and cultures viable for over 2 months.
My work planned to transfect these single cell cultures with the viruses used in this thesis,
both individually and in combination. 2 weeks after transfection, axon number, length, and
branching were to be measured using microfluidic chambers, where Tau staining could be
used to identify axons. I was awarded a small grant to pursue this part of the project but
unfortunately, was unable to complete the work due to logistical issues. However, it would
be interesting for future work. As mentioned in Chapter 3, the p110δ construct was then
tested by S. van Erpp in human neurons maturing in vitro (human embryonic stem cells).
The ultimate aim of such regenerative research is to re-establish the visual pathway
circuitry in the brain and restore visual function. Connection to central targets in the brain is
still not robust and pathfinding errors are common so further work investigating guidance
cues in the adult optic chiasm may help to address these issues. While this thesis focused on
assessing regeneration, the next step would be to measure functional recovery, using visual
field tests and electroretinography.
Overall, the data presented in this thesis demonstrates that RGC axonal regeneration is
possible. Further work is needed before this reaches the clinical setting, but the preliminary
work from this thesis and other studies in the field is promising and provides hope for
restoring vision loss from optic nerve disorders in the future.
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